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1. Introduction
Plasma exchange (PE) and immunoadsorption (IA) constitute important options in the treatment of
various autoimmune disorders across different medical disciplines. Their pathophysiological rationale
is mainly based on the removal of auto-antibodies and a beneficial modulation of the immune system.
From a theoretical point of view, apheresis offers an attractive therapeutical option since its effect relies on
eliminating pathogenic components rather than administering drugs which may cause significant side
effects. Neurological indications include, amongst others, steroid-refractory relapse of multiple sclerosis
(MS), myasthenia gravis, autoimmune encephalitis (AE), Guillain–Barré syndrome (GBS), and chronic
inflammatory demyelinating polyneuropathy (CIDP). Although frequently applied in clinical practice,
evidence regarding efficacy and safety for the use of PE and IA in the aforementioned indications
is generally low, which is directly related to the fact that drugs and medical devices are handled
differently with regard to regulatory approvals in most countries, i.e., adequate, indication-specific
phase III studies are generally not required in order to introduce medical devices into clinical practice.
Therefore, little is known about the efficacy of PE and IA compared to each other and compared to
other treatment options. Likewise, knowledge about optimal treatment regimens for conduction of PE
and IA is completely lacking.
Therefore, this Special Issue of the Journal of Clinical Medicine focuses on articles which either
present novel original data improving the evidence for efficacy and safety of PE and IA in specific
neurological indications or review the existing literature in order to understand their significance in
various autoimmune neurological diseases and to provide recommendations for their use in clinical
practice. Furthermore, various articles highlight potential future areas of application, even beyond
classical autoimmune-mediated diseases.
1.1. Methodological Differences between Plasma Exchange and Immunoadsorption
Although both PE and IA primarily focus on removing auto-antibodies from the blood, it is
important to understand that both methods imply further immune-modulating mechanisms, including
up- and down regulation of anti- and pro-inflammatory proteins [1] and potentially other alterations
not yet explored. While, in PE, the plasma including all proteins is removed and substituted by human
albumin or fresh frozen plasma, IA is more selective, mainly removing immunoglobulins while largely
sparing other plasma constituents. Therefore, theoretically speaking, IA is supposed to offer a low-risk
alternative compared to PE, since the preservation of coagulation factors should imply fewer bleeding
complications, and since no volume replacement solution is needed, a lower risk of allergic reactions
has to be expected. On the other hand, evidence for efficacy for IA is even lower compared to PE for
many indications, which does not necessarily imply inferiority compared to PE, but may be simply
explained by the fact that IA is the most recent method, and therefore, fewer clinical trials have been
performed. Furthermore, preservation of certain pro-inflammatory proteins might compromise the
efficacy of IA compared to PE, which may be a concern especially in autoimmune diseases like MS and
CIDP, in which distinct disease-related auto-antibodies have not been characterized in the majority of
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patients. As long as the immunological mechanisms underlying both the diseases and the treatments
are not fully understood, therapeutic decisions solely depend on the outcomes of clinical studies
comparing different treatment options.
1.2. The Importance of Specific Treatment Regimens
While at least some studies to date have addressed the question of whether to prefer IA or PE
in various indications, the question of which specific treatment regimen offers the best ratio between
efficacy and safety has so far been completed neglected. Theoretically speaking, a wide array of
treatment regimens is possible for both PE and IA with regard to plasma volumes (PVs) processed per
treatment, number and frequency of treatments, time intervals between treatments, and peri-procedural
medication such as antibiotics, anticoagulants, immunoglobulins, and volume substitution solutions.
Due to missing evidence, generally accepted guidelines are lacking, and treatment regimens are
therefore chosen based on local expertise and preference. The importance of considering specific
treatment regimens is highlighted by our data presented in this Special Issue [2], which show that
the advantages of IA compared to PE regarding safety and tolerability, as previously described [3],
completely disappear when reducing the PV exchanged during each session in PE. On the other hand,
it has, of course, to be questioned if a low-volume PE is equally effective. These questions can only be
addressed by future comparative randomised controlled trials (RCTs).
1.3. Evidence for the Use of Plasma Exchange and Immunoadsorption in Specific Indications
In this Special Issue, several articles address the use of PE and/or IA in specific auto-immune
mediated neurological diseases by either systematically analysing the existing literature or presenting
original data.
1.3.1. Multiple Sclerosis
PE constitutes an established treatment option in MS, mainly based on the RCT published by
Weinshenker et al. in 1999 [4] which found a superiority of PE compared to sham treatment in patients
with steroid-refractory relapse. Although this study is well done and represents one of the very few
examples of an RCT investigating the efficacy of apheresis, the low number of subjects (n = 22) must be
kept in mind when interpreting the results. In 2019, we finalized an RCT comparing PE and IA in
60 patients with steroid-refractory relapse [5]. In this study, patients in both groups showed significant
improvements of clinical outcome parameters. Although PE patients responded faster, IA patients
showed significantly larger improvements after 4 weeks, indicating a potential superiority of IA.
In this study, we found no difference with regard to safety. In this Special Issue, Mark Lipphardt and
colleagues present a systematic meta-analysis [6] including all observational studies and RCTs to date.
They found response rates of 76.6% for PE and 80.6% of IA, indicating an about equal and good efficacy
for both methods, while safety was also equal.
Steffen Pfeuffer and colleagues investigated a related, equally important question: should another
ultra-high-dose methyl-prednisolone (MP) therapy be interpolated after an initial, unsuccessful
high-dose MP treatment, or should apheresis be performed directly? In their retrospective database
study in 145 patients [7], they found a surprisingly clear result in favour for the direct apheresis
(PE) approach, which seriously questions the recommendations of many national and international
guidelines and highlights the importance for a sufficiently powered RCT addressing this issue.
Finally, Leoni Rolfes and colleagues provided a comprehensive review about the topic [8] including
special situations like treatment of children and pregnant women.
1.3.2. Immune-Mediated Neuropathies
GBS and CIDP constitute the most important autoimmune-mediated neuropathies. GBS represents
the acute form and is generally treated with either PE or intravenous immunoglobulins (IVIg) based
on several RCTs and a recent Cochrane review [9] which, in summary, suggest equal efficacy. Evidence
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regarding the efficacy of IA is rather low and mainly relies on retrospective case reports and series.
CIDP is often considered as the chronic form of GBS, although it features strong heterogeneity with
regard to clinical symptoms and natural courses, which makes treatment and its evaluation difficult.
MP, IVIg, and PE are generally considered as the main treatment options of CIDP, and there is
no convincing evidence of which approach should be preferred with regard to efficacy and safety.
Additionally, immunosuppressive drugs such as azathioprine and rituximab are sometimes used in
therapy-refractory cases. Regarding IA, one small RCT suggested superior short-term effects compared
to PE [10], while we have demonstrated recently that repeated IA may offer a promising long-term
treatment option in therapy-refractory, chronic progressive cases [11].
Although to date distinct disease-related antibodies are not detected in the majority of patients,
the discovery of potential pathogenic auto-antibodies against proteins of the node of Ranvier and
paranodal regions [12] have corroborated the importance of auto-antibodies in at least a subgroup
of patients with immune-mediated neuropathies and therefore supported the rationale to apply
treatments which target these antibodies. Alexander Davies and colleagues [13] investigated whether
the existence of such antibodies may predict the response to apheresis in patients with GBS and CIDP.
Interestingly, they did not find a clear correlation between the presence of known auto-antibodies and
treatment response, suggesting that further, undiscovered antibodies may be present.
1.3.3. Autoimmune Encephalitis
The term autoimmune encephalitis (AE) refers to a group of diseases which are characterized
by antibodies against neuronal surfaces and synaptic proteins and feature a large spectrum of
clinical pictures, including focal neurological, psychiatric, and cognitive symptoms. As opposed to
the aforementioned indications, specific auto-antibodies against proteins like N-methyl-D-aspartate
(NMDA), gamma-aminobutyric acid (GABA), leucine-rich, glioma inactivated protein 1 (LGI1),
and many others have been described and associated with typical clinical presentations. Since
high-level evidence is lacking, no universally accepted treatment standards exist. Besides apheresis,
current therapeutic strategies include high-dose MP, IVIg, and long-term immunosuppressive drugs
such as cyclophosphamide and rituximab. IA is increasingly recognized as a promising therapeutic
approach in AE and is even considered as a first-line option in many centers. In their article [14],
Rosa Rössling and Harald Prüss review the most relevant studies regarding the use of therapeutic
apheresis in AE. Based on their evaluation, they conclude that apheresis constitutes a promising
treatment option in AE which should be applied early after disease onset, while they found no evidence
that prior treatment with IVIg or steroids yields any additional advantages. Furthermore, they found
a clear benefit for patients with antibodies against surface or synaptic antigens, while the effect on
patients with onco-neuronal antibodies is less clear.
1.3.4. Chronic Fatigue Syndrome
Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is a disease characterized
by severe fatigue as well as various cognitive, autonomic, and immunological symptoms.
The pathophysiological background seems to be complex and has not been fully understood to
date. Various auto-antibodies have been described to be associated with the disease, most notably
antibodies against the muscarinic acetylcholine receptors (MAR) and β2-adrenoreceptors (β2AR).
In their previous pilot study [15], Carmen Scheibenbogen and colleagues reported that 7/10 patients
with ME/CSF showed rapid clinical improvement and significant reductions of β2AR antibodies after
IA therapy. In this special issue, they present follow-up data from 5 patients who had previously
responded to IA treatment and who underwent a subsequent, adjusted IA protocol 2 years later [16].
They found a positive response in 4/5 patients, confirming their previous results that IA may constitute
a viable treatment option in ME/CSF, although further controlled studies with higher numbers of
patients are certainly needed.
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1.3.5. Potential Future Indications and Outlook
This Special Issue also features two articles which focus on potential future areas of application,
including diseases which are not generally considered to feature pronounced autoimmune-
mediated mechanisms.
Stefan Kayser and colleagues review potential indications for C-reactive protein (CRP)
apheresis [17], aiming at removing CRP from the patients’ blood by using specific adsorbers. The
pathophysiological background of this approach is based on the finding that CRP—most commonly
known as an inflammatory biomarker—in fact plays an important role in immunological processes
itself by mediating phagocytosis of damaged cells. Under certain conditions including myocardial
infarction and ischemic stroke, these mechanisms may have negative impacts as they imply destruction
of potentially salvageable tissue. The authors describe preliminary results from a multi-center trial
on CRP apheresis in myocardial infarction as well as an upcoming trial in ischemic stroke. They also
briefly touch on further potential indications for this interesting approach.
Finally, Sylvia Stracke and colleagues describe the IMAD trial (Efficacy of immunoadsorption
for treatment of persons with Alzheimer dementia and agonistic autoantibodies against alpha
1A-adrenoceptor) [18] which tests a novel therapeutic approach for Alzheimer dementia using
immunoadsorption. The study is based on the finding that agonistic autoantibodies against α1-
and β2-adrenoceptors are present in 50% of patients with dementia and expands on a previous
small trial in 8 patients [19] which demonstrated that IA was safe and able to significantly reduce
α1-adrenoceptor antibodies. Furthermore, the Mini Mental State Examination (MMSE) scores of these
patients remained rather stable over the following 12–18 months. The IMAD trial aims at investigating
the effects of IA on brain perfusion and disease progression on 15 patients with Alzheimer dementia
and agonistic auto-antibodies.
2. Conclusions
The articles presented in this Special Issue reveal a broad spectrum of present as well as
potential future indications for therapeutic apheresis and unanimously support the view that
both PE and IA constitute promising, low-risk therapeutic options in the treatment of various
autoimmune neurological diseases. However, they also highlight the need to improve indication-specific
evidence, which can mainly be achieved by conducting sufficiently-powered RCTs which aim
at comparing different treatment options. Along with a better understanding of underlying
immunological processes and development of novel prognostic biomarkers, such studies will facilitate
adequate therapeutic decision-making and eventually improve clinical outcomes of patients with
autoimmune-mediated diseases.
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Abstract: Plasma exchange (PE) and immunoadsorption (IA) are frequently used for treatment of
various autoimmune-mediated neurological diseases, including multiple sclerosis (MS), chronic
inflammatory demyelinating polyneuropathy (CIDP), and Guillain–Barré syndrome (GBS). Although
both methods are generally regarded as well-tolerated treatment options, evidence for safety
and tolerability is low for most indications and largely relies on small case series. In this study,
we retrospectively analysed adverse events (AEs) and laboratory changes in 284 patients with various
neurological indications who received either PE (n = 65, 113 cycles) or IA (n = 219, 435 cycles)
between 2013 and 2020 in our Neurology department. One standard treatment cycle for PE as well as
IA consisted of five treatments on five consecutive days. During every treatment, the 2.0–2.5-fold
individual plasma volume (PV) was treated in IA, while in PE, the 0.7-fold individual PV was replaced
by human albumin solution. Overall, both methods showed an excellent safety profile; no deaths
of life-threatening adverse events were recorded. Severe AEs (corresponding to grade 3 on the
Common Terminology Criteria for Adverse Events grading scale v5.0) including three patients with
sepsis, one pneumonia, and one pneumothorax were present in 5/435 IA cycles (1.1%); in the PE
group, no severe AEs were recorded. Furthermore, although advantageous tolerability is generally
considered the main advantage of IA over PE, we found that overall frequency of AEs (including
grades 1 and 2) was higher in IA (67.1% of all cycles) compared to PE (35.4%; p < 0.001). The low
incidence of AEs in PE might be caused by the lower PV exchanged during each treatment (0.7-fold)
compared to previous studies which predominantly exchanged the 1.0–1.5-fold PV. In order to verify
this hypothesis as well as confirming the efficacy of this lower-dosed scheme, prospective studies
comparing different treatment regimens are needed.
Keywords: therapeutic plasma exchange; immunoadsorption; neurological diseases; multiple
sclerosis; chronic inflammatory demyelinating polyneuropathy
1. Introduction
Plasma exchange (PE) and immunoadsorption (IA) are used in various autoimmune-mediated
neurological diseases in order to remove autoimmune antibodies and other pathological constituents
from the patients’ blood. Currently, indications include multiple sclerosis (MS), myasthenia gravis,
autoimmune encephalitis, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain–Barré
syndrome (GBS), and many others. Although PE constitutes the standard technique for most diseases,
IA is increasingly recognized as a more specific alternative and generally appreciated for its potentially
advantageous safety profile. However, safety and tolerability of both methods have rarely been directly
compared under standardized, monocentric conditions.
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Originally, both treatment options primarily aimed at removing auto-antibodies from the blood,
although various additional immune-modulating mechanisms like up- and downregulation of anti-
and pro-inflammatory interleukins have been discussed [1]. Substantial methodological differences
have to be considered which may affect efficacy as well as safety. Since in PE the plasma is removed
and substituted by a volume replacement solution (human albumin or fresh frozen plasma (FFP)),
all circulating proteins are removed, including coagulation factors. In contrast, IA relies on adsorbers
which selectively bind human immunoglobulins (Ig) while largely sparing other plasma proteins;
the processed plasma is led back to the patient, and no replacement solution is needed. Theoretically
speaking, these factors should favor IA in terms of adverse events (AEs), while on the other hand
the preservation of pro-inflammatory cytokines and other pathogenetically important proteins may
weaken its efficacy dependent on the specific immunology of the respective disease, which is however,
not fully understood in many cases. Furthermore, it has been shown that even in IA other plasma
proteins are also affected which might explain its efficacy in diseases which are not regarded to be
primarily antibody-mediated [2].
Apart from the method itself, specific techniques and treatment regimens have to be taken
into account when assessing efficacy and safety of PE and IA. Various regenerable (protein A,
recombinant proteins) and non-regenerable (tryptophan, phenylalanine) IA adsorbers are routinely
used in clinical practice which feature different binding characteristics with regard to immunoglobulin
classes, subclasses, and other plasma proteins [3,4]. For example, protein A adsorbers have a stronger
binding affinity to IgG compared to IgA and IgM [3]. Furthermore, various treatment regimens can
be applied for PE and IA with regard to number and frequency of treatments as well as the plasma
volume (PV) treated during each session. Usually, 5–7 treatments are performed in both PE and IA,
while treatment frequencies vary between daily and 2-day applications depending on fibrinogen levels.
In IA, processing of the 2.0–2.5-fold individual PV constitutes the standard [5], which allows a daily
treatment regimen for regenerable protein A and recombinant protein adsorbers, while a two-day
treatment regimen with fixed PV (usually 2 or 2.5 L) is usually applied for non-regenerable tryptophan
and phenylalanine adsorbers (due to loss of fibrinogen) [6–8]. In PE, various regimens with different
PVs have been used. For example, the original randomized controlled trial (RCT) which built the
foundation for the use of PE in MS applied 7 treatments within 14 days, exchanging the 1.1-fold PV
during each session [9], while a more recent RCT showed that a daily treatment regime with 5 sessions
and replacement of the 0.7-fold PV during each session was also effective [5]. Importantly, across all
neurological indications there are no RCTs which directly compare different treatment regimens,
and only few regimens have been tried; therefore, it seems very likely that the optimal regimen with
regard to efficacy and safety has not yet been found.
Furthermore, specific peri- and intra-procedural measures vary between centers. In order
to prevent blood in the extracorporeal circuit from clotting, heparin and/or citrate are most
commonly used which carry various potential complications like heparin-induced thrombopenia and
hypocalcemia. Some centers replace immunoglobulins after each treatment in order to account for
the immunodeficiency induced by the therapy, while others rely on the periprocedural prophylactic
administration of antibiotics. For all these measures, no reliable evidence exists.
Previous studies comparing PE and IA with regard to safety and tolerability in neurological
diseases predominantly reported either no differences [6,8,10], or advantages for IA [11,12]. Since PE is
unspecific, various complications due to loss of coagulation factors and other plasma constituents have
been reported such as thrombosis, bleeding, hypotension (due to volume-shift), and sepsis [13,14].
Furthermore, the need of a volume replacement solution carries the risk of severe allergic reactions [13].
Life-threatening complications have been reported in 0.12% of patients [14], and a higher risk of
adverse events in patients with neurological diseases compared to non-neurological diseases has been
described [13]. On the other hand, IA has repeatedly been described as a safe and well-tolerated
procedure [3,4,15]. Two studies in myasthenia gravis found that side effects were reduced in IA
compared to PE [11,12]. In MS, the majority of studies did however not report any differences between
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IA and PE with regard to safety [5,6,8] which was confirmed by a recent meta-analysis [10]. The only
prospective study comparing IA and PE in CIDP [16] reported a good safety profile for both methods
and comparable incidences of AEs. One retrospective study reported that both PE and IA were safely
applied in 19 patients with GBS [17]. In summary, safety data for PE and IA in neurological diseases
largely rely on studies with rather low numbers of subjects, which might explain the large range of
reported incidences of AEs as well as the diverging assessments of safety profiles for both methods.
Considering the lack of RCTs regarding the use of PE and IA in neurological diseases, the extensive
differences with regard to treatment regimens and peri-procedural measures, and the absence of reliable
therapeutic standards for specific disease entities, it is of crucial importance to collect systematic clinical
data. In this study, we retrospectively analyzed tolerability and safety data (including adverse events
and laboratory abnormalities) in 284 patients (548 treatment cycles, 2470 treatments) with various
neurological indications who were treated with either PE (n = 65) or IA (n = 219) between 2013 and
2020 in our center. We primarily aimed at (1) verifying the advantageous safety and tolerability profile
of IA as proposed by previous studies and (2) evaluating our specific PE-regimen which features




All patients who were treated with either PE or IA between 2013 and 2020 in the Department
of Neurology, University of Ulm, were analysed. All clinical information including medical history,
neurological status, adverse events, laboratory data, and clinical scales were collected by reviewing
the complete medical records of each patient, including discharge letters, diagnostic findings, and
monitoring documents. We included patients with all neurological diagnoses who received at least
one treatment of PE or IA. Overall, 284 patients (65 PE, 219 IA) were identified. Because some patients
received more than one cycle, 548 cycles (113 PE, 435 IA) were performed and analysed. Reasons for
multiple cycles per patient included chronic diseases like CIDP which necessitate the application of
multiple cycles in regular time intervals, or insufficient treatment response. One cycle consisted of 5
treatments, resulting in a total of 2740 treatments (565 PE, 2175 IA) which were separately documented
and analysed.
All patients with MS fulfilled the 2017 MacDonald diagnostic criteria for MS [18] or CIS at the
time of treatment. Patients with CIDP fulfilled the European Fedaration of Neurological Societies
(EFNS) criteria for possible, probable, or definite CIDP. Patients with GBS showed the typical clinical
picture including rapidly progressive bilateral limb weakness and sensory deficits, hypo-/areflexia,
electrophysiological signs of demyelination, and increased protein levels in cerebrospinal fluid. Patients
with other diseases were likewise diagnosed based on the respective internationally accepted guidelines.
2.2. Indication for PE/IA
All patients were treated in the Neurological Department of Ulm University, Neurological Center
of Apheresis and Therapies (Neurologisches Apherese- und Therapiezentrum, NATZ). The decision
to perform PE or IA was based on individual evaluation, taking into account diagnosis, clinical and
diagnostic findings, and response to previous treatments. In patients with MS or clinically isolated
syndrome (CIS), prerequisite for apheresis was the unsuccessful application of at least one cycle of
high-dose intravenous methyl-prednisolone (MP). In cases of incomplete improvement, a second cycle
of high-dose intravenous MP was performed in some patients. In CIDP, apheresis was only applied
in therapy-refractory cases, i.e., patients who deteriorated despite MP and/or IVIg therapy (usually
both). In case of a positive treatment effect, apheresis was applied in regular time intervals, based on
the individual course of disease, i.e., PE/IA was performed when symptoms began to worsen again
after the initial improvement. In GBS, apheresis was used as a first-line therapy as an alternative to
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IVIg. In some cases, PE/IA was performed after an initial unsuccessful application of IVIg. In all other
indications, apheresis was usually performed as an escalation therapy after unsatisfying response to
the first-line/standard therapies. The decision for the specific method (PE or IA) was individually
made based on current evidence, personal preference/experience, pathophysiological considerations,
and comorbidities/contraindications in a process of shared decision-making after in-depth information
of each individual patient about all therapeutic options. In 21 patients (8 MS, 2 CIDP, 3 GBS, and 8
other) PE was switched to IA, and in 22 patients (4 MS, 4 CIDP, 3 GBS, and 11 other) IA was switched
to PE after one initial unsuccessful cycle.
2.3. Procedures
PE and IA were both applied on 5 consecutive days. The majority of patients received a Shaldon
catheter in the right jugular vein. In patients who received several cycles over a prolonged period of
time (mainly CIDP), a cubital arteriovenous shunt was used in a few cases. Heparin and citrate were
used as anticoagulants, and no prophylactic antibiotics or post-procedural IVIg were given. Before each
treatment, a systemic infection was ruled out by blood and urine analysis, and ACE inhibitors were
paused at least 3 days before IA. Patients were extensively informed about risks as well as alternative
treatment options and gave their written informed consent. During each treatment, a continuous
monitoring was performed including blood pressure, heart rate, and oxygen saturation. Laboratory
testing including blood count, CRP, electrolytes, liver, and kidney parameters were routinely done on a
daily basis during PE/IA.
During PE, a fixed PV of 2 L (corresponding to a mean individual 0.7-fold PV) was exchanged
until 07/2018; afterwards, we instead exchanged the 0.7-fold individual PV. Since comparative studies
regarding different treatment regimens for PE/IA are completely lacking, these parameters are mainly
based on local experience and expertise. A COM.TEC cell separator (Fresenius Kabi Deutschland
GmbH, Bad Homburg, Germany) was used during PE.
During IA, the 2.0-fold individual plasma volume was processed on the first day, and the
2.5-fold individual plasma volume was processed on days 2–5. The individual plasma volume was
calculated according to the formula published by Sprenger et al. [19]. Three different regenerable
double-column adsorbers were used: protein A (Immunosorba, Fresenius Medical Care, Bad Homburg,
Germany), Peptid-GAM (Globaffin, Fresenius Medical Care, Bad Homburg, Germany), and recombinant
proteins (Miltenyi Biotec, Bergisch Gladbach, Germany). All three adsorbers selectively bind human
immunoglobulins while largely sparing other plasma proteins. The choice of adsorber was mainly
based on availability. ADAsorb (medicap clinic GmbH, Ulrichstein, Germany) and Life 21 (Miltenyi
Biotec, Bergisch Gladbach, Germany) were used as immunoadsorption devices; COM.TEC (Fresenius
Kabi Deutschland GmbH, Bad Homburg, Germany) and ART Universal (Fresenius Medical Care,
Bad Homburg, Germany) were used for cell separation.
2.4. Outcome Parameters
Adverse events were retrospectively collected by reviewing the medical reports and monitoring
curves of each patient and treatment. Laboratory changes were assessed based on daily laboratory
reports. Adverse events were classified as Grade 1–5 according to the Common Terminology Criteria
for Adverse Events grading scale v5.0.
Efficacy parameters before and after treatment were collected as documented in the medical
reports. In patients with MS, these include the Expanded Disability Status Scale (EDSS) and the
Multiple Sclerosis Functional Composite (MSFC) as the best validated and frequently used standardized
clinical scales. In patients with CIDP, we routinely performed the CIDP score [20], which incorporates
the Inflammatory Neuropathy Cause and Treatment (INCAT) score [21], the Oxford muscle strength
grading score, and vibration sensitivity testing with a 256-Hz Ryder-Seiffel tuning fork. Since no
generally accepted and adequately validated standardized scale exists for GBS, evaluation of efficacy
in these patients was based on neurological examination before and after PE/IA and classified as large,
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partial, equivocal, or no improvement. For other indications, no systematic evaluation of efficacy
was done due to low numbers of patients. Efficacy data refer to subgroups of patients with sufficient
clinical data and have been published previously [5,20,22].
2.5. Statistical Analysis
Adverse events and laboratory changes were evaluated per cycle. Adverse events were additionally
analysed on a per-patient basis in order to exclude bias based on the per-cycle approach (i.e., one patient
may present one specific AE during multiple cycles, causing an overestimation of this AE). Statistical
analysis was based on absolute/relative frequencies (categorial variables) and median/interquartile
range (continuous variables). For evaluation of laboratory changes, we calculated the change between
baseline and second day of PE/IA (not shown) as well as fifth day of PE/IA (before last treatment);
we also recorded the share of cycles/patients with pathological values for each laboratory parameter.
Changes of patient related continuous data were investigated with the Wilcoxon signed rank test.
Group comparisons for patient related continuous data were performed using the Mann–Whitney-U-test.
Group comparisons for patient related categorical data were carried out with the chi-square test or
Fisher’s exact test as appropriate. Group comparisons for cycle related continuous data were
investigated using linear mixed effects regression models in order to account for patients receiving
multiple cycles. Group comparisons for cycle related binary data were investigated using mixed effects
regression models for binary outcomes.
The level of significance was set as p≤ 0.05 (two-sided). To estimate treatment effects, we calculated
median differences including a two-sided 95% confidence interval. Statistical analyses were done using
SAS, version 9.4, and GraphPad Prism, version 7.05. Because of the explorative nature of this study,
all results from statistical tests have to be interpreted as hypothesis-generating rather than proof of
efficacy. No adjustment for multiple testing was done.
3. Results
3.1. Demographics and Clinical Characteristics
Demographic and clinical characteristics are depicted in Table 1. PE and IA patients were not
different with regard to age, sex distribution, and body mass index (BMI). For more detailed clinical
information for patients with the most common diagnoses (MS, CIDP, and GBS) see Tables S1–S3.
Prognostic factors in patients with MS, CIDP, and GBS were evenly distributed between PE and IA.
Table 1. Baseline Characteristics.
IA PE Total p
Patients (cycles) 219 (435) 65 (113) 284 (548)
Treatments per cycle 5 5
Processed PV per treatment 2.0–2.5-fold 0.7-fold
Age (years) 51.0 (36.0 to 62.0) 45.5 (34.5 to 63.0) 50.0 (36.0 to 62.0) 0.68
Sex 0.89
male 94 (42.9%) 27 (41.5%) 121 (42.6%)
female 125 (57.1%) 38 (58.5%) 163 (57.4%)
BMI (kg/m2) 24.3 (21.8 to 27.8) 25.2 (21.6 to 27.5) 24.6 (21.8 to 27.8) 0.67
Diagnosis
MS 72 (32.9%) 21 (32.3%) 93 (32.7%)
CIS 28 (12.8%) 10 (15.4%) 38 (13.4%)
NMOSD 3 (1.4%) 2 (3.1%) 5 (1.8%)
AE 15 (6.8%) 2 (3.1%) 17 (6.0%)
CIDP 30 (13.7%) 4 (6.2%) 34 (12.0%)
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Table 1. Cont.
IA PE Total p
GBS 17 (7.8%) 10 (15.4%) 27 (9.5%)
MG 4 (1.8%) 0 4 (1.4%)
SPS 3 (1.4%) 1 (1.5%) 4 (1.4%)
SLE 1 (0.5%) 2 (3.1%) 3 (1.1%)
Other 46 (21.0%) 12 (18.4%) 58 (20.4%)
IA—immunoadsorption; PE—plasma exchange; PV—individual plasma volume; BMI—body mass index;
MS—multiple sclerosis; CIS—clinically isolated syndrome; NMOSD—neuromyelitis optica spectrum disorder;
AE—autoimmune encephalitis; CIDP—chronic inflammatory demyelinating polyneuropathy; GBS—Guillain–Barré
syndrome; MG—myasthenia gravis; SPS—stiff person syndrome; SLE—systemic lupus erythematodes.
3.2. Adverse Events
Overall, both methods showed an excellent safety profile; no treatment-associated deaths or
life-threatening adverse events were recorded. Severe AEs (corresponding to grade 3 on the Common
Terminology Criteria for Adverse Events grading scale) in the IA group included three patients with
sepsis, one severe pneumonia, and one pneumothorax, corresponding to 5/435 affected IA cycles (1.1%).
In the PE group, no severe AEs were recorded.
Importantly, all three patients with sepsis were diagnosed with CIDP, two-thirds were older than
80 years and multimorbid. One patient had type 2 diabetes mellitus and recurrent urinary infections in
medical history. Primary focus was the Shaldon catheter in all three cases. All patients recovered with
antibiotic treatment. One severe pneumonia occurred in a 49 year old female with severe myasthenic
crisis who was monitored on intensive care unit and dependent on non-invasive ventilation when
IA was initiated; she eventually recovered. The pneumothorax (IA group) was a complication of
Shaldon catheter placement and necessitated a Bülau drainage as well as a short stay on intensive
care unit. The patient recovered completely and received several IA cycles afterwards without any
further complications.
Surprisingly, we found that mild and moderate adverse events per cycle (grade 1 and 2; Table 2)
were more frequent in the IA group (67.1%) compared to PE (35.4%; p < 0.001). With the exception
of fatigue, all adverse events were more frequent in the IA group. Most common were intermittent
hypotonia (24.0% of all patients), hematoma caused by Shaldon placement (16.4%), and mild infections
(6.9%). All adverse events were uncomplicated and did not necessitate any specific therapy. Thrombotic
events included deep venous thromboses, most commonly of the Shaldon-affected jugular vein, which
were treated with oral anticoagulants and healed without permanent consequences in all cases.
Thrombotic events were most frequently seen in patients with GBS.
Table 2. Adverse Events per Cycle.




















Hypotonia 7.4 23.0 5.6 16.3 0.0 31.8 8.8 28.0 24.0
Hematoma (Shaldon) 3.7 18.0 16.7 6.3 13.3 9.1 11.5 17.7 16.4
Mild Infections 0.0 4.0 5.6 7.5 20.0 13.6 5.3 7.4 6.9
Technical Complications 0.0 6.0 0.0 7.5 0.0 13.6 0.8 5.7 4.7
Nausea 3.7 3.0 0.0 1.3 0.0 9.1 3.5 4.8 4.5
Tachycardia 0.0 3.0 0.0 7.5 13.3 4.5 1.8 4.6 4.0
Edema 0.0 3.0 0.0 3.8 0.0 4.5 0.0 4.8 3.8
Allergic Skin Reaction 0.0 10.0 5.6 2.5 0.0 4.5 0.8 4.6 3.8
Thrombosis 3.7 0.0 0.0 3.8 6.7 13.6 2.7 3.4 3.3
Thoracic Pain 0.0 3.0 0.0 1.3 0.0 13.6 0.8 3.9 3.3
Fatigue 0.0 0.0 5.6 1.3 6.7 0.0 3.5 1.1 1.6
Thrombosis 3.7 0.0 0.0 3.8 6.7 13.6 2.7 3.4 3.3
Data are %. Table presents all adverse events that occurred in >3% of patients in at least one of the treatment
groups. IA—immunoadsorption; PE—plasma exchange; MS—Multiple Sclerosis; CIDP—Chronic Inflammatory
Demyelinating Polyneuropathy; GBS—Guillain–Barré syndrome.
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Per-patient analysis yielded similar results as per-cycle analysis (not shown). Albeit CIDP
patients were older and had more co-morbidities compared to MS, we did not detect any meaningful
disease-specific characteristics with regard to AEs.
3.3. Laboratory Changes
Median laboratory changes between the day of last treatment (before last treatment) compared
to baseline of each cycle in both groups are displayed in Table 3. While loss of thrombocytes was
more pronounced in IA, loss of erythrocytes was more pronounced in PE. IA patients showed larger
decreases of potassium and calcium; sodium was rather stable in PE as well as IA. The substitution
of proteins masks the assumedly larger loss of plasma proteins in PE compared to IA. Importantly,
fibrinogen levels were similar in PE and IA. As described previously, we found that in the IA group IgG
was removed more effectively than IgA and IgM; consistently, IgG reduction was more pronounced in
IA, while IgA and IgM reduction were more pronounced in PE. Supplementing the absolute changes,
Table 4 displays the share of patients above/below the pathological threshold for each laboratory
parameter per group which yielded congruent results.







Leukocytes (G/L) –0.3 (–1.6 to 0.9) 0.1 (–1.4 to 1.3) 0.98
Erythrocytes (T/L) –0.55 (–0.72 to –0.21) –0.35 (–0.59 to –0.14) <0.001
Hemoglobin (g/L) –15 (–23 to –8) –10 (–17 to –4) <0.001
Hematocrit (%) –4 (–2 to –6) –3 (–1 to –5) <0.001
Thrombocytes (G/L) –53 (–90 to –26) –91 (–128 to –55) <0.001
MPV(fL) 0.1 (–0.3 to 0.4) 0.4 (0.1 to 0.8) <0.001
Quick (%) –24 (–37 to –12) –10 (–39 to 2) 0.18
INR 0.13 (0.07 to 0.44) 0.06 (–0.01 to 0.37) 0.66
pTT (s) 11.6 (4.6 to 32.3) 6.5 (3.1 to 26.0) 0.52
Fibrinogen (g/L) –1.7 (–1.9 to –0.1) –1.6 (–3.4 to –0.8) 0.96
Sodium (mmol/L) 1 (–1 to 3) 2 (1 to 4) 0.003
Potassium (mmol/L) –0.23 (–0.60 to 0.08) –0.47 (–0.77 to –0.17) <0.001
Calcium (mmol/L) 0.02 (–0.08 to 0.10) –0.17 (–0.25 to –0.06) <0.001
Urea (mmol/L) –0.12 (–0.98 to 0.76) –0.94 (–2.14 to 0.05) 0.019
Creatinine (μmol/L) –1.5 (–8.5 to 1.8) 2 (–5.5 to 8) 0.002
GFR (ml/min) 2.0 (–3.5 to 10.5) –2.5 (–13 to 7.3) 0.002
AST (U/L) 9.0 (–6.25 to 13.8) 1.0 (–4.0 to 10.0) 0.98
ALT (U/L) –6.0 (–13.0 to 7.0) –3.5 (–9.3 to 9.0) 0.85
GGT (U/L) –17.0 (–27.5 to –12.0) –9.0 (–22.0 to –4.0) 0.92
AP (U/L) –39.0 (–43.0 to –26.0) –19.0 (–30.3 to –12.0) 0.03
Bilirubin (μmol/L) 3.5 (0.5 to 5.3) 0.1 (–2.4 to 11.4) 0.09
Protein (g/L) –5.9 * (–9.4 to –1.8) –19.9 (–23.9 to –15.8) <0.001
CRP (mg/L) 0.08 (–1.02 to 1.40) 0.81 (–0.28 to 3.81) 0.23
IgA (mg/L)# –866 (–572 to –1100) –1362 (–1197 to –1536) <0.001
IgG (mg/L)# –6639 (–5428 to –7367) –5770 (–5562 to –6582) <0.001
IgM (mg/L)# –711 (–316 to –924) –713 (–324 to –1066) 0.008
Median laboratory changes (IQR) between the day of last treatment compared to baseline of each cycle in both groups.
IA—immunoadsorption; PE—plasma exchange; MPV—mean platelet volume; INR—international normalized ratio;
pTT—partial thromboplastin time; GFR—glomerular filtration rate; AST—aspartate aminotransferase; ALT—alanine
aminotransferase; GGT—gamma glutamyl transferase; AP—alkaline phosphatase; CRP—C-reactive protein; * after
substitution with human albumin solution; # Immunoglobulins A, G, and M were measured in a subset of 61 MS
patients who participated in a randomized controlled study [5]. Bold p-values mark significant values.
13
J. Clin. Med. 2020, 9, 2874





(n = 435) p
Leukocytes (G/L) 18.3% 19.0% 0.64
Erythrocytes (T/L) 53.9% 38.5% 0.05
Hemoglobin (g/L) 58.7% 46.0% 0.08
Hematocrit (%) 54.8% 45.8% 0.09
Thrombocytes (G/L) 12.6% 41.5% <0.001
MPV(fL) 4.9% 6.1% 0.46
Quick (%) 44.8% 37.5% 0.15
INR 90.0% 91.0% 0.82
pTT (s) 78.6% 79.9% 0.85
Fibrinogen (g/L) 80.0% 66.7% 0.82
Sodium (mmol/L) 5.8% 0.3% 0.13
Potassium (mmol/L) 9.7% 27.0% 0.001
Calcium (mmol/L) 5.2% 17.8% 0.11
Urea (mmol/L) 8.3% 7.1% 0.90
Creatinine (μmol/L) 23.4% 28.1% 0.80
GFR (ml/min) 85.3% 82.6% 0.42
AST (U/L) 33.3% 23.8% 0.07
ALT (U/L) 18.2% 20.6% 0.49
GGT (U/L) 0.0% 15.7% 0.15
AP (U/L) 100.0% 88.5% 0.64
Bilirubin (μmol/L) 16.7% 11.4% 0.52
Protein (g/L) 92.0%* 99.1% 0.004
CRP (mg/L) 24.5% 40.3% 0.23
Share of patients with values below or above the pathological threshold for each parameter at last day of apheresis
in each group. IA—immunoadsorption; PE—plasma exchange; MPV—mean platelet volume; INR—international
normalized ratio; pTT—partial thromboplastin time; GFR—glomerular filtration rate; AST—aspartate aminotransferase;
ALT—alanine aminotransferase; GGT—gamma glutamyl transferase; AP—alkaline phosphatase; CRP—C-reactive
protein; * after substitution with human albumin solution. Bold p-values mark significant values.
3.4. Efficacy
Efficacy data for patients with sufficient standardized data have previously been published.
These data refer to subsets of the study population investigated in the current study and were treated
with the same IA and PE protocols.
In steroid-refractory MS, we conducted a randomized controlled trial in 61 patients (31 IA vs.
30 PE, 5 treatments on 5 consecutive days as outlined above) [5]. We found a significant improvement
of symptoms after four weeks compared to pre-treatment in both groups as measured by MSFC and
EDSS. In the PE group, median MSFC improved from 0.22 (–0.27 to 0.55) to 0.57 (0.15 to 0.82; p < 0.001),
and median EDSS improved from 3.0 (2.0 to 3.5) to 2.0 (1.0 to 3.5; p < 0.001). In the IA group, median
MSFC improved from 0.09 (–0.19 to 0.39) to 0.63 (0.21 to 0.90; p < 0.001), and median EDSS improved
from 3.0 (2.0 to 4.0) to 2.0 (1.0 to 3.1; p < 0.001). Although improvement started earlier in the PE group,
MSFC improvement (0.385 vs. 0.265; p = 0.03) and response rates (86.7% vs. 76.7%) after four weeks
were larger in the IA group.
In CIDP, we performed a prospective observational study in 17 patients with therapy-refractory
courses (insufficient response to steroids and/or IVIg) who underwent IA [20]. Overall, median CIDP
scores improved from 308.0 (266.0 to 374.5) pre-treatment to 330.0 (290.0 to 393.5; p = 0.02) after
two weeks. Furthermore, we were able to stabilize disease progression in 6/7 patients who received
long-term IA treatments in regular intervals. Before IA, these patients lost 6.7 (3.0 to 13.1) points of
CIDP score per month, while during IA, they lost 0.1 (0.0 to 0.8) points. Due to the insufficient number
of patients treated with PE, we cannot provide any comparative results.
A retrospective analysis of 20 patients with GBS [22] yielded response rates of 61.5% for IA and
71.4% for PE after the last treatment based on the documented neurological examinations.
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4. Discussion
This study aimed at evaluating safety and tolerability of PE and IA as main options of apheresis in
autoimmune-mediated neurological diseases. Pre-existing evidence suggested that IA may be superior
to PE in this regard, although comparative studies with high numbers of patients are missing. For this
purpose, we analysed data from 284 patients (548 cycles, 2740 treatments) who were treated with
either PE or IA between 2013 and 2020 in our center under standardized conditions. Importantly,
we used an adjusted protocol for PE, aiming for a comparatively small volume of exchanged plasma
volume per day (0.7-fold individual PV per day) compared to other commonly used regimens which
imply higher volumes (1.0–1.5-fold individual PV per day). This protocol is based on our own clinical
experience, including a randomized controlled trial in MS [5] which suggested an excellent safety
and good efficacy profile for this specific regimen. The retrospective nature of this study has to be
mentioned as a limitation, since we cannot exclude that AEs occurred or diagnoses changed after
discharge. We regard the high number of treatments under standardized, monocentric conditions and
the continuous, systematic recording of safety data as strengths of this study.
Overall, we found that both methods were very safe across all neurological indications, since we
did not record any life-threatening complications or deaths, and grade 3 AEs were recorded in only
1.1% of IA cycles while in PE, we did not record any grade 3 AEs. Therefore, the incidence of serious
AEs was even rarer in PE compared to IA. Surprisingly, we found that the share of mild and moderate
AEs, including thrombosis, hypotonia, allergic reactions, nausea, and vegetative symptoms were also
lower in PE which contradicts the common conception of IA as a better tolerated method of apheresis.
However, a closer look at current literature reveals that this question has not been conclusively
answered as highlighted by several studies in MS [6,8] as well as a recent meta-analysis [10] which
found similar incidences of adverse events. The generally favourable safety profile of both PE and IA
should also be considered when weighing against alternative treatment options, for example whether
a second high-dose MP cycle should be performed in steroid-refractory MS relapse before apheresis.
As highlighted by a recent publication [23], sparing a second MP cycle and applying apheresis directly
may be superior in terms of efficacy and safety.
Data about complication rates of PE are heterogenous, varying between 4.2% and 25.6% [13,24–26],
most likely due to heterogenous treatment regimens with regard to PV treated per session, type and
dosage of applied anticoagulants, type of venous access (peripheral or central), and type of volume
substitution (human albumin or FFP). Basic-Jukic et al. found moderate allergic reactions in 1.6%
of 509 patients treated with PE as well as severe anaphylactic reactions in five cases; accordingly,
Schneider-Gold et al. found a higher incidence of allergic reactions in patients with myasthenia
gravis treated with PE compared to IA [11]. However, the incidence of allergic reactions in PE may
presumably be lowered by using human albumin solution instead of FFP, since allergic reactions are
commonly associated with FFP [27], but very rarely with human albumin solution [28]. Accordingly,
the incidence of allergic reactions was extremely low in our PE study population (0.8%), and lower
compared to IA (4.6%). Since no volume substitution is needed in IA, the higher incidence of allergic
reactions in IA may be associated with the higher amounts of anticoagulants needed for IA, especially
heparin. Furthermore, it cannot be ruled out completely that adsorber substances may be reinfused.
Importantly, in order to utilize the advantageous safety profile of human albumin solution
compared to FFP in PE, it is essential to limit fibrinogen loss by either reducing the frequency of
treatments (i.e., performing treatments on a two-day instead of a daily basis) or reducing the PV
processed during each treatment. Based on our data, it was possible to perform daily PE treatments
with 0.7-fold PV without any treatment interruptions while maintaining acceptable fibrinogen plasma
levels, i.e., fibrinogen levels remained above 0.8 g/L before each treatment. Applying this scheme,
we found comparable fibrinogen levels in PE and IA, suggesting that (1) fibrinogen loss in PE can
be sufficiently controlled by attenuating PV per treatment, and (2) significant loss of fibrinogen is
also present in IA. In line with our finding of similar and acceptable fibrinogen levels in both PE
and IA, we did not record any bleeding complications with both measures, while the incidence of
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thrombotic events was similar (2.7% in PE, 3.4% in IA). Therefore, we can conclude that maintaining
higher fibrinogen levels during PE may contribute to improve safety, since bleeding complications
have previously been described to occur more frequently in PE (3.1% of treatments) compared to IA
(1.3%) [15].
In addition to allergic reactions and bleeding complications, infections induced by the
immune-modulating effects of PE/IA are a major concern. Based on our data, both measures were
very safe in this regard. We found severe infections with consecutive sepsis in three patients who
were all diagnosed with CIDP; two of them were >80 years old. Therefore, we conclude that these
clinical characteristics constitute risk factors which have to be considered. Mild infections occurred in
only 5.3% (PE) and 7.4% (IA), respectively. These data corroborate the conception that peri-procedural
prophylactic application of antibiotics or immunoglobulins is not needed. We could not confirm the
finding of Schneider-Gold et al. who found a higher frequency of respiratory infections in PE compared
to IA [11]. Again, different treatment regimens (0.7-fold vs. up to 1.5-fold PV treated in PE patients)
do most likely account for this discrepancy, since treating lower PVs per session implies a higher
preservation of antibodies and other anti-infective plasma proteins. Accordingly, we found that overall
reduction rates of immunoglobulins were about similar in PE and IA; regarding subclasses, we found
that reduction rates of IgA and IgM were higher in PE, while reduction rate of IgG was higher in IA.
This was expected since the applied IA adsorbers feature a higher IgG affinity [29].
Regarding mild adverse events such as hypotonia, nausea, and palpitations, we generally found
higher incidences in the IA group. This finding is not necessarily caused by technical differences of PE
and IA, but may simply be explained by the significantly prolonged treatment times in IA. Applying
the treatment regimens outlined above and dependent on the patient’s individual PV, one IA treatment
requires about the double amount of time compared to PE due to the excessive amount of blood treated
during each session. Apart from the higher incidence of adverse events which are associated with
longer treatment times, this also implies a larger burden for the patient.
Subclinical laboratory changes were unproblematic in all cases and did not necessitate specific
treatment, with the exception of potassium and protein substitution which are routinely done in PE
as well as IA. Interestingly, we found a higher incidence of anemia in PE, but a higher incidence
of thrombopenia in IA, confirming previous findings [5]. The latter may possibly be explained by
the higher demand for heparin during IA, since the external blood circuit has to be maintained for
a longer timeframe and heparin may cause heparin-induced thrombopenia (HIT). While cell count
abnormalities can be contributed to the procedures themselves, changes of plasma constituents like
liver transaminases or urea do not necessarily imply organic disturbances, but rather signify that these
substances are removed by the procedures. Regarding electrolytes, hypokalemia and hypocalcemia
(due to citrate binding) are both known phenomena in PE and IA. In our study electrolyte disturbances
were more frequent in the IA group.
Despite the lower incidence of AEs and laboratory abnormalities found for the low-PV PE
treatment regimen compared to IA, this finding has to be interpreted carefully because of the following
limitations of this study: First, the safety profile was compared with IA, which is quite a novel
therapeutic approach itself, especially with regard to neurological diseases. A superiority of our PE
regimen compared to other commonly applied regimens can however only be proven by conducting a
direct comparative prospective study. Secondly, lowering the PV treated each day may compromise
the efficacy of the procedure, which cannot be adequately analysed by means of a retrospective study
design. We investigated the efficacy of this approach in a randomized controlled study in patients
with steroid-refractory MS relapse versus IA [5]. Indeed, we found that after four weeks, IA patients
showed a significantly larger improvement of the MSFC; however, the difference between PE and IA
was rather small.
In summary, we conclude that:
1. PE and IA constitute safe and generally well-tolerated therapeutic options in autoimmune-mediated
neurological diseases.
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2. Contrary to previous publications, we found a lower incidence of adverse events in the PE
group—possibly due to the low-volume per treatment regimen (0.7-fold PV per day), which allows
to use human albumin solution while maintaining sufficient fibrinogen levels.
3. Safety and efficacy of this specific PE treatment regimen have to be further evaluated by means of
a directly comparative, prospective study.
4. This study highlights the importance to consider specific treatment regimens with regard to safety
and efficacy in general when assessing apheresis studies.
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Abstract: (1) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex
neuroimmunological disease. There is evidence for an autoimmune mechanism for ME/CFS
with an infection-triggered onset and dysfunction of ß2-adrenoreceptor antibodies (ß2AR-AB).
In a first proof-of-concept study, we could show that IA was effective to reduce ß2AR-AB and led to
improvement of various symptoms. (2) Five of the ME/CFS patients who had clinical improvement
following treatment with a five-day IA were retreated in the current study about two years later
with a modified IA protocol. The severity of symptoms was assessed by disease specific scores
during a follow-up period of 12 months. The antibodies were determined by ELISA. (3) The modified
IA treatment protocol resulted in a remarkable similar clinical response. The treatment was well
tolerated and 80–90% decline of total IgG and ß2AR-AB was achieved. Four patients showed a rapid
improvement in several clinical symptoms during IA therapy, lasting for six to 12 months. One patient
had no improvement. (4) We could provide further evidence that IA has clinical efficacy in patients
with ME/CFS. Data from our pilot trial warrant further controlled studies in ME/CFS.
Keywords: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; immunoadsorption;
ß2 adrenoreceptor autoantibody
1. Introduction
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disease that is
characterized by persistent fatigue and exertional intolerance with disproportionate worsening after
physical or cognitive exertion. Furthermore, it is accompanied by a variety of other symptoms that
are related to immunological and autonomous dysfunction [1]. With an estimated prevalence of
0.1–0.5%, ME/CFS is a frequent and chronic disease that is often triggered by an acute infection [2].
Around 2.5 million Americans suffer from ME/CFS causing an annual financial cost up to 24 billion
dollars per year [3]. ME/CFS affects all races, ages, and socioeconomic groups, with women affected
2–3 times more frequently than men [4,5]. Currently, the exact pathophysiology of ME/CFS is not
well understood. There is increasing evidence for an autoimmune pathomechanism in ME/CFS [6].
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Autoimmunity-related risk variants in PTPN22 and CTLA4 were found to be associated with ME/CFS
with infectious onset in a recent study [7]. Several studies described autoantibodies in ME/CFS,
including antibodies against nuclear and membrane structures, cardiolipin, neurotransmitter receptors,
and against autoantigens formed by oxidative or nitrosative damage [6,8–10]. Elevated autoantibodies
against the muscarinic acetylcholine receptors (MAR-AB) and ß2-adrenoreceptor antibodies (ß2AR-AB)
could be detected in a subgroup of patients [11–13]. There is first evidence for a dysfunction of
adrenergic receptor antibodies in ME/CFS [14,15]. A recent study showed a correlation between
ß2AR-AB and brain network alterations that was associated with pain [16]. Results from two clinical
studies in which rituximab was used for depleting CD20+ B lymphocytes provided first evidence
that B cells are involved in the pathogenesis of ME/CFS [17,18]. Approximately 60% of patients in the
treatment group showed a partial or complete remission of clinical symptoms, lasting for more than
six months in several patients. Interestingly, the clinical improvement was only seen after a time delay
of three to four months. This indicates that the immediate depletion of CD20+ B cells has no direct
effect, because CD20− antibody-producing plasma cells remain unaffected by rituximab treatment.
There was a sustained reduction in ß2AR-AB in patients who had a clinical response to rituximab [11].
An effective treatment option for autoantibody-mediated diseases is immunoadsorption (IA).
By using specific adsorbers, the plasma concentration of immunoglobulin G (IgG) can be quickly
and efficiently reduced [19]. Clinical symptoms of various autoimmune diseases that are associated
with autoantibodies, including dilative cardiomyopathy, therapy refractive lupus erythematosus,
and various neurological diseases, could be improved quickly by IA [20–22]. Recently, we described
a proof-of-concept prospective observational IA study in ten patients with ME/CFS, in whom ß2AR-AB
were elevated [23]. Five cycles of IA were conducted on days one–three and six–seven. In nine
patients, the ß2AR-AB decreased rapidly during IA treatment and it was still significantly lower than
the pretreatment level after six months. The frequency of memory B cells significantly decreased,
whereas the frequency of plasma cells increased after a five-day IA cycle. A rapid improvement
of symptoms was reported by 70% of patients already during IA. Three of these patients had long
lasting improvement for more than 12 months and four patients had short improvement. However,
two patients had a marked worsening of symptoms during IA and could not receive the fifth IA.
Here, we present data of a conformational trial. Patients who had responded to the first IA (IA1)
were retreated with a modified IA protocol (IA2) about two years later. Here, IA cycles were given
with longer intervals.
2. Materials and Methods
2.1. Patients
For the conformational trial, we adjusted the treatment protocol (IA2, see Figure 1). Five of the ten
participants of our first study in 2016 were included in the current study. These patients had a transient
or long-lasting improvement of clinical symptoms after the first IA therapy. Detailed inclusion criteria
were described before [23]. In short, all of the patients fulfilled the Canadian Consensus Criteria [1],
had increased ß2AR-AB levels, and an infection-triggered disease onset.
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Figure 1. Treatment protocols of both studies. X indicates the point of time when immunoadsorption (IA)
was conducted, black arrows when blood samples were collected, and blue arrow for immunoglobulin
G (IgG) supplementation.
2.2. Study Protocol
During the IA1 study, we learned that repeated IA can worsen fatigue. Four patients had worsening
of fatigue towards the end of treatment despite improvement of other symptoms. To improve the
tolerability of the treatment, we extended the treatment period and reduced the dose of IgG replacement.
IA was performed at day one, two, four, six, and eight (Figure 1) using Globaffin® columns (Fresenius,
Bad Homburg, Germany), a broadband-immunoadsorber containing synthetic peptide-GAM® as
ligand capable of binding IgG and immune complexes independent from their antigen specificity and,
thus, useful for the removal of autoantibodies. Patients received 10 g polyclonal immunoglobulin
substitution intravenously (Octagam, Octapharma, Langenfeld, Germany or Gammunex, Grifols,
Frankfurt/M., Germany) to restore IgG plasma levels after the final IA session. The study was approved
by the Ethics Committee of Charité - Universitätsmedizin Berlin (project code: EA2/063/15 from
10 September, 2018) in accordance with the 1964 Declaration of Helsinki and its later amendments. All
of the patients gave written informed consent.
2.3. Assessment of Autoantibodies, Ig, Albumin and Fibrinogen
ß1AR-/ß2AR-AB and M3AR-/M4AR-AB were determined using ELISA technology by CellTrend
GmbH (Luckenwalde, Germany), as in our previous study [23]. Total serum IgG, IgA, IgM,
albumin, and fibrinogen were determined at the Charité diagnostics laboratory (Labor Berlin GmbH,
Berlin, Germany).
2.4. Symptom Assessment by Scores
We assessed the presence and severity of symptoms, as described in our previous study [23].
In short, the patients quantified the severity of symptoms of the Canadian consensus criteria using
a questionnaire that was developed by Fluge et al. [17,18]. After the determination of a baseline value,
patients stated the improvement or worsening of symptoms (0–3: worsening; 3: no change from
baseline; 3–6: improvement). The patients filled this questionnaire daily during treatment and monthly
during follow-up. Furthermore, patients evaluated fatigue and cognitive impairment monthly using
FACT-F questionnaire [24].
2.5. Statistical Analysis
We conducted statistical data analyses using GraphPad Prism version 6.0 software similarly to the
first proof-of-concept study [23]. In short, we used nonparametric statistical methods, median and
interquartile range (IQR) for continuous variables. For univariate comparisons, we used Wilcoxon
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matched-pairs signed-rank test and Mann–Whitney-U test or Fisher’s exact test for independent groups.
A two-tailed p-value of <0.05 was considered to be statistically significant.
3. Results
3.1. Patient Characteristics and IA Treatment
All of the patients had an infection-triggered onset of ME/CFS and all showed elevated levels of
ß1/ß2-AR-AB and M3/M4-AR-AB (except patient 8 only ß2). Bell disability scale indicating the severity
of disease ranged from 30–75 (median of 45) and the median was significantly higher than before the
first IA study in 2016 (median of 30, range 10–50, p = 0.01, Figure S1) corresponding to an increase of
the ability to perform desk work from 2–3 h to 4 h daily [25]. Table 1 shows patient characteristics.
The intervals between the cycles were extended in the present protocol in order to improve the
tolerability of the treatment. Five cycles of IA were conducted within eight days (day 1, 2, 4, 6, and 8).
A citrate-based anticoagulation was used. We observed a drop of fibrinogen and albumin levels in a
similar extent compared to the first study (Figure S2). No albumin substitution was necessary and there
was no bleeding episode. Immediately after the fifth IA, all apatients received 10 g IgG intravenously,
as compared to 25 g in the first proof-of-concept study.
Table 1. Patients’ characteristics.
Patient No. from
2016 Study
Gender Age ME/CFS Onset
Disease Severity
Bell Score before IA1
Disease Severity
Bell Score before IA2
2 f 60 2011 30 45
4 m 50 2000 20 35
5 f 37 2012 40 75
6 f 32 2002 50 60
8 f 32 2005 10 30
3.2. Course of IgG and Autoantibodies
Before IA treatment, the total IgG levels were within the normal range in all patients (median
9.85 g/L, range 8.99 to 13.26 g/L). As expected, the absolute IgG levels were strongly reduced already
after the first IA with a minimum IgG level after the fourth IA (median 0.95, range 0.64 to 1.68 g/L).
The absolute level of autoantibodies decreased in a comparable way, as shown in Figure 2. Figure 3
shows the relative decrease in IgG and autoantibody concentrations in each individual patient. The IgA
and IgM levels did not change significantly (Figure S3).
3.3. Clinical Course
Before IA1, all of the patients suffered from severe exhaustion and post-exertional malaise grade
6–10 (0 none, 10 most severe symptoms) and from concentration impairment grade 4–10, muscle pain
(n = 4), and immune-associated symptoms of sore throat, flu-like symptoms, and painful lymph nodes
(Figure 4). Two years later, before the IA2, the total score of symptoms had improved in three of the
five patients (patient 2, 4, and 5), was similar in patient 6, and slightly worse in patient 8 (shown in
Figure 4). However, the Bell score was improved in patient 8 from 10 to 30 as she could not walk before
the first IA due to marked muscle fatigue, which had considerably improved following the IA1.
The assessment of symptoms was performed daily during the IA2 (Figure 5) and afterwards
monthly until month 12 (Figure 6). Interestingly, the course of symptoms was similar in IA2 as
compared to IA1. Patients 2 and 8 (Figure 5) showed rapid improvement of all symptoms during IA2.
In patient 4, muscle pain and immune symptoms improved. In patient 5, muscle pain disappeared
during IA and cognitive and immune symptoms slightly improved, but fatigue worsened. Patient 6,
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who had a short-term improvement of cognition during IA1, had no improvement during the IA2.
Patients 5, 6, and 8 had a transient worsening of symptoms after IgG infusion at day eight.
The course of symptoms during the 12 months after IA2 was again similar to the IA1 in all
patients (Figure 6). Patient 2, 4, and 5 again showed a sustained improvement in symptoms for ten
to 12 months, although with some fluctuations. Patient 8 had marked improvement for six months.
When patient 8 worsened at month six a further IA treatment was offered, but she preferred to receive
plasmapheresis on month 9 in her local hospital, which again almost completely resolved the symptoms.
Patient 6, who had a two months improvement during IA1 with consecutive worsening, experienced an
immediate worsening under IA2.
Further patients filled in FACT-F questionnaire monthly, assessing the severity of fatigue showing
a similar course to IA1. A strong improvement of fatigue was reported by patients 5 and 8, while patient
2 and 4 only had a slight improvement of fatigue in accordance to the fatigue that was reported in the
symptom score (Figures 6 and 7).
Regarding tolerability, three of the five patients had a worsening of fatigue from day 6 on during
IA1, but two patients had marked worsening of fatigue also during IA2.
Figure 2. Absolute IgG and autoantibody levels during treatment. Total and ß1, ß2, M3, and M4 IgG
in the serum before and during IA. X indicates the point of time when IA was conducted. Gray area
indicates reference range of serum levels.
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Figure 3. Relative IgG and autoantibody levels during treatment. Relative changes of total IgG and ß1,
ß2, M3, and M4 autoantibody concentration in the serum before and during first IA 2016 (left) and
second IA (right). The daily levels are depicted as x-fold change to day 1 level for each single patient.
X indicates the single IA, arrow when patients received 10 g IgG i.v.
Figure 4. Patients condition before first and second treatment. Symptom scores before first IA (triangle)
and second IA (circle). Symptoms are indicated as 0 (absent) to 10 (most severe). Sum of each patient is
displayed in the upper right corner (left: IA1, right: IA2).
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Figure 5. Development of symptoms during IA. Symptom scores for fatigue, cognitive score, muscle
pain and immune score during IA1 (left) and IA2 (right) are shown for each patient (3 unchanged,
4 slight, 5 marked improvement, 6 complete disappearance, 2 slight increase, 1 marked increase).
The line indicates level 3 for unchanged symptoms.
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Figure 6. Development of symptoms during 12 months follow-up. Symptom scores for fatigue,
cognitive score, muscle pain and immune score during first IA (left) and second IA (right) are shown
for each patient (3 unchanged, 4 slight, 5 marked improvement, 6 complete disappearance, 2 slight
increase, 1 marked increase). The line indicates level 3 for unchanged symptoms.
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Figure 7. FACT-F score follow-up. Score of FACT-F questionnaire assessing severity of fatigue before
and up to 12 months after first IA (left) in comparison to second IA (right) for each patient. Scoring of
FACT-F fatigue questionnaire ranges from 0 (strongly fatigued) to a maximum of 52 (without fatigue).
Dotted line indicates the individual pretreatment score before IA.
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4. Discussion
In our first proof-of-concept study in ten patients with infection-triggered ME/CFS, we observed
that IA caused a rapid decrease in ß2AR-AB levels in nine of ten patients. Moreover, an improvement in
clinical symptoms could be achieved in seven of the patients, which lasted, in three patients, for more
than 12 months [23]. Furthermore, the ME/CFS patients frequently suffer from endothelial dysfunction,
which was also improved following IA [26]. These results provided first evidence that IA may be
a therapeutic option in ME/CFS patients and the rapid relief from clinical symptoms may be explained
by the removal of autoantibodies. We also found a decrease of memory B cells following IA1 and
significantly lower ß2AR-AB after six months, suggesting that IA may have an effect on autoreactive
memory B cells as well. Repeated IA were shown in other autoimmune diseases to enhance efficacy or
induce a second remission [19–21].
Therefore, we conducted a conformational study in five patients with a clinical response in the
first study and retreated them with second IA. Remarkably, disease severity was still improved before
IA2 when compared to before IA1 two years earlier, with a higher Bell score in all five patients. During
IA1, two patients had considerable worsening of all ME/CFS symptoms, which may be attributed to
their enhanced susceptibility to stress and changes in the water and electrolyte balance. In addition,
four patients had worsening of fatigue during IA1. Despite longer intervals between the cycles during
IA2, two patients, however, had again marked worsening of fatigue. When compared to the IA1
protocol, the IA2 protocol resulted in a comparable decrease in IgG and autoantibody concentrations.
As in the IA1 study, the clinical symptoms that were associated with ME/CFS were assessed
with a questionnaire quantifying the most important symptoms of the CCC [1,17] The descriptions of
subjective self-reported symptom correlated well with the objective activity tracking of steps per day
in IA1 [23]. Similar to IA1, we could observe an improvement of several clinical symptoms during IA
in four of five patients lasting with some fluctuations for 6–12 months. The patient who experienced
marked worsening also only had a moderate and transient improvement in symptoms after IA1.
Of interest is that one patient received a plasmapheresis nine months after IA2, which again
almost completely resolved the symptoms. Plasmapheresis constitutes another possibility to eliminate
pathogenic antibodies by exchange of patient with donor plasma, but its efficacy has not been assessed
in ME/CFS to our knowledge. In other diseases, it was shown that IA and plasmapheresis both resulted
in comparable clinical efficacy [27].
Our observations are in line with the clinical results of IA in neuro-immunological diseases
or dilative cardiomyopathy [27,28]. Dilative cardiomyopathy is often associated with ß1AR-AB,
which could be effectively reduced by IA leading to a long-term improvement in the clinical outcome [28].
Clinical features of a refractory lupus erythematosus, like proteinuria, SLEDAI (activity index for
systemic lupus erythematosus disease) and autoantibody concentrations, could be successfully
improved and stabilized at levels that meet the criteria of remission in the long term by the regular use
of an IA for up to ten years [20].
In our first study, a sustained decrease of ß2 IgG was observed at month six, which could
also be shown in responder to the rituximab therapy [11]. The long-term decline of autoantibody
concentrations may be explained due to enhanced B cell differentiation with a higher apoptosis rate of
autoreactive B cells and consecutive loss of short living autoreactive plasma cells [11]. This hypothesis
would correspond to the observed decrease in ß2AR-AB six months after IA1, when the levels of
total IgG and tetanus and pneumococcal IgG corresponded to the pretreatment ones [11]. However,
the effect of adrenergic stimulation on immune cells is complex and does not directly correlate with
levels of ß2AR-AB [14]. ß2AR-AB belong to a network of natural antibodies against G-protein coupled
receptors, which has been described to be dysregulated in various autoimmune diseases [29]. In our
recent study, we found that ß2AR-AB activate the ß2AR. The ß2AR activation by IgG was attenuated
in ME/CFS patients, which could explain many symptoms of ME/CFS [14]. As IA removes total
IgG, we have, however, no direct evidence from our study that the removal of ß2AR itself leads to
improvement. Several other autoantibodies were reported in ME/CFS [6].
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In this study, the patients received a single IgG infusion at the end of IA protocol in order to partially
restore the strong IgG depletion. IgG treatment is also effective in autoantibody-mediated autoimmune
diseases [30]. Doses applied for treatment of autoimmune disease are usually above 1.0 g/kg body
weight. In the current study, an approximately 10-fold lower and single dose of IgG was applied,
so that the treatment effect due to the IgG administration seems unlikely.
Limitations of the current trial are the small number of patients and the lack of a placebo
control group. One aspect of this study was to investigate the reproducibility of the effect of IA
on clinical symptoms in a subset of patients from the first study. In all patients, the effect of IA
treatment could be reproduced. Although some placebo-treated patients showed an improvement
in randomized placebo-controlled trials (RCT) in ME/CFS [18,31], the reproducibility and the long
lasting symptom improvement associated with a significantly decreased frequency of memory B cells,
increased frequency of plasma cells, and lower autoantibody concentration six month after IA1 rather
speaks against an unspecific effect. Further, although being considered unlikely, IgG replacement at
the end of IA may have an immunomodulatory effect. Therefore, we have intentionally kept the IgG
dose in the current study lower to minimize this potential effect.
Our study was designed to get further evidence for efficacy and tolerability prior to performing
a consecutive RCT. We have evidence for similar clinical and immunological efficacy of this schedule.
5. Conclusions
In summary, the current study provides further evidence that IA is effective in ME/CFS. This
result warrants further studies of repeat IA therapy to maintain clinical remission, as shown for
other autoimmune diseases [20]. Another option is to include IA in a therapy algorithm as initial
therapy for autoantibody-positive ME/CFS patients in order to achieve rapid symptom relief and,
therefore, shorten the known time latency of four months or longer until the onset of efficacy of B
cell-targeting therapies.
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Abstract: The inflammatory neuropathies are disabling conditions with diverse immunological
mechanisms. In some, a pathogenic role for immunoglobulin G (IgG)-class autoantibodies is
increasingly appreciated, and immunoadsorption (IA) may therefore be a useful therapeutic option.
We reviewed the use of and response to IA or plasma exchange (PLEx) in a cohort of 41 patients with
nodal/paranodal antibodies identified from a total of 573 individuals with suspected inflammatory
neuropathies during the course of routine diagnostic testing (PNAb cohort). 20 patients had been
treated with PLEx and 4 with IA. Following a global but subjective evaluation by their treating
clinicians, none of these patients were judged to have had a good response to either of these treatment
modalities. Sequential serology of one PNAb+ case suggests prolonged suppression of antibody
levels with frequent apheresis cycles or adjuvant therapies, may be required for effective treatment.
We further retrospectively evaluated the serological status of 40 patients with either Guillain-Barré
syndrome (GBS) or chronic inflammatory demyelinating polyneuropathy (CIDP), and a control
group of 20 patients with clinically-isolated syndrome/multiple sclerosis (CIS/MS), who had all been
treated with IgG-depleting IA (IA cohort). 32 of these patients (8/20 with CIDP, 13/20 with GBS, 11/20
with MS) were judged responsive to apheresis despite none of the serum samples from this cohort
testing positive for IgG antibodies against glycolipids or nodal/paranodal cell-adhesion molecules.
Although negative on antigen specific assays, three patients’ pre-treatment sera and eluates were
reactive against different components of myelinating co-cultures. In summary, preliminary evidence
suggests that GBS/CIDP patients without detectable IgG antibodies on routine diagnostic tests may
nevertheless benefit from IA, and that an unbiased screening approach using myelinating co-cultures
may assist in the detection of further autoantibodies which remain to be identified in such patients.
Keywords: Inflammatory neuropathy; chronic inflammatory demyelinating polyneuropathy;
Guillain-Barré syndrome; multiple sclerosis; paranodal antibodies; plasmapheresis; plasma
exchange; immunoadsorption
1. Introduction
The inflammatory neuropathies are a heterogeneous group of disorders in which peripheral
nerve function and structure are disturbed by largely ill-defined immunological mechanisms [1]. They
can broadly be divided into acute and chronic forms, typified by the umbrella terms Guillain-Barré
syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), respectively.
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Humoral and cellular immunity are likely to play a role in the pathogenesis of both syndromes. For
some clinically defined subtypes, a role for the humoral immune system and pathogenic autoantibodies
appears to be more prominent [2,3], but particularly at the level of the individual patient, a direct and
consistent link between the clinical syndrome, serological profile, and underlying immunopathological
mechanism remains difficult to establish.
Randomised controlled trials have demonstrated that therapeutic plasma exchange (PLEx) speeds
up recovery from GBS [4], and provides at least a short-term improvement in disability in CIDP [5]. In
both conditions there is evidence that intravenous immunoglobulin (IVIg) has similar efficacy [6,7].
Two small, randomised studies have compared immunoadsorption (IA) with PLEx or IVIg in CIDP.
Response rates to IA (6/9 using tryptophan-based columns [8] and 4/5 using protein A [9]) were
not significantly different to their respective comparators. The trial comparing IA (using protein
A) with IVIg had a high drop-out rate and was excluded from the relevant Cochrane review due
to a high risk of bias [9]. Two further reports described the crossover from PLEx to IA in CIDP, in
a single patient each, reaching opposite conclusions about which was more efficacious [10,11]. A
number of retrospective case series and case reports have favourably evaluated immunoadsorption in
both GBS and CIDP [12–21]. A retrospective Japanese report of IA in GBS found that patients who
received IA within 6 days of onset of their neuropathy had a more rapid improvement in disability
compared to those who received supportive care alone, whereas patients who received IA later than
this in their disease course did not [22]. However, high-quality evidence demonstrating the efficacy
of IA in the inflammatory neuropathies is lacking [23]. There is also some evidence that apheresis
can improve recovery from multiple sclerosis relapses, and these approaches are often used after
inadequate responses to corticosteroids [24,25].
Certain subtypes of GBS are associated with immunoglobulin (Ig) G ganglioside antibodies [26],
with a handful of small studies showing an effective reduction of antibody titres using IA [19,27]. More
recently a subset of CIDP-like neuropathies have been linked to predominantly IgG4-subclass antibodies
directed against nodal or paranodal cell-adhesion molecules [28–32]. It has been speculated that
patients with such antibodies may respond particularly well to selective IgG immunoadsorption [33].
A recent case series of four patients with CIDP and neurofascin-155 (NF155) antibodies reported that
PLEx was effective in 3, and partially effective in 1, whilst tryptophan-based IA was ineffective in one
such patient [34].
There are of course substantial differences between PLEx and IA. The former removes a broad
range of circulating molecules and requires the use of replacement fluid, typically fresh frozen plasma,
or albumin. Replacement fluid is not required in IA, and the range of circulating factors removed is
more limited. This is advantageous in reducing complications, such as those due to the unwanted
removal of coagulation factors [35], but may also lead to a loss of therapeutic effect if this depends on
the removal of pro-inflammatory cytokines, or other pathogenically-relevant molecules, rather than
immunoglobulins. It is also important to appreciate that there are variations in the biological effects
between the different types of IA, which may also influence their clinical efficacy. For example, Yuki
and colleagues have previously demonstrated that tryptophan-based columns are more effective than
phenylalanine for adsorbing anti-ganglioside antibodies [36]. IA using protein A or synthetic ligands
has been proposed as a method to remove a larger fraction of circulating IgG more selectively and
quickly, whilst more modestly affecting IgM and IgA levels, and leaving complement, albumin and
fibrinogen largely unaffected [37].
Intuitively, it may be assumed that patients who respond to “Ig-selective” IA do so because
pathogenic Ig is being removed from the circulation. However, previous assessments of IA efficacy
rarely report serological status. It is therefore currently unclear as to whether the presence of known
serum autoantibodies in GBS and CIDP prospectively identifies a subpopulation of patients who are
likely to respond more favourably to IA. It is also unclear as to whether any particular IA system or
treatment programme is more likely to produce a positive outcome.
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In this study we provide a retrospective evaluation of apheresis in two serologically-defined
patient cohorts. We first reviewed the subjective clinician-reported overall impression of response
to IA or PLEx in a cohort of neuropathy patients identified during routine diagnostic testing (PNAb
cohort), and compared patients in which nodal/paranodal antibodies were or were not detected. We
present the detailed case history and parallel serological analysis of a patient with NF155 antibodies
who was treated with IA. Finally, we perform a retrospective analysis of the serological status of a
sample of 60 patients who had been treated with IgG-depleting IA (IA cohort) and compare this with
clinician-reported outcomes.
2. Experimental Section
2.1. Paranodal Antibody (PNAb) Patient Cohort
Since 2015, 88 patients with confirmed or suspected inflammatory neuropathies presenting to the
neuropathy clinic in Oxford have been recruited to an observational study. This study was approved by
the National Health Service (NHS) National Research Ethics Service Committee (South Central–Oxford
A, 14/SC/0280). Patients recruited prior to 2017 were tested retrospectively, and those recruited
from 2017 prospectively, for nodal/paranodal antibodies by the methods described in Appendix A.
Since August 2017, serum samples from a further 537 external patients with confirmed or suspected
inflammatory neuropathies have been received for diagnostic nodal/paranodal antibody testing by the
Oxford laboratory. Clinical information was requested for all patients, including details of treatments
used, and a clinician-led, subjective, overall impression of their efficacy.
2.2. IA Patient Cohort
The IA cohort consisted of 60 subjects (20 with CIDP, 20 with GBS, and a control group of 20 with
multiple sclerosis/clinically-isolated syndrome, MS/CIS) who were selected from patients treated with
IA between June 2013 and January 2018 in the University of Ulm, Department of Neurology based on
the inclusion criteria outlined below. The study was reviewed by the appropriate ethics committee of
the University of Ulm (approval number 20/10) and was performed in accordance with the ethical
standards of the Declaration of Helsinki from 1964. Written informed consent for the sample collection
was obtained from all patients participating in this study.
2.2.1. CIDP
All patients with CIDP fulfilled the EFNS criteria for possible, probable, or definite CIDP, had
a continuously progressive course of disease, and had previously received several cycles of steroids
(n = 5), IVIg (n = 2) or both (n = 13), with insufficient response. Fifteen patients who had previously
received IVIg showed further disease progression under IVIg therapy, therefore we opted for a new
therapeutic approach with IA. In 5 patients who had never received IVIg we chose IA instead of IVIg
based on our favourable clinical experience with IA in CIDP. Two patients had never been treated with
prednisolone because of severe diabetes mellitus. Further treatments included azathioprine (n = 5),
cyclophosphamide (n = 1), mycophenolate mofetil (n = 2), and methotrexate (n = 1). Assessment of
the clinical outcome directly and 2 weeks after IA was based on the Inflammatory Neuropathy Cause
and Treatment (INCAT) score [38] and the Ulmer CIDP score, which includes the INCAT, the Oxford
muscle strength grading scale (Medical Research Council, MRC), and vibration sensitivity testing [33].
2.2.2. GBS
All patients with GBS showed the typical clinical picture including rapidly progressive bilateral
limb weakness and sensory deficits, hypo-/areflexia, electrophysiological signs of demyelination,
and increased protein levels in cerebrospinal fluid. Anti-ganglioside antibodies were not tested
prospectively. In contrast to CIDP and MS, IA was a first-line therapy in 4 GBS patients, and used as
an escalation therapy in 9 more. In order to establish equally sized subgroups, the GBS group included
35
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7 patients who received PLEx rather than IA. Classification of the clinical outcome (no improvement,
equivocal improvement, partial improvement, large improvement) directly after the last treatment
was retrospectively based on the neurological examination as documented in the medical records
(discharge letter) of each patient.
2.2.3. MS/CIS
All patients fulfilled the 2017 MacDonald diagnostic criteria for MS [39] or CIS. All patients treated
with IA suffered from a steroid-refractory relapse, i.e., an acute relapse without complete remission
after one or more cycles of high dose intravenous methylprednisolone (IVMP) therapy (at least 3 × 1000
mg). Assessment of the clinical outcome directly after the last treatment was based on the Expanded
Disability Status Scale (EDSS).
2.3. IA Treatment
One cycle of IA consisted of five treatments on 5 consecutive days. The total plasma volume
of each patient was calculated using body weight, height, and haematocrit. Two plasma volumes
were processed during the first treatment, and 2.5 plasma volumes were processed during all the
subsequent treatments. The Adsorber system (ADAsorb, medicap clinic GmbH, Ulrichstein, Germany)
contained two regenerating protein A columns (Immunosorba, Fresenius Medical Care, Bad Homburg,
Germany).
2.4. Sample Collection and Storage
Eluate samples were obtained during each IA treatment and buffered with bicarbonate (pH
7.0). Serum samples were obtained before and after each IA treatment. A standardized protocol
for serum and eluate collection was applied as previously recommended [40]. All biosamples were
stored according to the predefined standard operating procedure (SOPs) at the local biobank in Ulm at
minus 80 ◦C within two hours. Later they were transferred for measurement on dry ice to Oxford for
further analysis.
2.5. Serological Analysis
Sera and eluates from the 3 patient cohorts and from control subjects were analysed using a
nodal/paranodal antibody cell-based assay, paranodal, ganglioside and sulfatide ELISA, and against
myelinating co-cultures. Methodological details for these experiments are given in Appendix A.
3. Results
3.1. Nodal/Paranodal Antibody (PNAb) Diagnostic Cohort
3.1.1. Demographics, Clinical and Serological Characteristics
Since August 2018, serum samples from 537 different patients with confirmed or suspected
inflammatory neuropathies have been received for diagnostic nodal/paranodal antibody testing by the
Oxford laboratory, and we have tested a further 88 patients from our own research cohort. Overall,
42/625 patients (6.7%) were positive for nodal/paranodal antibodies (PNAb+), comprising 16 (2.6%)
with NF155 specific antibodies, 1 (0.2%) with NF186 specific antibodies, 6 (1%) with pan-neurofascin
antibodies, 12 (1.9%) with contactin-1 (CNTN1) antibodies and 7 (1.1%) with contactin-associated
protein (Caspr1) or CNTN1/Caspr1-complex antibodies. The median age of the PNAb+ patients
was 58 (range 15 to 79) and 30/42 (71.4%) were male. The initial clinical diagnosis was CIDP in 28
(66.6%), GBS in 13 (31.0%) and atypical multifocal motor neuropathy in 1 (2.4%). In one patient, the
diagnosis of CIDP was subsequently revised to motor neuron disease; the diagnosis of an inflammatory
neuropathy was retained at follow up in all other antibody positive cases. The remaining 583 patients
were paranodal antibody negative (PNAb-negative), with clinical data available for 185 patients. The
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median age of the PNAb-negative patients was 62 (range 4 to 90) and 120/185 (64.9%) were male. The
initial clinical diagnosis was CIDP in 100 (53.8%), combined central and peripheral demyelination in 3
(1.6%), GBS in 38 (20.4%), and multifocal motor neuropathy in 16 (8.6%). In 9/131 (6.9%) patients for
whom follow up data was available, the diagnosis was subsequently revised away from that of an
inflammatory neuropathy. Summary demographic and clinical details of the subgroups of apheresis
treated PNAb-positive and PNAb-negative patients are given in Table 1. There was no significant
difference in the median age, sex distribution, clinical diagnosis, or other serological results between
the 2 subgroups. There was a non-significant trend towards more severe disease and more frequent
IgG and less frequent IgM paraprotein detection in PNAb-positive patients. The frequencies of prior
IVIg, steroid, PLEx and immunosuppressant use was also similar between the groups, while rituximab
and IA were significantly more likely to have been used in the PNAb-positive group. PLEX aside,
there was, however, no statistically significant difference in the clinician reported responses to these
therapies between the 2 groups, although there was a trend to rituximab being more often judged
effective in the PNAb-positive compared to PNAb-negative group.







Age: median, (range) 58 (35–79) 62 (5–90) ns p = 0.94 Mann-Whitney
Male sex: n, (%) 16 (76.2%) 23 (69.7%) ns p = 0.76 Fisher’s exact
Initial clinical diagnosis:
• GBS: n (%) 6 (28.6%) 10 (30.3%) ns p > 0.99 Fisher’s exact(GBS or not)
• CIDP: n (%) 14 (66.7%) 18 (54.5%) ns p = 0.41 Fisher’s exact(CIDP or not)
• Other: n (%) 1 (4.7%) 5 (15.1%) ns p = 0.39 Fisher’s exact(Other or not)
Peak severity/nadir mRs
(median, range) 5 (2–6) 4 (2–5) ns p = 0.10 Mann-Whitney
Other serology: n/n (%)
Any ganglioside Ab 1/16 (6.3%) 3/18 (16.7%) ns p = 0.60 Fisher’s exact
• GM1 1/16 (6.3%) 2/18 (11.1%) ns p > 0.99 Fisher’s exact
• GQ1b 0/16 1/18 (5.6%) ns p > 0.99 Fisher’s exact
MAG 0/4 1/8 (12.5%) ns p > 0.99 Fisher’s exact
Paraprotein 2/17 (11.8%) 6/26 (23.1%) ns p = 0.45 Fisher’s exact
• IgM 0/17 5/26 (19.2%) ns p = 0.14 Fisher’s exact
• IgG 2/17 (11.8%) 1/26 (3.8%) ns p = 0.55 Fisher’s exact
Treatment
% treated (% of those judged to have good response)
Difference in
proportion treated/proportion with good response
IVIg 90.5 (5.3%) 87.9% (3.4%) ns/ns p > 0.99/p > 0.99 Fisher’s exact
Steroids 85.7% (0) 75.8% (8%) ns/ns p = 0.50/p = 0.50 Fisher’s exact
PLEx 95.2% (0) 100% (24.2%) ns/* p = 0.39/*p = 0.01 Fisher’s exact
IA 19% (0) 0 (0) ***/ns ***p < 0.001/ p > 0.99 Fisher’s exact
Rituximab 66.7% (64.3%) 18.2% (16.7%) ***/ns ***p < 0.002/p = 0.14 Fisher’s exact
Other immuno-suppression 33.3% (28.6%) 24.2% (12.5%) ns/ns p = 0.54/p = 0.47 Fisher’s exact
GBS, Guillain-Barré syndrome; CIDP, chronic inflammatory demyelinating polyneuropathy; GM1,
monosialoganglioside GM1; GQ1b, tetrasialoganglioside GQ1b; MAG, myelin associated glycoprotein;
IVIg, intravenous immunoglobulin; PLEx, plasma exchange; IA, immunoadsorption, * and ***, indicate
statistical significance.
3.1.2. Physician-Reported Subjective Evaluation of Responses to Plasma Exchange or
Immunoadsorption
Of the PNAb+ patients, 17 were treated with PLEx alone, 1 with IA alone, and 3 with both
modalities. Protein A columns were used for three of the IA treated patients, the other (described in
detail below) was treated with a GAM-peptide-ligand-based column (Globaffin, Fresenius Medical
Care (UK) Ltd, Sutton-in-Ashfield, UK). Serial disability measures are available for only one other
PNAb+ patient: a 68-year-old lady with a clinical diagnosis of GBS. Neither her overall neuropathy
limitations score (ONLS, 12/12) nor inflammatory neuropathy Rasch-built overall disability score
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(iRODS, 0/48) improved following 2 cycles 5 treatments of PLEx starting on days 40 and 69 of her
illness, prior to her death on day 110 from infectious complications. For all other PNab+ patients,
only clinician-reported, retrospective, and subjective evaluations of response were available. None of
the treating clinicians judged that either PLEx or IA had produced a subjectively “good” response
in any of the PNAb+ patients. With PLEx, 5 patients (25.0%) were reported as having had a partial
response, 2 (10.0%) an equivocal response, 12 (60.0%) no response, and one to have deteriorated (5.0%).
With IA, 1 (25%) partial response, and 1 (25%) equivocal response were reported, with 2 patients (50%)
reported as showing no response (Figure 1A,B). The proportion of PNAb+ patients subjectively judged
as showing a partial or better response to PLEx (25.0%) versus IA (25.0%) was identical.
Figure 1. Physician-reported subjective evaluation of response to plasma exchange or immuno-
adsorption in paranodal antibody positive and negative patients. Paranodal antibody positive patients
treated with (A) plasma exchange (n= 17), (B) immunoadsorption (n= 4), or (C) either modality (n = 21),
compared to (D) paranodal antibody negative patients (n = 33) (all treated with plasma exchange).
Of the PNAb-negative patients, 33 were treated with PLEx: 8 patients (24.2%) were subjectively
reported as having a good response, 10 (30.3%) a partial response, 1 (3.0%) an equivocal response, 8
(24.2%) no response, and 2 (6.1%) as deteriorating. For 4 patients, the response to PLEx was not reported.
Amongst the 3 ganglioside antibody positive patients, 2 were reported as having a partial response,
and 1 no response, to PLEx. Apheresis, with or without IA, was significantly more likely to have
been reported by treating clinicians to have produced partial or better response in the PNAb-negative
patients (62.1%) compared to the PNAb+ patients (25.0%) (p = 0.01, Fisher’s exact test, OR 4.9 (95%
CI 1.52 to 14.88) (Figure 1C,D). It should be emphasised that this is a comparison of the physicians’
subjective overall impression of response, rather than an evaluation of the true efficacy, or otherwise,
of these treatments.
3.2. Detailed Profile of an NF155 Antibody Positive Patient Treated with Immunoadsorption
This 46-year-old male first presented to neurology in July 2019 with a 6-week history of ascending
numbness and paraesthesia in his feet, then hands. He had lost the ability to run and found walking
to be unsteady. On examination, power was full, but there was global areflexia with distal sensory
loss to temperature, pin-prick, vibration and proprioception. His gait was broad-based and unsteady
and Rhomberg’s test was positive after 20 s of eye closure. There was a postural tremor of both hands
without cerebellar or extrapyramidal signs. The presentation was felt to be consistent with sensory
ataxic CIDP. Neurofascin-155 antibody mediated disease was high in the differential. A positive result
on the NF155 CBA and ELISA was duly returned 2 days later, at an initial titre of 1:6400. IgG4 was the
dominant subclass, with IgG1 and IgG2 also represented (Figure 2A,B). CSF was acellular with an
elevated protein (1.8 g/L). Nerve conduction studies showed absent median but preserved sural sensory
nerve action potentials. Distal motor latencies and F-wave latencies were significantly prolonged, with
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slowing of intermediate motor conduction velocities. There was conduction block without temporal
dispersion in the sampled peroneal nerve between the ankle and fibular head. Pulsed dexamethasone
was commenced 4 days later (40mg per day for 4 days every 4 weeks for 3 cycles). There was no
change in the examination findings. A progressive deterioration in symptoms and disability measures
prompted a trial of IVIg (2 g/kg over 5 days) which resulted in a pompholyx-type skin rash, and no
neurological benefit over the next 6 weeks. Approval was then sought for rituximab, and IA was
arranged as a potential temporising measure.
Figure 2. Serological results of NF155 antibody positive patient at baseline and during IA treatment.
(A) Serum contains IgG (green) which binds to the cell membrane of NF155-transfected HEK293T cells,
and co-localises with a commercial pan-neurofascin antibody (red). No signal is seen with NF186
or CNTN1/Caspr1-transfected cells. (B) The predominant IgG subclass of the NF155 antibodies is
IgG4, with IgG1>IgG2 also represented. (C) The antibody signal intensity at 1:100 before, during and
immediately after the first cycle of IA shows a progressive decline. (D) NF155 antibody titre (red) and
total IgG levels (blue) over 2 cycles of IA, before and after rituximab.
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Four treatment sessions of 2–2.5 plasma volumes were given on 4 consecutive days using a multiple
pass, GAM-peptide-ligand-based column (Globaffin, Fresenius Medical Care Ltd, Sutton-in-Ashfield,
UK). IA was effective in rapidly and substantially reducing the NF155 antibody titre (Figure 2C),
but this had returned to baseline by 1 month (Figure 2D) and there was no observed clinical benefit.
Rituximab was then given (1g on 2 occasions 2 weeks apart) followed by a second cycle of 5 treatments
sessions of IA 1 month later. This was again associated with a rapid and substantial reduction in NF155
antibody titre, which on this occasion recovered more slowly and incompletely (Figure 2D). This more
persistent suppression of antibody titres was associated with a progressive improvement in symptoms
and disability, which is currently ongoing (Figure 3).
Figure 3. Antibody titres and outcome/disability measures during treatment of a patient with an
NF155-antibody-mediated neuropathy. (A) Patient global rating of change after treatment with
dexamethasone, IVIg, IA and rituximab. (B) NF155 antibody titre. (C) Inflammatory neuropathy
Rasch-built Overall Disability Score. (D) Sensory sum score. (E) Overall neuropathy limitations score.
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3.3. Demographics and Clinical Characteristics of the IA Treated Cohort
3.3.1. CIDP
Details of this cohort are given in Appendix B (Table A1). Sixteen of these 20 CIDP patients have
been described in a previous publication [33]. 16/20 (80%) were male. At the start of IA treatment, the
cohort had a median age of 66 (range 27 to 80), and a median disease duration of 95.5 months (range
63 to 139). All had progressive disease and met the European Federation of Neurological Societies
(EFNS) criteria for definite, probable, or possible CIDP [41]. 18/20 had been previously treated with
corticosteroids and 14/20 with IVIg, with sub-optimal responses. Six patients were treated with at
least one of azathioprine, cyclophosphamide, mycophenolate mofetil or methotrexate. Nine patients
received multiple (range 2–9) cycles of IA. Five patients showed improvements in their Inflammatory
Neuropathy Cause and Treatment (INCAT) disability score when assessed 2 weeks after initial IA
treatment, and 8 patients showed substantial improvements (at least 10 points) in the CIDP score.
3.3.2. GBS
Details of this cohort are given in Appendix B (Table A2). 10/20 patients (50%) were male. At the
start of IA or PLEx treatment, the cohort had a median age of 66 (range 31 to 89). IA was applied to
13/20 patients. IA was used as a first-line therapy in 3, as a second-line therapy (after unsuccessful
treatment with IVIg) in 9, and as a third-line therapy (after both IVIg and PLEx) in 1 patient. This
subgroup was supplemented with 7 patients who received PLEx, instead of IA. In these patients,
PLEx was used as a first-line therapy in 6, and as a second-line therapy (after IVIg) in 1 patient. 18/20
patients received 1 cycle of IA or PLEx, and only 2 patients received 2 cycles. 4/20 (3/13 IA, 1/7 PLEx)
patients showed no clinical improvement after the last treatment, 3 patients (2/13 IA, 1/7 PLEx) showed
equivocal improvement, 8 patients (4/13 IA, 4/7 PLEx) showed partial improvement, and 5 patients
(4/13 IA, 1/ PLEx) showed large improvement.
3.3.3. MS/CIS
Details of this cohort are given in Appendix B (Table A3). 15/20 patients (75%) were female. At the
start of IA treatment, the cohort had a median age of 29 (range 15 to 57). Patients were diagnosed with
MS (16/20) or CIS (4/20), and had all been treated unsuccessfully with at least one cycle of high-dose
intravenous methyl prednisolone (MP). 8 patients had received 2 or more cycles of high-dose IVMP.
11/20 patients showed an improvement of EDSS after the last IA treatment, while 9/20 patients did
not improve.
3.4. Glycolipid and Nodal/Paranodal Antibodies in the IA Cohort
Pre-treatment serum samples from the IA cohort were tested for sulfatide and GM1- and
GQ1b-ganglioside IgG antibodies by ELISA. None of these sera were positive on these assays. Serum
samples taken pre and post-treatment, as well as first treatment session eluates from the IA cohort
(20 CIDP, 20 GBS and 20 MS/CIS patients), were tested by both cell-based assay (CBA) and ELISA
for antibodies to nodal (neurofascin-186) and paranodal (neurofascin-155, contactin-1 and Caspr) cell
adhesion molecules. None of the sera were positive on either assay. One eluate from the MS/CIS
cohort (patient 09) was positive on the neurofascin-155 CBA (blind scored as ‘2+’ at 1:100, end-point
titre 1:200, Figure 4A) (For scoring method see Appendix A.1). The sole detected subclass was IgG1.
The corresponding pre-treatment serum was negative for NF155 antibodies at 1:100, the standard
screening titre for this assay, but scored 3+ when repeated at 1:20. Two further eluates, one from
the MS/CIS cohort and one from the CIP cohort, also produced faint membrane binding (1+) on the
neurofascin-155 CBA that was not sufficient to be called positive at 1:100. Repeat testing of these
eluates at 1:20 increased the signal to 2+ and 3+ respectively. However, this titre is below the usual
positivity cut-off for this assay, and no signal was produced with any of the IgG subclass-specific
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secondary antibodies. All of these eluates were negative on the neurofascin-155 ELISA and negative for
all other antigens by both CBA (including neurofascin-186, Figure 4B) and ELISA (results not shown).
 
Figure 4. Nodal/paranodal cell-based assays. (A) MS/CIS eluate weakly positive on the neurofascin-155
CBA at 1:100 (Score 2+, end-point titre 1:200) and (B) negative on the neurofascin-186 CBA. (C) Strong
positive at 1:100 (Score 4+, end-point titre 1:3200) from the antibody positive CIDP cohort shown
for comparison.
3.5. Screening the IA Eluates for Novel Antibodies Using Myelinating Co-Cultures
In this experiment, eluates from the first treatment session of each IA cohort were compared
with purified IgG from the serum of 22 healthy control volunteers (gratefully received from A/Prof
Sarosh Irani, University of Oxford) isolated by Protein G purification. Serum was not available in
sufficient quantities from PNAb cohort to purify IgG and these samples were therefore not tested in
this experiment. IgG from IA eluates (1:50 dilution) and protein G purification (1:12.5 dilution) were
applied to myelinated human sensory neuron cultures in a 96 well, flat-bottom imaging plate format
enabling high-throughput staining and imaging. The mean IgG concentration after dilution was not
significantly different between the groups (One-Way ANOVA: F(3,78) = 1.500, p = 0.2211) (Figure 5A).
Out of 82 samples tested, 1 CIDP (patient 11), 1 GBS (patient 07, who was also concurrently identified
as HIV positive, see Appendix B.2 for further detail) and 1 MS/CIS (patient 13) sample were scored as
‘positive’ for either axonal, glial or nodal IgG deposition by an observer blinded to the patient group; a
further 1 MS/CIS patient sample with weak IgG labelling was marked ‘equivocal’. All 4 of these sera
and IA eluates were negative on the glycolipid and paranodal antibody assays, as above. Pre-treatment
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serum from MS patient 13 was also negative on our in-house live CBAs for aquapaorin-4 and MOG
antibodies. Neither of the MS/CIS eluates which produced a weak signal on the neurofascin-155 CBA
were positive on the co-culture assay.
Figure 5. IgG deposition in myelinated co-cultures. (A) IgG concentration of dilution-adjusted eluates
used for screening on myelinated cultures. (B–D) Immunofluorescence images of IgG binding patterns
in myelinating co-cultures of IA eluates (1:50) from three patients with neurological disease identified
in the screening assay: B) GBS (patient 07), C) CIDP (patient 11), and D) MS/CIS (patient 13) (arrow
indicates IgG deposition at the node of Ranvier). (E) IgG labelling in myelinated co-cultures of serum
(1:50) sampled from the CIDP (patient 11) before (Pre-treatment) and after IA (Follow-up). Note all IgG
immunoreactivity is lost at follow-up. NF200, neurofilament 200; MBP, myelin basic protein.
Serum samples taken pre- and post-IA from the four candidate patients (1:50 dilution) were
further validated on myelinated cultures plated on 13 mm coverslips with careful attention paid to
media changes and washing steps. Strong IgG deposition aligned with neurofilament positive axons
was observed in the serum and IA eluate of the GBS (patient 07) (Figure 5B) and CIDP (patient 11)
(Figure 5C) patients. We confirmed nodal reactive IgG in the serum and IA eluate of one MS patient
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(Figure 5D and Video S1), which was absent from post-IA serum. The post-treatment follow-up
serum from the CIDP (patient 11) patient was negative for any IgG reactivity (Figure 5E). No IgG
reactivity was observed in the serum or eluate of the MS/CIS patient 13 previously marked as equivocal,
confirming this as a false positive. Clinical vignettes describing the patients with IgG deposition on
co-cultures are given in Appendix B.
4. Discussion
In the PNAb cohort, we found that PLEx or IA were more often subjectively judged to have
been effective in seronegative cases, and that in contrast, detection of at least one of the known
nodal/paranodal antibodies in patients with inflammatory neuropathies was not associated with
clinicians perceiving a positive response to either treatment. The proportion of PNAb-negative patients
judged to have had a partial or better response (62.1%) was similar to the proportion of patients judged
to have had a partial or better response in the IA cohort (52.5% overall), all of whom were also negative
for known nodal/paranodal antibodies. We emphasise that the evaluation of the PNAb cohort is limited
by the retrospective and subjective nature of the patient assessment. In addition, the small number of
cases precludes us from reaching any conclusions regarding the objective benefits of one treatment
modality compared to the other in this setting. In addition, improvement in neurological symptoms
following IA/PLEX may occur after a delay, which may not be reflected in the immediate judgement of
the treating physician. Blinding, randomisation, standardised follow up, as well as a control group to
judge the natural history of these heterogeneous diseases, are required for a definitive evaluation of
apheresis treatment efficacy in these patient groups. However, it is notable that treating physicians
were less likely to think that apheresis had been effective in PNAb-positive patients.
Why seropositive patients were rarely assessed to have responded positively to either IA or PLEx
is unclear. Our close monitoring of a prospectively-identified neurofascin-155 positive individual
showed that while IA given as a mono-therapy was able to effectively reduce antibody titres, levels
quickly rebounded and reached pre-treatment levels inside 4 weeks. This transient serological effect
was not sufficient to reduce disability. More prolonged suppression of antibody titres, with frequent
apheresis cycles or adjuvant therapies, may therefore be required for effective treatment in such cases.
Rituximab has previously been suggested as an effective treatment for paranodal antibody positive
patients [42,43], but may take several weeks (or even months) to produce benefit. In this case, a second
cycle of IA, 4 weeks after a course of rituximab, produced a more persistent suppression of antibody
titres, which was associated with clinical improvement. The extent to which IA contributed to this
effect is unclear. Theoretically, the more rapid action of IA might be complementary to the delayed but
more sustained effects of rituximab. Whether this combination of treatment offers significant benefit
over rituximab alone requires further investigation.
Retrospective analysis of serum samples from 60 IA-treated patients failed to identify any
individuals who would have been classified as positive on routine diagnostic testing for previously
described nodal/paranodal and glycolipid antibodies. A small number of first-treatment IA eluates did
produce a low-level signal on the neurofascin-155 CBA. Whilst the diagnostic importance of low-titre,
non-IgG4 results has been doubted [44], a pathogenic role for these antibodies cannot be ruled out.
The apparently better response of seronegative patients to apheresis, particularly IA, has several
possible explanations. One is that these differences simply reflect variation in the disease characteristics
and natural progression of seropositive versus seronegative inflammatory neuropathies: Overall,
seropositive patients tend to have more severe, aggressive disease that is refractory to treatment [30–32].
Conversely, less severely affected, seronegative, patients may be more likely to have a monophasic
disease course and stabilise or improve, independent of any particular therapy. Indeed, the median
peak disability, measured by nadir modified Rankin score (mRs), of apheresis-treated PNAb+ patients
in our series was higher, albeit non-significantly, than that of the apheresis-treated seronegative group
(median nadir mRs 5 v 4, p = 0.1, Mann-Witney test, Table 1), although there was no significant
difference in the use of, or clinician evaluated response to, other treatment modalities. There was
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also no significant difference in the proportion of patients initially diagnosed as GBS (28.6% and
30.3%, p > 0.99) compared to CIDP (66.7% and 54.5%, p = 0.41) in the PNAb+ and PNAb-negative
groups, respectively (Fisher’s exact test, Table 1). However, this does not exclude the possibility that
patients in the seronegative group may often have a shorter disease course, with less irreversible
axonal degeneration.
Another explanation for perceived apheresis efficacy in seronegative patients is the presence of
antibodies below the threshold for positive detection on diagnostic testing, leading to a correspondingly
slower rebound in titres following PLEx/IA and a more sustained suppression of antibody levels.
A further possibility is that the response to IA in diagnostically seronegative patients is due to the
therapeutic removal of as-yet uncharacterised, pathologically relevant antibodies in these patient
groups. We therefore tested for further nerve-related antigens by screening eluates from the IA cohort
against myelinating co-cultures. Three positive IA eluate samples were identified in the original
96-well co-culture screen and were further validated in a larger 24-well format, confirming similar
binding patterns. IgG from one GBS patient co-localised with NF200 suggesting an axonal antigen.
One CIDP patient serum and IA eluate showed IgG binding that aligned with NF200-positive axons
but may also reflect deposition on non-myelinating Schwann cells.
One patient’s serum and IA eluate from the MS/CIS group revealed nodal specific IgG binding.
The presence of antibodies against nodal antigens such as neurofascin, has precedence in MS, and
although uncommon, is more predominant in chronic progressive forms of the disease [45]. However,
this sample was negative for antibodies against both the glial/paranodal and nodal/axonal isoforms of
neurofascin (NF155 and NF186, respectively). The original focus on peripheral neuropathies led us to
use a sensory neuron system for the myelinating cultures. Nevertheless, multiple peripheral nerve
antigens are also found in the CNS (and vice versa), including NF155, CNTN1 and the ganglioside
GM1. Therefore, it is quite feasible for the unknown antigen targeted by IgG in this CIS/MS patient to
be mutually expressed in the peripheral and central nervous systems (CNS). Other autoantibodies
against nerve and glial structures in the CNS including myelin basic protein, myelin-associated lipids,
contactin-2, and KIR4.1 are among those proposed in MS patients [46]; however, their presence may
not be specific to the disease [47]. For this reason, the inclusion of MS/CIS patients as a control
group is potentially problematic. However, as patients with non-autoimmune neurological disease
essentially never receive apheresis treatment, the inclusion of this group was a pragmatic way to obtain
non-neuropathy IA eluates for use in our unbiased screening assays. With some similarity to the
discovery of nodal/paranodal antibodies in chronic neuropathies, MS has recently been separated from
other distinct, serologically-defined disorders, characterised by the presence of aquaporin-4 or myelin
oligodendrocyte glycoprotein (MOG) directed autoantibodies. Whether the nodal antigen targeted by
antibodies in this MS patient has a pathogenic role and might similarly define a non-MS disease entity
is currently unknown. Further investigation using brain tissue may help elucidate the antigen target,
pathological potential, and clinical relevance. Unfortunately, purified Ig/eluate was not available from
the PNAb-negative apheresis cohort, and it is possible that novel autoantibodies are also present in
some of these patients.
The two patients for whom follow-up samples were available (CIDP and MS/CIS) had no detectable
IgG labelling in their serum after IA compared to pre-treatment. Thus, IA is effective at removing both
established and potentially novel pathogenic autoreactive IgG from the circulation. Follow-up serum
samples at later time points will help correlate any changes in disease progress with antibody titres.
Development of myelinated hiPSC-derived neuronal cultures in a 96-well format allowed for
efficient simultaneous screening of >80 IgG eluates from patients and controls. The benefits of using
live cultures for screening are the presence of complex structures including nodes of Ranvier, paranodal
and juxtaparanodal regions, and compact myelin internodes, that provide an unbiased substrate for
antibody screening against nerve-related antigens in their native conformation. IgG binding patterns
ranged from broad axonal coverage to focal nodal localisation, reflecting morphologically distinct
antigens. Images were acquired by an experienced observer who was blind to the sample identity.
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Although time-consuming, acquisition in such a supervised manner aids the detection of localised
signals, such as the node-specific labelling identified in one MS/CIS patient.
A single sample that was marked as ‘equivocal’ on the 96-well assay was subsequently confirmed
as negative. The minimal occurrence of non-specific IgG labelling in the 96 well format may reflect a
lower washing efficiency in the smaller volume of the 96-well plate. Nevertheless, no healthy control
samples were identified as positive in the screen, suggesting the cultures are useful as a selective
substrate for nerve-targeted autoantibodies.
IA is rarely performed on healthy subjects; therefore control IgG were prepared from the sera
of healthy volunteers by protein G purification. IgG concentrations in the healthy samples were
normalised to the patient IA eluates such that the mean IgG concentrations were not significantly
different, however the variation within each group was maintained in order to reflect the original
sample. The detection of specific signals in both the serum and IA eluate of each of the three positive
patients suggests that a uniform dilution of 1:50 is sufficient for antibody screening within IA eluates.
We cannot, however, exclude the possibility of further antibodies below the level of detection. In
summary, our findings of nerve antigen reactive antibodies in three ‘seronegative’ neurological patients
suggest the utility of an unbiased screening system such as we have described here for the myelinating
co-cultures. The development of equivalent cultures containing CNS antigens and cell-types may be of
further benefit to relevant MS cases.
5. Conclusions
Currently available serological tests do not unambiguously identify patients who are likely to
respond to IA or PLEx. In patients with nodal/paranodal antibody associated neuropathies, frequent
plasmapheresis and/or additional therapies may be required to produce an acceptable level and
duration of clinical improvement. Prospective longitudinal studies involving standardized and
validated outcome measures, with serial monitoring of auto-antibodies, are needed to optimise
apheresis treatment regimens and accurately assess efficacy.
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Appendix A. Detailed Experimental Methods
Appendix A.1. Nodal/Parnodal Cell-Based Assays
All sera and IA eluates were screened for IgG antibodies to neurofascin-155, neurofascin-186,
contatctin-1 and Caspr1 using a live, cell-based assay (CBA), following previously described methods
with slight modification [32]. In brief, HEK293T cells on poly-L-lysine coated 13mm coverslips at 80–90%
confluence were transiently transfected with human neurofascin-155 (RC228652, Origene) or human
neurofascin-186 (courtesy of Jerome Devaux, University of Marseille) mammalian-expression vectors,
or co-transfected with both human contactin-1 (CNTN1, EXA1153-MO29 Genecopoeia, Maryland, US)
and human Caspr1 (EXMO417-MO2 Genecopoeia, Maryland, US) at equimolar concentrations, using
Jet-PEI transfection reagent (101-10; Polyplus). After 16 h, the cells were washed and replaced with
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) containing 10% fetal bovine serum (FBS). 24
hours later, sera and eluates diluted 1:100 in DMEM + BSA (1%) were incubated with the cells for 1
h at room temperature. Co-incubation with commercial chicken anti-neurofascin primary antibody,
(1:1000) (Cat no. AF3235; R&D Systems, Bio-Techne) was used to confirm successful transfection and
to assess for co-localisation with any bound human IgG. Following serum/eluate incubation, cells were
washed 3 times with DMEM +HEPES (20 mM), and fixed for 5 minutes in 4% PFA. Secondary antibody
incubation was with goat anti-human IgG-Fc specific-Alexa Fluor 488 (1:750) (Cat no. H10120; Life
Tech) and goat anti-Chicken Alexa Fluor 546 1:1000 (Cat no. A11040; Life Tech). To determine antibody
subclass unconjugated mouse anti-human IgG subclass 1-4 antibodies were used at 1:100 (Cat nos.
I2513, I25635, I7260 I7385; Sigma-Aldrich, Merck) followed by a fluorescently tagged tertiary antibody
goat anti-mouse Alexa Fluor 488 (1:750) (Cat no. A11029; Life Tech). Positivity was assessed by an
observer blinded to the clinical data using fluorescence microscopy. Taking into account the intensity
of the membrane signal and co-localisation of the human IgG signal with the commercial antibody, the
assay was scored on a 5 point scale as follows: 4+ very strong positive, 3+ strong positive, 2+ positive,
1+ negative (non-specific background or faint/poorly co-localised human IgG signal only), 0 no human
IgG binding seen.
Appendix A.2. Nodal/Paranodal ELISA
Individual wells of Nunc Maxisorp ELISA plates (Fisher Scientific) were coated overnight at 4 C
with either human recombinant neurofascin-155 (NF155) (8208-NF; R&D systems), NF186 (TP329070;
OriGene Technologies) or CNTN1 (10383-H08H; Sino Biological Inc) diluted to 1 g/ml in PBS. The
coating solution was then removed and the plate blocked with 5% milk in PBS for 1 h at room
temperature. Serum or eluates diluted 1:100 in 5% milk were then applied for 1h at room temperature
then washed by 5 cycles of immersion in PBS. Anti-human IgG (Fc specific) peroxidase-conjugated
anti-human IgG (A0170; Sigma) was used as the secondary antibody at 1:3000. The detection reaction
was performed using 50 l o-Phenylenediamine dihydrochloride solution (OPD fast, Sigma), stopped
after 20 minutes by the application of 25 l 4M sulphuric acid, and optical densities measured at 492
nm using a FLUOstar Omega plate reader (BMG Labtech). Wells with ODs greater than 0.1 above
uncoated (PBS only) control wells were considered positive.
Appendix A.3. Ganglioside and Sulfatide ELISA
Ganglioside and sulfatide ELISAs were performed using Immunolon 2HB 96 well plates [48].
Wells were coated with 100 ul of GM1 or GQ1b bovine gangliosides diluted to 2 g/ml, or sulfatide
to 5 g/ml, in methanol. Negative control wells contained methanol only. Plates were then air-dried
overnight in the fume hood, placed at 4 C, and blocked with 2% BSA/PBS. Sera/eluates were diluted
1:100 in 1% BSA/PBS and incubated for 2 h at 4 C. Secondary antibodies and detection were the same
as the nodal/paranodal ELISA, except that secondary antibody incubation was performed at 4 C.
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Appendix A.4. Protein G IgG Purification
Healthy control sera (100 μl) were diluted 1:1 in sterile PBS, added to protein G columns (Cat.
28-4083-47, Ab SpinTrap, GE Healthcare) prepared according to the manufacturer’s instructions.
Briefly, samples were incubated 15 min at 4 ◦C on rollers to bind IgG. Serum was then removed by
centrifugation (100 g, 30 s) and columns washed twice with binding buffer (20 mM Na2PO4, pH 7.0).
IgG were eluted with 320 μl 0.1M glycine (pH 2.6) and neutralised with 80 μl Tris-HCl (pH 8.0). Elution
was repeated once more and samples taken forward for IgG quantification.
Appendix A.5. IgG ELISA
IgG in serum and eluates was quantified by enzyme-linked immunosorbent assay (ELISA) using
a human IgG ELISA quantification kit (Cat. E80-104, Bethyl Laboratories Inc. TX, US) according
to the manufacturer’s instructions. Briefly, 96 well plates (Maxisorp, Nunc) were coated with goat
anti-human IgG-Fc capture antibody (10 μg/ml) in coating buffer (0.05M carbonate-bicarbonate, pH 9.6)
(100 μl/well) for 1h at room temperature (RT). Plates were washed 5 times by immersion in wash buffer
(50mM Tris, 0.14M NaCl, 0.05% Tween 20, pH 8.0), blocked for 1h at RT in blocking buffer (50mM Tris,
0.14M NaCl, 1% BSA, pH 8.0), followed again by immersion 5 times in washing buffer. Serum samples
and IgG eluates were prepared at 1:10,000 dilution in sample diluent, as well as a dilution series of
human reference serum standards (50mM Tris, 0.14M NaCl, 1% BSA, 0.05% Tween 20, pH 8.0). All
samples and standards were prepared in duplicate (100 μL/well) and incubated 1h at RT. After 5x
immersion washes 100 μL of HRP-conjugated goat anti-human IgG-Fc Detection Antibody (1:200,000)
was incubated 1h at RT followed by 5 immersion washes. Plates were developed by the addition
of 100 μL of TMB substrate solution (20 min, RT) and reaction stopped by adding equal volume of
0.18M H2SO4. Absorbance values were read immediately on a plate reader (FLUO Star Omega, BMG
Labtech) at 450nm (signal) and 630nm (background). A standard curve was constructed from the
background subtracted absorbance (OD) values obtained from the human serum standards using a
4-parameter function (https://mycurvefit.com/). IgG concentrations of each sample were calculated
from averages of the duplicate, background-subtracted OD values, multiplied by the original dilution.
All values for diluted samples fell within the standard curve (1–1000 ng/mL).
Appendix A.6. Myelinating Co-Cultures
Myelinating co-cultures were prepared using human induced pluripotent stem cells
(hiPSC)-derived sensory neurons and primary rat Schwann cells with some modifications to previously
described methods [49]. hiPSCs from control subjects were obtained via the StemBANCC consortium
at the University of Oxford (https://www.ndcn.ox.ac.uk/research/stembancc). In brief, hiPSCs were
differentiated to sensory neurons using a combination of small-molecule mediated dual-SMAD
inhibition and wnt activation. On day 11 of differentiation, sensory neuron precursors were seeded
onto 13 mm diameter glass coverslips (approximately 20,000 cells per coverslip) or 96-well flat,
glass-bottom imaging plates (Sensoplate Microplate, Greiner-Bio) (approximately 5000 neurons per
well) previously coated with poly-D-lysine (PDL) (10 μg/mL) overnight and reduced growth-factor
matrigel (Corning). Neurons were maintained in neurobasal media supplemented with N2, B27,
Glutamax and anti-anti (all Gibco, Life Technologies) (‘complete’ neurobasal) plus recombinant human
β-NGF (rhNGF) (Cat. 450-01, Peprotech), NT3 (Cat. 450-03, Peprotech), GDNF (Cat. 450-10, Peprotech),
and BDNF (Cat. PHC7074, Life Technologies) (all growth factors 25 ng/ml), supplemented with
Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor (10 μM) (Tocris, Bio-Techne) on
days 11–12, CHIR99021 (3 μM) (Sigma) on days 11–14 and cytosine arabinoside (Ara-C) (1 μM) (Sigma)
on days 12–14. Neurons were incubated at 37 ◦C in 5% CO2 for 4 weeks with twice-weekly medium
changes prior to addition of Schwann cells for myelination.
Primary Schwann cells were isolated from the sciatic nerves of rat pups (P2-3). Mother and pups
were killed by rising concentration of CO2 in accordance with Schedule 1 of the UK Home Office
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Animals (Scientific Procedures) Act 1986. Sciatic nerves were rapidly dissected and digested in a
mixture of collagenase (3mg/ml) (Worthington, Lorne Labs) and dispase II (3.5mg/mL) (Roche) for
1 h at 37 ◦C with frequent gentle agitation. Nerves were washed in DMEM + FBS (10%) and gently
triturated using a fire-polished glass Pasteur pipette. Dissociated cells were seeded into tissue culture
flasks overnight and expanded in Schwann cell expansion medium containing charcoal-stripped FBS
(10%) (Sigma), Forskolin (4 μM), recombinant human NRG1-β1 EGF domain (80 ng/mL) (Cat. 396-HB,
R&D Systems) and recombinant murine NGF (10 ng/ml) (Cat. 450-34, Peprotech) in DMEM/F12
(Gibco). Cells were serially treated with 5–10 μM Ara-C to eliminate fibroblasts. Expanded Schwann
cells were added to the neuronal cultures (25,000 cells per coverslip or 5000 cell per 96-well) and
allowed to proliferate and align with the axons for 1 week in basal media containing: (CS-FBS) (10%),
insulin (5 mg/ml) (Sigma), holo-transferrin (100 mg/mL) (Sigma), rhNGF (25 ng/mL) (Peprotech)
(Sigma), Selenium (25 ng/mL) (Sigma), 25 ng/ml thyroxine (Sigma), progesterone (30 ng/ml) (Sigma),
triiodothyronine (25 ng/mL) (Sigma) and putrescine 8 mg/mL (Sigma) in DMEM/F12 media (Gibco,
Life Technologies). From this point on, cultures were maintained in ‘myelination medium’ containing:
5% CS-FBS, ascorbic acid (25 μg/mL), phenol-free matrigel (1:300) (Corning) and hrNGF (25 ng/mL) in
‘complete’ neurobasal medium. Myelinating cultures were matured for at least 4 weeks before use in
subsequent experiments.
Appendix A.7. Myelinated Co-Culture Immunreactivity Screening
Sera or IgG eluates were diluted in neurobasal ‘complete’ media (including 1% BSA and human
NGF, 50 ng/mL), added to myelinated co-cultures either in a 96 well plate (100 μL/well) or coverslips
in a 24 well plate (300 μL/well) format and incubated for 1h at 37 ◦C. Serum containing antibodies
to known antigens, as well as normal human serum, were run as positive and negative controls,
respectively. For 96-well plate screening, serum samples were blinded by an independent investigator.
Cultures were then washed 4x with pre-warmed PBS and fixed with 2% PFA in PBS for 30 min at RT.
Wells were washed with PBS followed by DMEM plus HEPES (20 mM). Cultures were then labelled
with Alex488-conjugated goat anti-human IgG (H+L) (A11013, Life Technologies) secondary antibody
(1:750) in DMEM/HEPES plus 1% BSA, 1h at RT followed by washing 2x with DMEM/HEPES and
3x PBS. Cultures were then permeabilised with ice cold methanol (45 min on ice), blocked with 5%
normal goat serum and incubated with chicken anti-neurofilament (NF)200 (1:10,000) (ab4680, Abcam)
and rat anti-myelin basic protein (MBP) (1:500) (ab7349, Abcam) primary antibodies overnight at 4 ◦C.
After washing in PBS antibodies were labelled with goat anti-chicken biotin (1:500) (BA-9010, Vector
Laboratories) and goat anti-rat Alexa 546 (1:1000) (A11081, Life Technologies) secondary antibodies
for 1h at RT, followed by streptavidin pacific blue (1:500) (S11222, Life Technologies) 45–60 min at RT.
After washing in PBS coverslips were mounted onto glass slides (SuperFrost, ThermoScientific) with
Vectorshield (H1000, Vector Laboratories) and stored at −20 ◦C prior to imaging. 96-well plates were
flooded with PBS containing 0.02% NaN3 and sealed with plate-sealing film. Plates were stored at 4 ◦C
until imaging. Confocal images were acquired with a x63 oil-immersion lens (1024 × 1024 resolution)
and exported as maximum intensity projection of 4–5 × 1 μm interval z-section images. Plates were
allowed to reach room temperature before imaging.
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Appendix B.1. CIDP (Patient 11)
This 66-year-old male first developed sensory deficits, myalgia, and gait disturbance in 2007,
followed in 2009 by asymmetric distal weakness in the legs then arms, and after 3 years, worsening
neuropathic pain and trigeminal nerve dysfunction. Routine bloods, serum protein electrophoresis with
immunofixation, and an extensive autoantibody screen revealed no abnormalities. Neve conduction
studies showed a demyelinating, sensory-motor neuropathy (reduced nerve conduction velocities,
prolonged motor distal latencies, prolonged F-wave latencies, and temporal dispersion in multiple
nerves), meeting the EFNS criteria for definite CIDP. EMG showed no evidence of myopathy. First
line treatment with high dose then tapering corticosteroids was initiated in 2007. This produced some
improvement in myalgia but no other benefit and was stopped after a few weeks due to unacceptable
side effects (multiple infections). Further progression in 2009 led to the use of IVIg and the introduction
of azathioprine, which was again stopped after a few weeks due to adverse reactions. High-dose,
pulsed, corticosteroids were again used in 2011, and methotrexate was also introduced. The clinical
picture stabilised but these therapies could not be continued due to recurrent urosepsis. The patient
then received 1 cycle (5 treatment sessions and 12 plasma volumes in total) of IA in 2015 without
further improvement in his clinical picture after 2 weeks.
Appendix B.2. GBS (Patient 07)
This 52-year-old male presented in 2017 with neuropathic pain, limb-weakness, and facio-bulbar
cranial nerve dysfunction. There was a rapid worsening over the next few days to complete
tetraplegia, with autonomic involvement (bradycardia) and respiratory insufficiency, necessitating
transfer to intensive care for ventilatory support. Nerve conduction studies showed a demyelinating,
sensory-motor neuropathy. The CSF protein was elevated at 1.2 g/L, as was the CSF white cell
count at 19 per mm3. The white cells were classified as activated lymphocytes and monocytes. No
infectious organisms were identified in the CSF despite extensive testing. A subsequent serological
HIV test was positive, initially showing 376000 HIV RNA copies per ml. This confirmed a new
diagnosis of HIV infection, and raises the possibility that this gentleman’s GBS was associated with
HIV seroconversion. However, in the absence of serial serological testing, we cannot confirm this
unequivocally. The CD4/CD8 ratio was 0.34 (reduced). Standard IVIg treatment did not produce any
immediate improvement. Antiretroviral therapy was commenced with an associated decline in viral
load over the next few weeks, reducing HIV RNA copies to 100/ml. IA therapy had to be delayed
multiple times due to recurrent infections and other complications. It was finally started about 6
weeks after onset of symptoms. Following 5 days of IA, there was a slow improvement in strength
over the next 14 days, with a limited return of movement in the arms and legs. After a subsequent
cycle of plasma exchange, this slow improvement continued. The patient was transferred to an early
rehabilitation clinic about 3 months after onset of symptoms.
Appendix B.3. MS (Patient 13)
This 37-year-old male was diagnosed with highly active multiple sclerosis in 1998. This followed
a relapsing-remitting course, with an accumulation of residual deficits producing a persistent spastic
tetraparesis. Brain and spinal MRI were performed, showing multiple supra- and infratentorial, as well
as spinal T2-hyperintense lesions with Gadolinum-enhancement in the cervical cord. Aquaporin-4-
and MOG- antibodies were negative. The patient had previously received multiple disease modifying
therapies, including beta-interferon, natalizumab, and currently fingolimod, but continued to experience
relapses in the last year. A 2015 relapse with left sided optic neuritis was treated with high-dose
prednisolone. This was associated with partial improvement and was followed with 5 days of IA.
Further outcome data is not available.
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Abstract: Background: agonistic autoantibodies (agAABs) against G protein-coupled receptors
(GPCR) have been linked to cardiovascular disease. In dementia patients, GPCR-agAABs against
the α1- and ß2-adrenoceptors (α1AR- and ß2AR) were found at a prevalence of 50%. Elimination of
agAABs by immunoadsorption (IA) was successfully applied in cardiovascular disease. The IMAD
trial (Efficacy of immunoadsorption for treatment of persons with Alzheimer dementia and agonistic
J. Clin. Med. 2020, 9, 1919; doi:10.3390/jcm9061919 www.mdpi.com/journal/jcm57
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autoantibodies against alpha1A-adrenoceptor) investigates whether the removal of α1AR-AABs
by a 5-day IA procedure has a positive effect (improvement or non-deterioration) on changes of
hemodynamic, cognitive, vascular and metabolic parameters in patients with suspected Alzheimer’s
clinical syndrome within a one-year follow-up period. Methods: the IMAD trial is designed
as an exploratory monocentric interventional trial corresponding to a proof-of-concept phase-IIa
study. If cognition capacity of eligible patients scores 19–26 in the Mini Mental State Examination
(MMSE), patients are tested for the presence of agAABs by an enzyme-linked immunosorbent
assay (ELISA)-based method, followed by a bioassay-based confirmation test, further screening
and treatment with IA and intravenous immunoglobulin G (IgG) replacement. We aim to include
15 patients with IA/IgG and to complete follow-up data from at least 12 patients. The primary
outcome parameter of the study is uncorrected mean cerebral perfusion measured in mL/min/100 gr
of brain tissue determined by magnetic resonance imaging with arterial spin labeling after 12 months.
Conclusion: IMAD is an important pilot study that will analyze whether the removal ofα1AR-agAABs
by immunoadsorption in α1AR-agAAB-positive patients with suspected Alzheimer’s clinical
syndrome may slow the progression of dementia and/or may improve vascular functional parameters.
Keywords: Alzheimer’s clinical syndrome; dementia; immunoadsorption; autoantibodies;
α1-Adrenergic receptor
1. Introduction
Nearly 50 million people worldwide suffer from Alzheimer’s disease (AD) or other forms of
dementia, and around 10 million new cases emerge every year, leading to a number of 150 million
affected people expected in 2050 [1–3] Dementia has a lifetime prevalence ranging between 5% and
7% for those aged ≥60 years and is a major cause of disability among older adults [4,5] AD is the
leading cause of dementia, responsible for two-thirds of all cases [6]. Since no causal treatment for AD
is available yet, prevention strategies, psychosocial interventions and symptomatic pharmacological
interventions are recommended and are central components of the treatment [7].
Up to now, research of causal therapies is focusing on the knowledge of typical neuropathological
features of AD like amyloid plaques and neurofibrillary tangles which are associated with the
tau-pathology [8,9]. In particular, the ß-amyloid hypothesis of AD has stimulated the development of
therapy concepts directed against the amyloid protein and amyloid deposits in the brain of patients
with AD.
One strategy is passive immunization with monoclonal antibodies which bind to ß-amyloid.
Although it has been demonstrated that these antibodies may reduce the amyloid burden in the brain
of AD patients, positive clinical effects were minimal or absent so far. Many promising compounds
like Bapineuzumab, Gantenerumab or Solanezumab have failed in phase III of clinical trials or are still
being evaluated (Aducanumab) [10–12].
Other ß-amyloid (Aß)-directed therapies focus on the enzymatic cleavage of the amyloid precursor
protein (APP). It is known that ß-secretases contribute essentially to the production of Aß40/42 which
is the toxic aggregating form of amyloid. Thus, ß-secretase inhibitors have been identified to be
therapeutically beneficial. However, recently, a world-wide clinical trial on the secretase inhibitor
Verubecestat was withdrawn because Verubecestat did not improve clinical ratings of dementia among
patients with prodromal Alzheimer’s disease. Some measures even suggested an impairment of
cognition and daily function compared to placebo [13].
The focus on Aß also led to the concept of removing it from plasma by therapeutic plasma exchange
(TPE). Aß is bound to serum albumin by >90% which in turn is removed and discarded by TPE [14,15].
TPE-treatment with albumin replacement favored the stabilization of cerebral perfusion in mild to
moderate AD patients compared to non-treated controls [15]. The same Spanish group currently
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conducts a prospective multicenter, randomized, blinded and placebo-controlled, parallel-group,
phase IIb/III trial in patients with mild to moderate AD (“Alzheimer’s Management by Albumin
Replacement (AMBAR)”). This study evaluates TPE with different replacement volumes of therapeutic
albumin (5% and 20%), with or without intravenous immunoglobulins and is still ongoing [14].
Another group sought to remove Aß and developed an ex vivo adsorptive filtration system that
resulted in an 80–100% reduction of Aβs within 30 min of circulation but has not yet been tested in
humans [16].
In view of the numerous negative results, it seems to be necessary to shift attention to new
therapeutic targets. In this respect, different pathologies of cognitive decline besides the Aß and the
tau-pathologies may be considered. Importantly, clinical, pathological and epidemiological data point
to a relevant overlap between cerebrovascular disease (CVD) and Alzheimer’s clinical syndrome [17].
Furthermore, cerebral microvascular lesions that are detected as white matter hyperintensities (WMH)
on magnetic resonance imaging (MRI) are associated with typical gray matter atrophy patterns of
AD in a considerable number of patients [18]. Thus, factors that alter the microenvironment of the
endothelium and the smooth muscle cells of blood vessels may compromise the molecular exchange
between blood and brain.
Rationale of the Clinical Investigation
Naturally occurring agonistic autoantibodies (agAABs) against G protein-coupled receptors
(GPCR) have been linked to cardiovascular disease such as dilated cardiomyopathy, myocarditis,
malignant hypertension, vascular renal rejection, diabetes mellitus type 2 or dementia [19]. Agonistic
AABs are functional antibodies that can activate the respective receptor. Agonistic AABs differ clearly
from non-functional AABs. The latter trigger autoimmune disease in an Fc-receptor mediated manner
whereas functional agAABs are able to bind cell receptors and activate intracellular signaling pathways
that are normally triggered by endogenous ligands [20]. A pathological example of agAABs is Graves’
hyperthyroidism with autoantibodies activating the thyroid-stimulating hormone (TSH)-receptor and
with subsequent overproduction of thyroid hormones [21]. Other examples for GPCR-agAABs are
AABs directed against adrenoceptors (AR; e.g., ß1AR and ß2AR, α1AR), the angiotensin (2) receptor
type 1 (AT-R1) and the endothelin receptor type A (ETA) [19]. The agAABs against AR are directed
against the first or second extracellular loop of the receptor. They bind to constant epitopes defined by
the amino acid sequence in the respective loop. These AABs belong to the immunoglobulin class G
(isotypes 1–3). GPCR-agAABs elicit a long-lasting dimerization of adrenoceptors and continuously
activate cellular processes such as phosphorylation of intracellular proteins and modulation of calcium
signaling that results e.g., in the case of agAABs against the α1AR in the proliferation of smooth
muscle cells and thickening of vessel walls [22]. In response to their natural agonists, the receptor
density on the cell membrane is regulated by receptor desensitization. This mechanism is inhibited
by agAABs [22]. In an animal model, continuous stimulation triggered by α1AR-AABs leads to
cerebrovascular remodeling and obliteration [23].
In a small clinical trial, treatment of Graves’ disease with rituximab, a B-cell depleting monoclonal
antibody specifically reduced the production of TSH-receptor antibodies [24]. In a case of thyreotoxic
crisis, TPE is also used to remove agAABs against TSH-receptor and albumin-bound thyroid
hormones [25].
Cerebrovascular remodeling may lead to disturbances in cerebral blood flow and a lack of outflow
of Aß. A clearing defect for Aß rather than an Aß-overproduction has been proven experimentally for
AD patients [26]. From this view, AABs against the α1AR may interfere with Aß clearance mechanisms
and act as a risk factor and a modulating component of dementia in patients with Alzheimer’s
clinical syndrome.
In line with this, the GPCR-α1AR was also reported to be a target for agAABs in patients with
essential and malignant hypertension [27]. In a pilot study in five α1AR-AAB-positive patients with
resistant hypertension, removal of these AABs by immunoadsorption lowered the mean arterial blood
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pressure significantly by approximately 10 mmHg, and the effect was still present after 180 days [28].
In line with this, a recent study in 816 subjects showed that the occurrence of α1AR-AABs predicted
arterial stiffness progression even in normotensives over a 5-year period [29].
A disease that has been very well investigated with regard to agAABs is dilated cardiomyopathy
(DCM). Among others, agAABs against the GPCR-ß1-adrenoceptor (ß1R) seem to play an important
role in DCM. Their elimination from the blood by immunoadsorption (IA) has been transferred to a
therapeutic intervention in clinical praxis. Removal of circulating antibodies by IA with subsequent
intravenous immunoglobulin G substitution (IA/IgG) has been shown to result in improvement of
cardiac function, in better exercise capacity, and in decrease of myocardial inflammation in DCM [30–33].
Removal of functional AABs does not have to be a constant process as in non-functional AAB triggered
disease. Already a one-week-course of IA seems to yield a so-called legacy effect that may persist for a
long time [34]. In DCM, removal of the agAABs by a one-week-course of IA lasts for up to 12 months
and even longer [35,36].
Noticeably, in dementia patients, agAABs against both the α1R- and ß2R-adrenoceptors were
also found at a prevalence of approx. 50%. Thus, in a primary care cohort who screened positive for
dementia, 40 out of 95 participants were also positive for agAAB (29 subjects with α1AR-AABs and 21
with ß2AR-AABs) [37]. However, agAABs could not discriminate between Alzheimer’s Dementia and
other forms of dementia. Patients with coronary heart disease were more likely (OR = 4.23) to have
α1AR-AABs than those without coronary heart disease. The presence of agAAB against adrenoceptors,
especially α1AR-agAABs, in persons suffering from dementia motivated a first pilot trial on the effects
of IA on the course of dementia [38]. In this trial, in four out of eight patients an effective depletion of
agAAB could be achieved by a 4-day per-protocol IA treatment, while another four patients received
a less effective 2–3 day treatment due venous access problems. IA was safe to use in these patients,
and the mean change in Mini Mental State Examination (MMSE) score of these patients remained
constant over 12 to 18 months.
The IMAD trial (Efficacy of immunoadsorption for treatment of persons with Alzheimer dementia
and agonistic autoantibodies against alpha1A-adrenoceptor) aims to ascertain whether the positive
effects of IA on slowing down dementia progression can be replicated. Moreover, IMAD will
comprehensively examine potential effects of this treatment in patients with Alzheimer’s clinical
syndrome by a combination of brain and vessel imaging along with cognitive tests and further
cardiovascular, cerebrovascular and laboratory examinations.
2. Methods
2.1. Objectives
The IMAD trial is designed as an exploratory monocentric interventional trial corresponding
to a proof-of-concept phase-IIa study. The aim of IMAD is to evaluate whether IA with subsequent
IgG-substitution (IA/IgG) is related to an improved uncorrected mean brain perfusion after 12 months
as a surrogate for potential beneficial effects on disease progression in patients with an Alzheimer’s
clinical syndrome and mild to moderate cognitive impairment. In addition, potential effects of IA/IgG
on cognitive measures as well as cardiovascular, cerebrovascular and laboratory parameters will
be investigated.
2.2. Patients
Potential participants for this trial need to have an Alzheimer’s clinical syndrome, according to
the definition as outlined in Jack et al. [39]. In patients without obvious exclusion criteria, cognitive
capacity is again assessed before inclusion using the MMSE. If a mild to moderate impairment (defined
by a MMSE score between 19 and 26) is confirmed, patients are tested for the presence of agAABs by an
ELISA-based method, followed by a bioassay-based confirmation test (methodological details are given
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in Section 2.5.8). Patients with a positive test result by the bioassay are eligible for further screening.
We aim to include in total 15 patients with IA/IgG and 12 patients with complete follow-up data.
2.3. Inclusion and Exclusion Criteria
Criteria that have to be fulfilled for all participants (inclusion criteria) and reasons that prevent
inclusion into the study (exclusion criteria) are summarized in Table 1.




- Previous or suspected diagnosis of Alzheimer’s clinical syndrome
- Presence of agAAB against alpha1-adrenoceptor (α1AR)
- Mini mental state examination score between 19 and 26
- Written informed consent
Exclusion
- Presence of autoantibodies against the NMDA receptor
- Defective blood coagulation at time of inclusion
- Severe protein deficiency disorders
- Known manifest vitamin/folic acid deficiency (substitution allowed)
- Active infectious disease, or sings of ongoing infection with CRP >10 mmol/L
- Impaired renal function (serum creatinine >220 μmol/L)
- Any disease requiring immunosuppressive drugs or therapeutic antibodies
- Non-curative treated malignant disease or another life-threatening disease with poor
prognosis (estimated survival less than 2 years), except for basal-cell carcinoma
- Unstable angina pectoris, second or third degree atrioventricular block or
symptomatic sick sinus syndrome without implanted pacemaker, history of
myocardial infarction, bypass or other revascularization procedures, valvular heart
defect (≥2. degree)
- Severely reduced left ventricular systolic function (LVEF <30%) and/or heart failure
symptoms according to NYHA class III/IV
- Clinical manifestation of arterial disease, vascular surgery: ACl-Stenosis >60%; PAD
> IIb, history of stroke, diffusion disorder or expired territorial stroke in MRI
- Endocrine disorder excluding diabetes mellitus
- Severe hepatic disorder (Child–Pugh score 5 or more)
- Drug therapy against dementia since less than 3 months
- Psychopharmacological drug therapy since less than 3 months
- Dialysis requirement
- MRI contraindications (e.g., pacemaker)
- Legal tutelage
- Previous treatments with IA or immunoglobulins
- ACE-treatment during the IA
- Severe mental disorder (bipolar disorder, schizophrenia, depression)
requiring treatment
- Alcohol or drug abuse
- Inability to undergo the study procedure
- Participation in any other clinical/interventional study within less than 30 days prior
to screening
ACE, angiotensin converting enzyme; ACI, internal carotid artery; agAAB, agonistic autoantibodies; CRP, C reactive
protein; IA, immunoadsorption LVEF, left ventricular systolic function; MRI, magnetic resonance imaging; NMDA,
N-methyl-D-aspartate; NYHA, New York Heart Association; PAD, peripheral artery disease.
2.4. Study Design
During the screening phase, patients are checked for eligibility according the inclusion and
exclusion criteria (Table 1). Patients fulfilling these criteria are comprehensively examined during a
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baseline visit, followed by IA/IgG treatment. All participants of the IMAD trial are followed up after 1,
6 and 12 months. The complete study flow is illustrated in Figure 1.
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Figure 1. Study flow.
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The IMAD trial is an interdisciplinary project which involves the departments and institutes of
radiology, neurology, psychiatry, cardiology, nephrology and laboratory medicine of the University
Medicine Greifswald. The study complies with the Declaration of Helsinki and it has been approved by
the Ethics Committee of the University of Greifswald (MPG 02/16; MPG 02/16a). The trial is registered
at ClinicalTrials.gov (NCT03132272).
2.5. Examinations and Assessments
Patients undergo a comprehensive examination program including brain perfusion assessment by
MRI (primary outcome parameter: uncorrected mean brain perfusion assessed by arterial spin labeling
[ASL]) and assessment of further structural and vascular brain MRI parameters. In addition, several
cognitive, cardiovascular, cerebrovascular and laboratory parameters are assessed during baseline
and all follow-up visits. Table 2 gives an overview about methods, main parameters and respective
time points.
Table 2. Methods, main outcome parameters and time points.
Method Parameter Screening Baseline Follow-Ups Comments
Arterial Spin Labelling MRI Cerebral blood flow X X
MRI Basic protocol Brain Volume, WMH, CBM;MTA X X
Time-of-flight MR
angiography Vessel anatomy and size X X
Diffusion Tensor Imaging Fractional anisotropy X X
ADAS-Cog Cognition X X
MMSE Cognition X X X
GDS Depression X X
VLMT Cognition X X
Benton Test Cognition X X
Brachial blood Brachial blood pressure values X X X





Echocardiography Cardiac function and structure X
Transcutaneous oxygen
measurement Oxygenation X X
Kidney sonography Renal function X X
Doppler Sonography Carotid Arteria blood flow X X
Liquor analytics Tau/P-Tau (X) (X) Optional
Liquor analytics ß-A40/42 (X) (X) Optional
IA, immunoadsorption; MRI, magnetic resonance imaging; CBM, cerebral microbleeds; MTA, medial temporal lobe
atrophy; DTI, diffusion tensor imaging; ADAS, Alzheimer’s Disease Assessment Scale; MMSE, Mini-Mental State
Examination; GDS, Geriatric Depression Scale; VLMT, Verbal Learning and Memory Test; LVEF, left ventricular
ejection fraction; WMH, white matter hyperintensities; optional parameters are depending upon patient agreement;
follow-up visits are conducted 1, 6 and 12 months after IA treatment.
For examinations with a high potential for an observer bias (e.g., MRI, echocardiography), images
will be stored and the reading will be done offline in a blinded manner. Specifically, they will be
assessed without knowledge of the respective patient and time point. All examinations and methods
used are described in more detail in the following sections.
2.5.1. Brain Magnetic Resonance Imaging (MRI)
MR Imaging Protocol
All subjects undergo brain imaging at 1.5T (Magnetom Aera, Semens, Germany) using a 20-channel
head coil for image acquisition. Structural MR imaging protocol includes a sagittal 3D T1-weighted
sequence with an inplane resolution of 1 × 1 mm and a slice thickness of 1.3 mm (repetition time
[TR] = 1860 ms, echo time [TE] = 3.88 ms, inversion time [TI] = 1000 ms, 160 slices); a sagittal 3D
FLAIR dataset with 1 × 1 mm inplane spatial resolution and 1.1 mm slice thickness (TR = 5000 ms,
TE = 214 ms, TI = 1800 ms, field of view [FoV] = 265 × 265 mm); a diffusion weighted imaging (DWI)
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sequence with b-values 0/1000 s/mm2 (TR = 5600 ms, TE = 113 ms, 1.2 × 1.2 mm voxel size, 5 mm slice
thickness) and a time-of-flight angiography of the circle of Willis with 0.5 × 0.5 mm spatial resolution
with a slice thickness of 0.8 mm (TR = 31 ms, TE = 7.15 ms, FoV = 200 mm).
Cerebral perfusion is assessed using a 2D pseudo-continuous arterial spin-labeling sequence
(PICORE Q2T) with 5 mm slice thickness and an in-plane spatial resolution of 4 mm with 64 slices.
Other imaging parameters are a post labeling delay of 1.8 s, bolus duration of 700 ms, TR = 2500 ms
and TE = 13 ms.
A diffusion tensor imaging (DTI) dataset is acquired in all patients (TR = 4700 ms, TE = 116 ms,
b-value 0/1000 s/mm2, 12 directions) with a slice thickness of 4 mm and an in-plane spatial resolution
of 1.5 × 1.5 mm.
Total acquisition time is 42 min. All scans are checked by a board certified neuroradiologist for
gross abnormalities.
MR Image Analysis
For structural image analysis, all MR datasets are transferred to a dedicated Horos workstation
(www.horosproject.org). WMH are evaluated on axial reconstructions of the 3D FLAIR dataset with 3
mm slice thickness according to the Fazekas scale [40]. The Fazekas score are dichotomized into low
(Fazekas grade 0–1) and high (Fazekas grade 2–3). Cerebral microbleeds are defined as hypointense
lesions smaller than 10 mm on b = 0 diffusion weighted images. Lacunar lesions are defined as small
lesions in the deep white and grey matter with a diameter between 3 and 10 mm and cerebrospinal
fluid-like signal on all sequences. For quantitative analysis, lacunar lesions and microbleeds are
counted by visual inspection and for further statistical analysis dichotomized in present or absent.
Medial temporal lobe atrophy (MTA) score is rated on coronal reformations of the 3D T1w dataset
according to previously described criteria [41]. For statistical analysis, the mean MTA score of both
sides is dichotomized into high (>1.5) and low (≤1.5) as described elsewhere [42].
Vessel diameter of the internal carotid artery (ICA), the anterior (ACA) and middle cerebral artery
(MCA) and the basilar artery (BA) are evaluated by manual measurements. For the ICA, measurements
are performed at the level of the cavernous sinus, for the MCA in the median M1 segment, for the
ACA immediately distal the anterior communicating artery and for the basilar artery at the level of the
origin of the superior cerebellar artery, respectively.
Brain volume estimation are performed using T1w images. Therefore, the measured raw
DICOM data are converted into NIFTI (Neuroimaging Informatics Technology Initiative) format using
dcm2nii, which is part of the neuroimaging tool MRIcron. Preprocessing using FSL (version 6.0,
www.fsl.fmrib.ox.ac.uk/fsl) included correction for gradient nonlinearities, non-brain tissue removal,
linear registration to standard space, and tissue segmentation [43]. Evaluation of the pseudo-continuous
ASL images is performed as previously described by Binnewijzend et al. [43]. Therefore, ASL images
are also corrected for gradient nonlinearities in all three directions and then linearly registered to the
brain-extracted T1-weighted images. The brain mask is used to calculate uncorrected mean whole-brain
cerebral blood flow (CBF). These volume estimates are then transformed to the ASL data space to
correct partial volume-corrected cortical and white matter CBF maps [44]. CBF values are also extracted
using regions of interest (ROIs) in the frontal, temporal, occipital and parietal brain areas and the
hippocampus based on the MNI152 atlas and the Harvard–Oxford cortical atlas. The primary outcome
parameter of the study is uncorrected mean cerebral perfusion measured in mL/min/100 gr of brain
tissue determined by ASL.
Preprocessing of DTI data includes also conversion to NIFTI format. Then, the tool eddy
correct, part of FSL, is used to correct the diffusion-weighted data with respect to subject motion and
deformations introduced by eddy current artifacts of the MRI scanner. Fractional anisotropy (FA)
images are created by fitting a tensor model to the raw diffusion data using FSL DTI-FIT. FA analyses
was performed on a whole brain basis and using the ROI from CBF-analyses.
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2.5.2. Cognitive Assessment
Mini-Mental State Examination (MMSE)
We use MMSE-2 which is a revised version of the original MMSE [45,46] routinely used to measure
cognitive decline. The MMSE-2 consists of three versions: the standard version, the brief version and
the expanded version of the MMSE. In this study, the standard version is used in order to maximize the
benefit of the use of the scale while minimizing the duration of the cognitive assessment. The MMSE-2
shows a sufficient internal consistency (Cronbach’s alpha 0.66–0.79) [46].
Alzheimer’s Disease Assessment Scale - Cognition (ADAS-Cog)
The Alzheimer’s Disease Assessment Scale (ADAS) is commonly used to assess cognitive
dysfunction in individuals with Alzheimer’s Disease and other types of dementia [47,48].
The ADAS-Cog was developed as a two-part scale: one that measures cognitive impairment and one
that measures non-cognitive factors such as mood and behavior. In IMAD, only the cognitive scale of
the ADAS-Cog is applied, which consists of 11 parts and measures the cognitive functioning, language,
and memory in a 30-min test. Five parallel versions are available to avoid recall bias due to multiple
testing. The final score ranges from 0 to 70 points, with higher scores indicating more serious cognitive
impairment. The ADAS shows a good internal consistency (Cronbach’s alpha 0.61–0.76) [49]. During
the baseline visit, a cognitive profile over the 11 dimensions measured by the ADAS-Cog is created.
The profile is compared to reference values provided by Graham et al. [48] (Figure 2). According to the
reference values, the cognitive profile of patients with mild to moderate AD predominately shows
higher impairment in memory, and to a lesser extent, in cognitive functioning. In contrast, language is
hardly impaired in this stadium (Figure 2). Thus, patients with a different cognitive profile undergo
further examinations to exclude differential diagnoses. For patients included into the IMAD trial,
a cognitive change is estimated according to Stern et al. [50] to predict future cognitive decline during
the follow-up period. The estimated cognitive change is later compared to the observed cognitive
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Figure 2. Example of a patient’s cognitive profile of the Alzheimer’s Disease Assessment Scale–Cognition
(ADAS-Cog) with mild to moderate dementia from a patient included in the IMAD trial (own figure).
Continuous line, cognitive profile with mild to moderate dementia; dashed line, cognitive profile with no
cognitive impairment; grey area, 95% confidence interval for the cognitive profile. Without impairment
according to Graham, Emery and Hodges [48].
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Verbal Learning and Memory Test (VLMT)
The Verbal Learning and Memory Test (VLMT) allows a short and individual assessment of
verbal learning and memory. The VLMT [51] uses 15 semantically independent words to assess verbal
memory. In a second step, an interference list with 15 new words is learned and recalled to distract
from the first, target list. After 20–30 min a delayed recall of the target list and a recognition test with a
new list combining the 30 learned words with 20 semantically and phonemically similar words is done.
Benton Test
The Benton Test (first edition: Benton, 1946) is a visual retention test for clinical use testing the
memory of visuo-spatial stimuli. The patient has to reproduce, draw or recognize presented graphic
stimuli. In this trial, instruction A (10 figures shown for 10 s) and parallel forms C, D and E are used.
The Benton Test has been shown to have a high internal consistency (Cronbach’s alpha = 0.94–0.98)
and validity [52].
Geriatric Depression Scale (GDS)
The Geriatric Depression Scale (GDS) is used to measure depressive symptoms in older persons.
It is a 15-item questionnaire demanding a dichotomous (yes/no) evaluation of depressive symptoms.
It was also shown to be applicable for persons with advanced cognitive impairment [53]. The GDS
shows a high internal consistency (Cronbach’s alpha 0.91).
The standardized questionnaires used in the IMAD trial as well as the respective cut-off values
applied are summarized in Table 3.
Table 3. Assessments by standardized questionnaires.
Test Abbreviation No Impairment Severe Impairment Normal Range
Mini-Mental State Examination MMSE 30 0 26–30
Alzheimer’s Disease Assessment
Scale—cognitive Scale ADAS-Cog 0 70 0–4
Memory 0 22 -
Cognitive Functioning 0 28 -
Language 0 15 -
Verbal Learning and Memory Test VLMT
Learning 75 0 48–75
Loss after Interference 0 15 -
Loss after Delay 0 15 0–3
Recognition 0 15 -
Benton Test Benton Test
Number Correct Score 10 0 -
Error Score 0 - -
Geriatric Depression Scale GDS 0 15 0–5
ADAS-Cog, Alzheimer’s Disease Assessment Scale–Cognition; VLMT, GDS, Geriatric Depression Scale; Verbal
Learning and Memory Test.
2.5.3. Cardiovascular Examinations
All cardiovascular examinations are conducted according to standardized procedures by certified
study nurses and physicians at the cardiovascular examination center of the German Centre
for Cardiovascular Disease (DZHK) in Greifswald. The following examinations are part of the
IMAD phenotyping:
Brachial Blood Pressure Measurement
Measurements of the brachial blood pressure are taken using an Omron 705 IT (OMRON Healthcare
Europe) blood pressure monitor with appropriate cuff size after a resting period of at least 5 min in
a sitting position. Accordingly, three measurements are taken on the right arm, with a 3-min break
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between each measurement [54]. All individual measurements (systolic blood pressure [mmHg],
diastolic blood pressure [mmHg], heart rate [/min]) are recorded.
Pulse-Wave Analysis and Central Hemodynamics
To perform cuff-based non-invasive data capturing at the brachial artery, the invasively validated
Mobil–O–Graph pulse-wave analysis (PWA) monitor (IEM GmbH, Stolberg, Germany) with inbuilt
ARCSolver algorithm is used [55,56]. After conventional blood pressure measurements, the brachial
cuff is inflated additionally to the diastolic blood pressure level and held for about 10 s to record
pulse waves. Subsequently, central pressure curves are automatically obtained through a transfer
function. In total, three measurements are taken, with a 3-min break between each measurement.
The following parameters are assessed by this method: pulse-wave velocity (PWV [m/s]), augmentation
index (Aix [%]), heart-rate corrected augmentation index (Alx@75 [%]), central systolic blood pressure
(cSBP [mmHg]), and central diastolic (cDBP [mmHg]).
Digital Endothelial Vascular Function and Stiffness
Digital pulse amplitude is measured with a pulse amplitude tonometry device placed on the tip
of the right index finger (Endo-PAT2000, Itamar Medical, Caesarea, Israel) [57]. This device comprises
a pneumatic plethysmograph that applies uniform pressure to the surface of the distal finger, allowing
measurement of pulse volume changes. Throughout the study, the inflation pressure of the digital
device is electronically set to 10 mm Hg below diastolic blood pressure or 70 mm Hg (whichever is
lower). Baseline pulse amplitude is measured for 2 min 20 s. Arterial flow is interrupted for 5 min
by a cuff placed on a proximal forearm using an occlusion pressure of 200 mm Hg or 60 mm Hg
above systolic blood pressure (whichever is higher). The pulse amplitude is recorded electronically
and analyzed by the computerized, automated algorithm of the device that provides the average
pulse amplitude for each 30-s interval after forearm cuff deflation up to 4 min [57]. The following
parameters which are known markers of endothelial function and vascular stiffness is derived from
these measurements: augmentation index (Aix [%]), heart-rate corrected augmentation index (AIx@75%
[%]), reactive hyperemia index (RHI) [57].
Transcutaneous Oxygen Pressure (tcPO2)
Transcutaneous oxygen pressure (tcPO2) measurements are performed with the PRÉCISE
8008 device (medicap GmbH, Ulrichstein, Germany). After a resting period of at least 10 min
in supine position, four probes are placed at the dorsum of the feet and at the back of both hands.
Measurements are taken while patients are breathing ambient air, in a resting supine position at
room temperature, between 22 ◦C and 25 ◦C. The site on the foot is carefully cleaned before the
probes are applied to the skin, using adhesive rings and contact liquid, supplied by the manufacturer.
The measurements are performed after calibration and preheating of the transducer to approximate
44 ◦C [58]. After termination of the procedure tcPO2 [mmHg] values for the four measurement sites
are recorded.
Echocardiography
Transthoracic echocardiography as a non-invasive gold standard for the determination cardiac
function and morphology is performed by certified physicians (Vingmed Vivid 9, 5S transducer
2.0–5.0 MHz, GE Medical Systems GmbH, Hamburg, Germany). All images and loops are stored
digitally and are analyzed offline. The reading of the echocardiograms is performed according to
current recommendations [59] includes parameters of left atrial and left ventricular (LV) structure
(left atrial diameter in parasternal short axis [mm]; left atrial volume in 4 chamber view [cm2],
enddiastolic/endsystolic thickness of the intraventricular septum and posterial wall [mm], LV mass [g],
enddiastolic/endsystolic LV volume [mL]) as well as LV systolic and diastolic function (biplane LV
ejection fraction according to Simpsons rule [%], global longitudinal strain [%], peak velocity of the
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mitral E- and A-wave [cm/s], deceleration time of the mitral E-wave [ms], isovolumetric relaxation
time [ms], peak velocity of the excursion of the lateral and septal mitral annulus in the early diastolic
phase [cm/s], ratio between the peak velocity of the excursion of the mean lateral/septal mitral annulus
in the early diastolic phase and the peak velocity of the mitral E-wave).
2.5.4. Kidney Function and Ultrasound
Kidney function is determined by blood and urinary laboratory tests: estimated glomerular
filtration rate by serum creatine and urinary albumin–creatinine ratio.
Renal ultrasound is performed with a HITACHI EUB-7500 machine. Kidney length is determined
as the maximum longitudinal dimension. Parenchymal thickness is measured as the shortest distance
from the renal sinus fat to the renal capsule at three different points: at the upper and lower pole
and at the middle. The parenchymal-pyelon-index is calculated as the sum of ventral and dorsal
parenchymal thickness (in a cross-section of the kidney) divided by the width of the central echo
complex. The following categories are generally assessed: location, anomalies as agenesis, hypo-
or hyperplasia, horseshoe kidney; kidney length; kidney width; parenchymal thickness; surface
roughness; echogenicity; parenchymal-pyelon-index; medullary or parenchymal calcification; number
and size of cysts, stones, infraction zones and tumors [60].
2.5.5. Ultrasound of the Extracranial Arteries
Ultrasound of the extracranial arteries is performed with a Philips UI 22 machine. Extracranial
carotid and vertebral arteries (VA) are examined with linear ultrasound transducers (bandwidth
3–13 MHz). Systolic, diastolic, and mean flow velocities in common carotid artery, internal carotid
artery (ICA), and V2 segments of VA are documented after angle correction. We classify ICA stenosis
uniformly according to current ultrasound criteria for grading internal carotid artery stenoses of
the the German Society of Ultrasound in Medicine (DEGUM) and Transfer to grading system of the
North American Symptomatic Carotid Endarterectomy Trial (NASCET) [61]: if peak systolic velocity
(PSV) is ≥125 cm/s, ICA stenosis is defined as being equivalent to ≥50% according to North American
Symptomatic Carotid Endarterectomy Trial criteria. Occlusion is defined by absence of Doppler and
color signal, typical proximal biphasic Doppler spectra, and additional indirect criteria like crossflow.
Carotid plaque is defined as any arterial wall irregularity thicker than 1.5 mm or exceeding >50% of
the surrounding wall thickness that protruded into the vessel lumen.
VA measurements are taken in the V2 segment and considered abnormal if there is direct
evidence of local or indirect evidence of proximal or distal flow abnormalities. Overall, abnormal flow
characteristic of the posterior circulation is defined by at least unilateral (1) flow abnormality of the
(extracranial) V2 segment of either VA, (2) intracranial VA stenosis or occlusion, or (3) basilar artery
(BA) stenosis or occlusion.
2.5.6. Blood and Urine Samples
Blood and urine samples are obtained according to standard operating procedures. In total,
403.7 mL blood and 42.0 mL urine are obtained per participant (250.0 mL for serum analysis, 121.5 mL
for plasma analytics, 16 mL EDTA, 16.2 mL Citrate). At the study center, samples are analyzed
immediately after blood and urine sampling. Two aliquots of 0.5 mL serum are stored in a freezer
(−80 ◦C) for further analysis.
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For sample analyses at independent laboratories (see Section 2.5.8), blood samples (170.0 mL
for serum analytics, 49.5 mL for plasma analytics) are collected at the study center. Further sample
management is accomplished by biometec GmbH, Greifswald, Germany.
Blood samples are obtained according to standard operating procedures. In total, 29 mL were
obtained per participant (8.5 mL for serum analysis, 8 mL for plasma analytics, 10 mL EDTA, 2.5 mL for
blood RNA). At the study center they were stored in a freezer at −80 ◦C). For this analysis, 100 aliquots
were available.
2.5.7. Laboratory Parameters
A complete list of the laboratory parameters can be found in the Appendix A (Table A1).
Laboratory analytics of blood and urine are carried out in accordance with established standard
operating procedures and preanalytical protocols follow the schemes of the GANI_MED (Greifswald
Approach to Individualized Medicine) project [62].
2.5.8. Assessment of Autoantibodies
An enzyme-linked immunosorbent assay (ELISA) is used to detect agAAB as described
previously [37,63]. Analyses are performed by an independent laboratory (E.R.D.E.-AAK-Diagnostik
GmbH, Berlin, Germany) blinded to clinical patient data. In brief, peptides are directed against the
ß1-adrenergic receptor loop 1 and ß2- adrenergic receptor loops 1 and 2. Modified peptides are bound
to 96-well streptavidin-coated plates. Peptides are coupled to preblocked streptavidin-coated 96-well
plates (Perbio Science, Bonn, Germany). Patient serum is added in a 1:100 dilution and incubated for
60 min. As detection antibody a horseradish peroxidase conjugated anti-human IgG antibody is used
(Biomol, Hamburg, Germany). Antibody binding is visualized by the 1-Step Ultra TMB ELISA (Perbio
Science, Bonn, Germany). The absorbance is measured at 450 nm against 650 nm with an SLT Spectra
multiplate reader (TECAN, Crailsheim, Germany).
As confirmation test, a bioassay is used that has been established by Wallukat and Wollenberger for
the identification and quantification of GPCR-AABs [64], and that has been modified and standardized
as described previously [65,66]. Analyses are performed by an external laboratory (Berlin Cures GmbH,
Berlin, Germany) without knowledge about any further patient characteristics or parameters. In this
bioassay, the chronotropic response of spontaneously beating cultured neonatal rat cardiomyocytes to
patients’ IgG-containing GPCR-AABs is recorded [67].
Anti-NMDA (N-methyl-D-aspartate) autoantibodies are determined in the participant’s sera by
immunohistochemistry according to manufacturer’s instruction (Anti-Glutamate-Receptor-IgG (Typ
NMDA)–IFFT, EUROIMMUN, Lübeck, Germany).
Additional measurements are performed by biometec GmbH, Greifswald. This includes
analyzes of antibodies against oxidized low-density lipoprotein (oxLDL) and β-amyloid, vasculitis
marker (aab against myeloperoxidase (anti-MPO), proteinase 3 (anti-PR3), glomerular basement
membrane (anti-GBM)), B-cell activity and antibody development (B-cell activating factor (BAFF)) and
neurodegeneration (neurogranin).
2.6. Intervention
Immunoadsorption is performed with ADAsorb apheresis devices equipped with Globaffin
adsorber columns in the dialysis department of the University Medicine Greifswald.
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The Globaffin column is a regenerative twin adsorber system that utilizes peptide ligands
(Peptid-GAM®; Fresenius Medical Care, Bad Homburg, Germany) covalently bound to sepharose.
These peptide ligands have a strong affinity for Fc fragments of immunoglobulins from any source
and selectively remove immunoglobulins and immune complexes from plasma without affecting
other plasma proteins. The Globaffin adsorber system has previously been used in antibody mediated
disorders, such as dilated cardiomyopathy and acute renal transplant rejection [68].
In contrast to unselective plasma exchange where all plasma components including albumin,
clotting factors and immunoglobulins are discarded and replaced with a fluid containing either albumin
and colloid or donor plasma, immunoadsorption is a semi-selective device. First, the patient’s plasma
is separated from blood cells by a membrane. Plasma is then passed over the Globaffin twin adsorber
system which selectively remove IgG, IgA, and IgM before the plasma is re-infused to the patient.
Typically, approximately four column volumes (250 mL) are processed before the plasma stream is
directed to the second column within the device and the first column undergoes a four-step regeneration,
so that the apheresis cycle can be reiterated: (1) replacement of residual plasma by 0.9% NaCl solution; (2)
elution of bound immunoglobulin by hydrochloric acid [glycine-HCl] buffer at pH 2.8; (3) neutralization
by phosphate buffered saline [PBS] and 4. replacement of PBS by 0.9% NaCl (Figure 3).
Figure 3. Principle of immunoadsorption. Principle of the immunoadsorption treatment. Reprinted
from [68] with permission of John Wiley and Sons.
A separate twin-column pair is assigned to each patient. A total of approximately 2.0-fold of
blood plasma volume is processed per day (approximately 4 to 6 h per session) on five consecutive
days. After the immunoadsorption series, the patients receive 500 mg per kg body weight intravenous
immunoglobulin substitution on day 6 (during approximately 6 h). The dose is determined based
on body weight and amounts to 500 mg/kg, depending on the packaging size. The eluates of the
regeneration of the columns are collected automatically and are used for detailed immunological
analyses. The patients are hospitalized for the immunoadsorption procedures and Ig substitution
period in the neurological department of the University Medicine Greifswald.
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2.7. Statistical Considerations
The objective of this trial is to assess the effects of IA/IgG in patients with agAABs and dementia in
patients with suspected Alzheimer’s clinical syndrome. The primary target parameter is uncorrected
mean cerebral brain perfusion as assessed by ASL 12 months after treatment.
2.7.1. Statistical Analyses
Analyses will follow an exploratory approach since we plan n = 15 subjects but do not consider a
comparison group. Although the main focus of analysis is descriptive, there is an interest in comparing
the development of outcomes of 1 month before and 12 months after IA/IgG.
Effect sizes will be estimated using appropriate (generalized) linear mixed regression models.
If necessary non-parametric models will be used. To evaluate effect sizes, suggestions according to
Cohen (1988) are used [69]. Analyses are performed as intention-to-treat (ITT) and per-protocol (PP).
2.7.2. Missing Data
Missing values are not replaced with substituted values. Due to the small sample size and the
exploratory character of the investigation, imputation techniques are not recommended.
2.7.3. Effect Size Consideration
Assuming a prevalence of agAABs of 31.5% and a drop-out rate of 20%, 120 participants have to
be checked for eligibility to reach the aim of 15 participants enrolled in the intervention. With a sample
size of n = 12, an expected α-error of 5% and a power of 80%, standardized effect sizes of 0.766 can be
detected (for one-sided paired t-tests), thus allowing a possible drop out of maximal 3 participants.
For data analyses, Stata (Version 14, StataCorp, College Station, TX, USA), SPSS statistics version
22 (IBM Corp., Armonk, NY, USA) or MATLAB (Version R2015a, Mathworks Inc., Natick, MA, USA)
will be used.
3. Discussion
The IMAD study investigates a new pathophysiological and therapeutic aspect of Alzheimer’s
clinical syndrome, the removal of α1AR-agAABs by immunoadsorption in patients with cognitive
impairment and suspected AD. Outcome parameters comprise cerebral blood flow measured
by arterial spin labelling MRI (primary), cognition measured by validated cognitive tests and
other questionnaires (ADAS-Cog, MMSE, VLMT, Benton Test, GDS) and vascular effects assessed
by echocardiography, sonography, blood pressure, pulse wave velocity, plethysmography and
transcutaneous oxygen measurement.
Extracorporeal therapies for dementia in Alzheimer’s clinical syndrome and CVD are innovative
therapeutic options. Recently, three different medical devices have been tested: dialysis, TPE and
IA. The Spanish AMBAR study is currently examining whether the peripheral lowering of Aß by
TPE and concurrent albumin substitution has an impact on cognitive performance [70]. Kitaguchi
and colleagues use dialysis systems [71] and adsorptive double-filtration systems [8] to lower the
plasma levels of Aß. Both groups are assuming that the removal of Aß may reduce the cerebral Aß
load. By using IA, we contrary aim to target vascular effects of α1AR-agAABs and only secondarily at
a probably better clearance of Aß. The IMAD study can profit from the experience of a previously
performed open pilot trial [38]. In this earlier study, the applicability of apheresis to dementia patients
and safety aspects were examined. The sustainability of the elimination of α1AR-agAABs was proven
and the first indications of a stabilization of cognitive performance were observed. The IMAD study
now investigates whether the removal of α1AR-AABs by a 5-day IA procedure has a positive effect
(improvement or non-deterioration) on impairment-relevant hemodynamic, cognitive, neurological,
vascular and metabolic parameters within a one-year follow-up period.
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As an exploratory trial, the IMAD study has, owing to feasibility constraints, a small projected
sample size in a monocentric, single-arm and unblinded design. Thus, only large effects can reach
statistical significance and, even then, the absence of a control group and other trial site(s) will still
confine the validity of the results. Nevertheless, this trial may provide important insights whether
eliminating or reducing α1AR-agAABs as a contributing factor of dementia-related cerebrovascular
impairment opens up a completely new treatment approach for α1AR-agAABs-positive persons along
the course of dementia progression in patients with Alzheimer’s clinical syndrome. It is of course
possible that other agAABs also play a role in the disease course, e.g., ß2AR which has been found in
dementia patients in previous studies [37,38].
In this respect, the comprehensive and extensive set of measured endpoints has the potential
to indicate possible intervention effects on a broad (patho)physiological spectrum. Indeed, the trial
protocol has been devised deliberately to comprise as many measurable physiological and metabolic
parameters as possible besides the neurocognitive tests. Therefore, the IMAD trial results will
allow to correlate intervention effects with potential physiological or functional mode(s) of action.
Such correlations may form the basis of targeted, larger and statistically more robust trials to specifically
and precisely uncover the effects of immunoadsorption on affected patients. In the future, the optimal
intervention time during the disease progression and the determinants that predict and govern the
response profile should be addressed in order to achieve a maximal beneficial effect of IA. In this
regard, one challenge will be to pinpoint the actual pathomechanistically active autoantibodies or
autoantibodies to delineate less-invasive specific depletion or inactivation schemes.
However, if the IA treatment approach does turn out to have a beneficial capacity for at least a
well-defined subgroup of patients at risk of dementia progression in Alzheimer’s clinical syndrome,
its one-time character (a single week of hospitalization) will certainly be advantageous, discarding or
at least attenuating the pharmacotherapeutic need for long-term compliance adherence. For reasons
that have not yet been clarified, the GPCR-AABs seldom reoccur after being removed—both in
DCM [36,72,73] and in dementia [38].
In the case of a positive outcome of the planned study, functional vascular improvement and
cognitive stability or improvement over at least 12 months, knowledge and experience should have
been gained to start a well-planned controlled, prospective, multicenter and randomized clinical study.
Its data could then be used to prove that IA is suitable for the treatment of mild and moderate dementia
with vascular pathological AABs and complements antidementive drug therapies with other targets.
Our study design has potential strengths and limitations that merit further discussion. We see the
interdisciplinary approach where knowledge from different disciplines and viewpoints are combined
as a unique strength. A further strength resulting directly from this is the comprehensive phenotyping
with different end-points to generate a broad spectrum of results that may help design a subsequent
multicenter pilot study. As a potential limitation we see the small sample size with low statistical
power. For this reason, we are also not able to investigate other potential risk factors (e.g., genetic
disposition). As we include patients with cognitive impairment without additional testing of CSF
biomarkers we face limitations in the diagnostic classification of their syndromes. Thus, we prefer
to label their impairments as suspected or probable AD. On the other hand, we use well-validated
neuropsychological testing (MMSE, ADAS-cog, Benton Test, VLMT) and carefully exclude many
medical conditions that could lead to secondary and potentially treatable dementia. Moreover, based on
the MRI scans we can exclude patients with organic/structural brain damages from the study. In fact,
our intention behind this patient selection was the inclusion of patients in their beginning or early phase
of probable AD to detect possible changes due to immunoadsorption in physiological and cognitive
parameters which might not occur in later states of dementia and to ensure the ability of collaboration
and adherence throughout a 12-months follow-up period of the study. Furthermore, we may miss
results in the long-term for future associations and detection of causalities due to the relatively short
follow up time of 12 months. Additionally, knowledge about the prevalence of agonistic autoantibodies
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in other forms of dementia and in the general population is limited. Keeping these limitations in mind,
our study is designed as an exploratory study and aims at showing proof of principle.
4. Conclusions
IMAD is an important pilot study that will analyze whether the removal of α1AR-agAABs by
immunoadsorption inα1AR-agAAB-positive persons slows the progression of dementia in Alzheimer’s
clinical syndrome and/or improves vascular functional parameters.
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Abstract: Multiple sclerosis (MS) is an inflammatory disease mainly affecting the central nervous
system. In MS, abnormal immune mechanisms induce acute inflammation, demyelination, axonal
loss, and the formation of central nervous system plaques. The long-term treatment involves
options to modify the disease progression, whereas the treatment for the acute relapse has its focus
in the administration of high-dose intravenous methylprednisolone (up to 1000 mg daily) over a
period of three to five days as a first step. If symptoms of the acute relapse persist, it is defined as
glucocorticosteroid-unresponsive, and immunomodulation by apheresis is recommended. However,
several national and international guidelines have no uniform recommendations on using plasma
exchange (PE) nor immunoadsorption (IA) in this case. A systematic review and meta-analysis was
conducted, including observational studies or randomized controlled trials that investigated the effect
of PE or IA on different courses of MS and neuromyelitis optica (NMO). One thousand, three hundred
and eighty-three patients were included in the evaluation. Therapy response in relapsing-remitting MS
and clinically isolated syndrome was 76.6% (95%CI 63.7–89.8%) in PE- and 80.6% (95%CI 69.3–91.8%)
in IA-treated patients. Based on the recent literature, PE and IA may be considered as equal treatment
possibilities in patients suffering from acute, glucocorticosteroid-unresponsive MS relapses.
Keywords: multiple sclerosis; plasma exchange; immunoadsorption
1. Introduction
Multiple sclerosis (MS) is a disease which is defined as an inflammatory condition affecting the
central nervous system. Its main course of damage is due to abnormal immune mechanisms, resulting
in acute inflammation, demyelination, axonal loss, and the formation of central nervous systemplaques
consisting of inflammatory cells [1,2].
The epidemiology of MS differs greatly depending on the geographic regions with a prevalence
from high levels in North America and Europe (>100/100,000 inhabitants) to low rates in Eastern Asia
and sub-Saharan Africa (2/100,000 population). Women are generally more affected than men [3].
Symptoms that occur with the onset of MS are very unspecific, since MS can affect all regions
of the central nervous system and can make it hard for a physician to make an early diagnosis.
Symptoms of MS include vision problems with a decreased visual acuity (VA) and a prolonged visual
evoked potential (VEP), weakness, fatigue, spasms, ataxia, cognitive dysfunction, or numbness [4].
The occurrence of an optic neuritis in its typical form is considered to be associated with MS. However,
it is also regarded as a demyelinating clinically isolated syndrome (CIS) with the risk to convert to MS,
especially in the white population [5]. With such a variety of symptoms a thorough medical history and
examination is essential to make the right diagnosis of MS. Blood tests, lumbar punctures, magnetic
resonance imaging, and evoked potential tests help in the process of differentiating between other
diseases [6]. Based on the symptoms and the progression of the disease MS is divided in four types:
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Relapsing-Remitting MS (RRMS), Secondary-Progressive MS (SPMS), Primary-Progressive MS (PPMS),
and Progressive-Relapsing MS (PRMS).
MS can be characterized as a T-cell-driven disease with T helper (Th) cells, especially Th-1, Th-2,
and Th-17 cells, as the main players in a various inflammatory cascade [7]. For instance, Th-1 cells are
responsible for producing Interferon gamma (IFNγ) and tumor necrosis factor alpha (TNF-α) [8]. With the
secretion of IFNy and TNF-α inflammation can be maintained by inhibiting Th-2 cell differentiation, since
Th-2 cells produce anti-inflammatory cytokines like interleukin (IL)-4 and IL-13 [9,10]. Th-17 cells stimulate
inflammation via secreting a vast number of various cytokines like IL-17, IL-21, IL-22, and IL-26 [11–13].
As a counterpart regulatory T (Treg) cells inhibit autoimmune responses [14]. In addition to that
immunoglobulins (Ig) (especially IgG) are important in the pathogenesis of MS. Evidence of intrathecal
Ig production and oligoclonal IgG bands contribute to the diagnosis of MS. Further differentiation
shows various types of specific autoantibodies against myelin in subgroups of patients with MS, e.g.,
anti-myelin oligo-dendrocyte glycoprotein (anti-MOG) or anti-myelin basic protein (anti-MBP) [15].
Antibody-producing B-cells traveling between CNS, blood, and peripheral lymphatic organs clonally
expanded B-cells and aggregated B-cells in meninges corroborate a pathophysiological role of B-cells
and/or humoral immune answer in the pathogenesis of MS [16–19].
Based on the myelin protein loss, the geography and extension of plaques, the patterns of
oligodendrocyte destruction, and the immunohistopathological evidence of complement activation
Lucchinetti et al. described four different immunohistopathological patterns of demyelination in
MS [20]. Patterns I and II showed close similarities to T-cell-mediated or T-cell plus antibody-mediated
autoimmune encephalomyelitis. Patterns III and IV on the other hand were highly suggestive of a
primary oligodendrocyte dystrophy.
Neuromyelitis optica (NMO) on the other hand is described as an idiopathic, severe, demyelinating
disease of the central nervous system with the preference to affect the optic nerve and spinal cord.
NMO has been considered as a variant of MS. However, with the analysis of clinical, laboratory,
immunological, and pathological data the difference to MS is now acknowledged [21].
The treatment regime can be divided in treatment to modify the disease progression and treatment
for the acute relapse. In the latter, the administration of high-dose intravenous methylprednisolone
(up to 1000 mg daily) over a period of three to five days usually represents the first step in
acute MS relapse treatment. A higher second high-dose intravenous methylprednisolone pulse
with up to 2 g can be considered in unresponsive patients after an interval of 2 weeks [22–24].
Glucocorticoids may downregulate cellular cytotoxicity and lead to the death of activated B cells,
but they will not modulate tissue destruction or conduction blockade by local antibody deposition [25].
If symptoms persist, the relapse is defined as glucocorticosteroid-unresponsive and immunomodulation
by apheresis is recommended. However, several national and international guidelines have no uniform
recommendations on using plasma exchange (PE) or immunoadsorption (IA) in this case. The American
Society for Apheresis (ASFA) recommends PE for treatment to category II (“apheresis accepted as
second-line therapy”) and IA for treatment to category III (“optimum role of apheresis therapy is not
established”) [26]. The American Academy of Neurology also advises the use of PE for adjunctive
treatment of relapsing forms of MS (Level B), while IA is not addressed [27,28]. The German guidelines
are currently under reconstruction but formerly recommended both procedures as equivalent [29].
In this current issue, we review the use of IA and PE in treating, especially, the acute relapse of MS.
2. Effects of Apheresis Therapy
During PE, the patient’s plasma, including all plasma proteins, is removed and substituted by
human albumin solution or fresh frozen plasma. The concept of IA involves a selective elimination
of plasma proteins, e.g., antibodies, while sparing other plasma proteins [30]. Both techniques
include an extracorporeal circulation circuit with systemic and/or local anticoagulation, as well as
the need of a vascular access. The latter can either be peripheral venous, if individual vascular
situation allows it, or by a central venous catheter. In IA, a secondary circuit is established in which
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a defined physico-chemical interaction of selected plasma proteins with a defined matrix should
theoretically guarantee selective removal of circulating pathogens. In praxis, a bandwidth of proteins
are removed [31,32] which are responsible for therapeutic effects but also possible side effects of IA.
These effects differ with regard to used matrix of the adsorber, which physicians should be aware.
The exact mechanism by which apheresis treatment works is actually not fully understood.
MS patients may benefit by the immediate removal of plasma antibodies, immune complexes and
cytokines, induction of a redistribution of antibodies from the extravascular space, and subsequent
immunomodulatory changes [30]. Here, cell types with receptors for immunoglobulins (Fc receptors),
such as monocytes, macrophages, and natural killer cells, are especially of interest [25]. Besides effects
on humoral immune system, experimental data suggest a reduction of circulating autoantigens and
regulatory proteins [32] and induction of a higher relative quantity of Treg to Th17 cells [33], as well as
a silencing of cellular autoimmune response [32].
Early active MS lesions with an immunohistopathological type II pattern, which are selectively
associated with Ig’s and complement deposited along myelin sheaths, predict the best response to
apheresis therapy in patients with steroid-unresponsive relapse [34], corroborating the hypothesis of
effects on humoral immune response.
3. Plasma Exchange
3.1. Multiple Sclerosis (with Relapsing-Remitting and Progressive MS Sub-Sections)
The first study comparing the normal therapy regime with PE was performed by Khatri et al.
in 1985 and included fifty-four patients with chronic progressive MS [35]. The results showed that
patients with the additional PE have a higher improvement rate than patients with a “sham” PE.
Following the study of Khatri et al., Weiner et al. enrolled 116 patients in a multicenter, randomized,
double-blinded, controlled trial of 11 PE treatments in acute exacerbations of MS [36]. One of the main
results showed patients treated with PE to have a significantly enhanced improvement after four weeks.
In 1999, a study group of the Mayo Clinic conducted a randomized, sham-controlled, double-blinded
study of PE in MS patients with severe neurological deficits after acute relapses, unresponsive to
corticosteroids [37]. This study resulted in a moderate to greater improvement in neurological deficits
in 42.1% of patients with true PE versus 5.9% of patients with sham PE. With the improved work
with PE in the clinical setting, a variety of retrospective studies could demonstrate an improvement
rate between 59–87.5% [38–40]. In a large study with 153 patients enrolled, Magana et al. identified
90 patients with moderate to marked functional neurological improvement within 6 months after
treatment with PE [41].
An excellent and actual overview on apheresis in progressive MS forms is available in Reference [30].
So far, the ASFA recommends PE for treatment to category III: “Optimum role of apheresis therapy is
not established. Decision making should be individualized” [26].
3.2. Clinically Isolated Syndrome
More recent studies set their focus not only on the relapsing-remitting and progressive MS
sub-sections but also on the clinically isolated syndrome [42–44]. Therapy response rates ranged
between 72–76%, therefore achieving a clinical response in the majority of patients.
3.3. Optic Neuritis
Studies analyzing the use of PE in the setting of for severe steroid unresponsive optic neuritis
were performed by Ruprecht et al. and Deschamps et al. [45,46]. Ruprecht et al. al. demonstrated
an improvement of visual acuity in 70% of patients. Out of these seven patients, three continued to
improve with their visual acuity, two remained at a stable state, whereas two patients suffered from
worsening symptoms during the follow-ups [46].
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In the study performed by Deschamps et al., thirty-four patients with a remaining visual acuity of
0.1 were treated with PE. Afterwards, the median visual acuity was 0.8 [45].
Studies on PE are summarized in Table 1. However, the reader must be aware that the comparability
of the studies is limited by the different technical implementation of PE. This varied in frequency,
treated plasma volume, and total number of PEs. As a result, the ASFA defined a corridor of technical
implementation that recommended treatment of 1–1.5-fold plasma volume per session for a number of
5 to 7 treatments over a period of 10 to 14 days [26].
Table 1. Studies on plasma exchange (PE) in treatment of relapsing-remitting multiple sclerosis
(RRMS), clinically isolated syndrome (CIS), progressive MS, isolated optic neuritis, and neuromyelitis
optica (NMO). EDSS = Expanded Disability Status Scale.
“Relapsing-Remitting Multiple Sclerosis” and “Clinically Isolated Syndrome”




















[39] 2005 13 Retrospective 5 3000 Therapy response in71% of patients
Small number of
subjects






















[48] 2013 15 Retrospective ≥7 1.0-fold plasmavolume
Therapy response in
93.3% of patients RRMS + CIS
[49] 2014 11 Retrospective Median 7(3–8) 3000 (2200–3500)
Therapy response in
91% of patients CIS only
[43] 2015 90 Retrospective 3–8 1.0-fold plasmavolume
Therapy response in
72% of patients
The lack of a control
group
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the PE only group
[51] 2018 46 Retrospective Mean 7.39sessions n.a.
Complete therapy
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Table 1. Cont.
“Progressive Multiple Sclerosis”












































[46] 2004 10 Retrospective n.a. n.a. Therapy response in70% of patients
Small number of
subjects
[55] 2012 23 Retrospective 5 ~3000 Therapy response in70% of patients heterogenous












The lack of a control
group
“Neuromyelitis Optica”





[57] 2007 6 Retrospective 3–5 2000–3000 Therapy response in50% of patients
Small number of
subjects





[41] 2011 26 Retrospective 7 n.a. Therapy response in42.3% of patients
Historical cohort
study
[59] 2013 31 Retrospective n.a. n.a. Therapy response in65% of patients
No study controlled
treatment regimes









of EDSS scores as
the primary
outcome measure
[62] 2017 21 Retrospective 5 n.a. Therapy response in81% of patients
Use of EDSS scores
as the primary
outcome measure
[63] 2018 28 Retrospective 5 1000 Therapy response in42.9% of patients
Use of EDSS scores
as the primary
outcome measure
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Table 1. Cont.
“Neuromyelitis Optica”










[67] 2018 146 Retrospective ≥3 n.a. Therapy response in86% of patients
Heterogenous
treatment protocols




4.1. Multiple Sclerosis (with Relapsing-Remitting and Progressive MS Sub-Sections)
IA was firstly introduced in the treatment of MS by de Andres et al. in 2000 [69]. They managed
a prompt and unequivocal clinical response with a parallel decrease in IgG, fibrinogen, and C3
complement plasma levels in all three patients treated with IA. In the following years, retrospective
studies confirmed the initial results of de Andres et al., showing improvement rates from 85–88.3% in
MS patients receiving an IA therapy [70,71].
4.2. Clinically Isolated Syndrome
Studies incorporating patients with clinically isolated syndrome showed marked to moderate
clinical response with a total gain of function in 66–100% of patients after treatment with
immunoadsorption [42,72].
4.3. Neuromyelitis Optica
The first prospective study investigating effects of IA therapy in patients with MS with
steroid-refractory optical neuritis showed an improvement of the mean visual acuity in 8 from
11 patients at day 180 ± 10 after IA [32]. A more recent study confirmed the efficacy and good tolerance
of IA in relapses of MS patients with failure to respond to a steroid pulse therapy adequately. Moreover,
the study established IA as first-line relapse treatment during pregnancy and breastfeeding [73].
The most commonly used column was a tryptophane-linked polyvinyl alcohol adsorber, but also
a Sepharose-conjugated sheep antibodies to human IgG, as well as protein A column, have been used.
Table 2 gives an overview about IA-studies in acute relapses of MS.
5. Plasma Exchange vs. Immunoadsorption
5.1. Multiple Sclerosis (with Relapsing-Remitting and Progressive MS Sub-Sections)
Recently, studies have been designed to compare the efficacy of PE versus IA. The most impressive
work is that of Dorst et al. [42]. Sixty-one patients with acute relapse of multiple sclerosis or clinically
isolated syndrome and without complete clinical remission of symptoms after at least one cycle of
high-dose intravenous methylprednisolone were randomly assigned to receive IA (n = 31) or PE
(n = 30). In the IA group (using a protein A adsorber), the 2.0-fold individual total plasma volume was
processed on day 1, and the 2.5-fold on days 2–5. In the PE group, 2 L of plasma (corresponding to the
0.69 ± 0.12-fold individual total plasma volume) were removed each day and substituted by 5% human
albumin solution. The median improvement of Multiple Sclerosis Functional Composite after 4 weeks
compared to baseline was 0.385 (interquartile range (IQR) 0.200–0.675; p < 0.001) in the IA group and
0.265 (IQR 0.100–0.408; p < 0.001) in the PE group. Improvement in the IA group was significantly
larger (p = 0.034) compared to PE. Response rates after 4 weeks were 86.7% in the IA group and 76.7%
in the PE group. One deep venous thrombosis occurred in each group. One limitation in interpretation
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of this study, however, is that the apheresis dose applied was quite different in the two treatment arms
and the observation period was relatively short.
Hohenstein et al. reported the successful use of IA with regenerating adsorbers in MS patients as
a single center experience [78]. Faissner et al. compared PE and IA directly and demonstrated in a
grouped analysis of patients treated with combined PE/ IA, PE, or IA alone, that all groups presented
with a better result of visual evoked potentials, providing a valid treatment option in steroid-refractory
MS-relapses [50].
5.2. Clinically Isolated Syndrome
Dorst et al. [42] also enrolled patients suffering from a clinically isolated syndrome in their recent
study. The results are discussed above.
5.3. Neuromyelitis Optica
In a small cohort study, Faissner et al. showed equivalent results treating patients with
neuromyelitis optica spectrum disorder with IA instead of PE, constituting IA as a valid therapeutic
option [77]. Studies of our own also indicate PE and IA to be of equal efficacy and treatment
safety [44,79]. We assessed 140 adult patients treated with PE (n = 73) or IA (n = 67) in steroid refractory
multiple sclerosis or neuromyelitis optica. During our studies, we became aware of the fact that
differences in body-mass-index, duration of disease, number of treatments, vascular access and treated
plasma volumes between IA - and PE cohorts are a main concern for possible bias in the assessment of
IA and PE as a treatment for MS patients. We also performed a retrospective single-center cohort study
of pediatric patients with inflammatory CNS demyelinating disorders showing excellent tolerance and
favorable outcomes of PE and IA in all pediatric patients [31].
6. Meta-Analysis on Apheresis Effects on Demyelinating Diseases
6.1. Search Strategy and Inclusion Criteria
A systematic search was performed using Medline and Cochrane Library with combinations
of the search terms “plasma exchange” OR “immunoadsorption” in combination with the terms
“multiple sclerosis” OR “clinical isolated syndrome” OR “neuromyelitis optica” between 1980 and
January 2020. Reports were screened independently for relevance based on title and abstract content
by two authors (M.L. and M.J.K.). Randomized-controlled trials, as well as prospective cohort studies
and retrospective studies and case series, were included if sufficient information on therapy response of
PE or IA was provided. Studies with heterogeneous mixing MS, CIS, and/or NMO patients regarding
therapy response were excluded if the treatment response was not specified separately in the individual
indications. Moreover, case series with a case number less than five in the individual indication were
also excluded. It should be mentioned as a limitation that there was no uniform definition of the
term “therapy response” in the selected works and, with the exception of a few studies, the majority
was retrospective data collection. The flow chart in Figure 1 summarizes the selection of studies in
the meta-analysis.
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Figure 1. Flow chart of study selection. MS = multiple sclerosis, NMO = neuromyelitis optica,
PE = plasma exchange, IA = immunoadsorption.
6.2. Statistical Analysis
Analysis was performed using RevMan V.5.3 (Nordic Cochrane Centre, Copenhagen,
Denmark, the Cochrane Collaboration, 2014). Data were quantitatively synthesized by an
inverse-variance-weighted meta-analysis using a random-effect model because of the presence of
heterogeneity. The normal approximation interval (sqrt(p(1-p)/n)) was used to generate the confidence
interval for the therapy response rate. For studies where the normal approximation interval was
zero, the confidence interval was set to one to calculate the random effect model. The 95% normal
approximation confidence interval is provided in the meta-analyses.
7. Results
With the present search strategy and assessment of full-texts 690 studies, 40 observational and
1 randomized with a total of 1.383 patients could be analyzed. Figure 1 shows the flow chart of
study selection.
Effects of PE can be summarized as follows: in relapsing-remitting MS and clinically isolated
syndrome (12 studies and 398 patients) therapy response of 76.6% (95%CI 63.7–89.8%) (Figure 2A),
in progressive MS (5 studies and 112 patients) therapy response of 53.9% (95%CI 29.5–78.4) (Figure 2B),
in isolated optic neuritis (4 studies and 83 patients) therapy response of 71.5% (95%CI 56.4–86.6%)
(Figure 2C), and in NMO (13 studies and 401 patients) therapy response of 72.5% (95%CI 61.0–83.9%)
(Figure 2D).
Effects of IA can be summarized as follows: in relapsing-remitting MS and clinically isolated
syndrome (9 studies and 352 patients), therapy response of 80.6% (95%CI 69.3–91.8%) (Figure 2E);
and in NMO (2 studies and 37 patients), therapy response of 100% (95%CI 98.6–101.4%) (Figure 2F).
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(E) 
(F) 
Figure 2. The 95% normal approximation confidence interval is provided in the meta-analyses.
The given SE correspond to normal approximation confidence interval (sqrt(p(1-p)/n)). (A) Effects of PE
in RRMS and CIS. (B) Effects of PE in PMS. (C) Effects of PE in opticus neuritis. (D) Effects of PE in
NMO. (E) Effects of IA in RRMS and CIS. (F) Effects of IA in NMO. RRMS = relapsing-remitting multiple
sclerosis, CIS = clinically isolated syndrome, PMS = progressive multiple sclerosis, SE = standard error,
IV= instrumental variables. Figure 2A: Correia et al. [51], Dorst et al. [42], Ehler et al. [49], Ehler at al. [43],
Faissner et al. [50], Habek et al. [38], Lipphardt et al. [44], Magana et al. [41], Meca-Lallana et al. [48],
Schilling et al. [39], Trebst et al. [40], Yücesan et al. [47]. Figure 2B: Giedraitiene et al. [54], Hauser et al. [52],
Khatri et al. [35], Magana et al. [41], Medenica et al. [53]. Figure 2C: Deschamps et al. [45], Merle et al. [56],
Roesner et al. [55], Ruprecht et al. [46]. Figure 2D: Abboud et al. [61], Aungsmart et al. [62], Jiao et al. [64],
Kim et al. [60], Kleiter et al. [67], Kumar et al. [66], Lim et al. [59], Magana et al. [41], Mori et al. [65],
Song et al. [68], Srisupa-Olan et al. [63], Wang et al. [58], Watanabe et al. [57]. Figure 2E: Dorst et al. [42],
Heigl et al. [70], Hoffmann et al. [73], Koziolek et al. [32], Llufriu et al. [80], Mauch et al. [71],
Schimrigk et al. [75], Schimrigk et al. [76], Trebst et al. [72]. Figure 2F: Faissner et al. [77], Kleiter et al. [67].
Table 2. Studies on immunoadsorption in treatment of relapsing-remitting multiple sclerosis (RRMS),
clinically isolated syndrome (CIS) and neuromyelitis optica (NMO).
“RRMS” and “CIS”





Matrix of Adsorber Outcome Limitation
[69] 2000 3 Retrospective 5–6 n.a. n.a. Therapy responsein 100% of patients
small number of
subjects















[71] 2011 14 Retrospective 5–6 n.a. Tryptophan Therapy responsein 85% of patients
small number of
subjects
[75] 2012 24 Retrospective Mean 5(range 3–6) 2000–2500 Tryptophan
Therapy response






[72] 2012 10 Retrospective 5–7 2500 Tryptophan Therapy responsein 66% of patients
small number of
subjects




J. Clin. Med. 2020, 9, 1597
Table 2. Cont.
“RRMS” and “CIS”





Matrix of Adsorber Outcome Limitation




and clinical data on
tolerability were
available
[76] 2016 147 Retrospective n.a. 2000–2500 Tryptophan Therapy responsein 71% of patients
Expanded Disability
Status Scale was used
to measure a change
in relapse-related
disability
[73] 2018 23 Retrospective Mean 5.8 2031 ± 230 Tryptophan Therapy responsein 83% of patients
Lack of a control
group; use of
immunoadsorption
was limited in some
study centers





















protein A Therapy responsein 100% of patients









Matrix of Adsorber Outcome Limitation
[77] 2016 10 Retrospective Mean 5.2(3–7) 2000–2500 Tryptophan
Therapy response
in 100% of patients
Small number of
subjects
[67] 2018 27 Retrospective ≥3 n.a. Tryptophan or ProteinA
Therapy response





Another important fact to consider is the treatment safety. The noted rates of side effects during
those apheresis treatments are very heterogeneous. In the literature one can find complication rates
from 4.2% until 25.6% [81–84]. In 2011, Köhler et al. postulated lower side effects using IA in patients
suffering from myasthenia gravis [85]. They claim that a possible reason for the difference was due to
the absence of albumin-substitution. Zoellner et al. designed a study to investigate the fibrinogen
level and the occurrence of bleeding complications [86]. They demonstrated IA to have a lower
degree of fibrinogen reduction as PE. Bleeding complications occurred in 1.3–3.1% of treatments.
Schneider-Gold et al. reported allergic reactions, hypocoagulability, and bronchorespiratory infections
with a significant higher frequency in the PE-only group as compared to the IA-only group or the both
combined [87].
8.2. Multiple Sclerosis (with Relapsing-Remitting and Progressive MS Sub-Sections) and Clinically
Isolated Syndrome
In the recent study performed by Dorst et al. [42], a general well tolerance was observed with
5 mild infections in the PE group and 4 mild allergic reactions in the IA group. Furthermore, courses
of anemia and thrombocytopenia were documented with anemia being more frequent in the PE group
and thrombocytopenia being more frequent in the IA group.
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8.3. Multiple Sclerosis (with Relapsing-Remitting and Progressive MS Sub-Sections) and Neuromyelitis Optica
In our studies the complication rate was about 3.7% in over 780 apheresis cycles. Furthermore,
we could not detect any differences regarding the safety profile of IA versus PE [44,79].
All in all, both IA and PE have a high tolerability regarding the safety profile. It should be added
that the majority of the documented side effects are to be considered as mild. However, the use of IA and
PE should be reserved to specialized centers familiar with technical procedure and experienced with
this specialized patient population to ensure a high quality of treatment with low complication rates.
9. Treatment Predictors
9.1. General
One major predicting factor is the time to initiate apheresis treatment. Early initiation of apheresis
correlates with a higher response rate as was shown by several study groups [44,60,80,88]. In the onset
of sudden hearing loss, the early initiation of apheresis treatment was also beneficial [89].
Comparing the cumulative corticosteroid doses in apheresis-responders versus non-responders,
no significant difference was shown, which makes a synergistic effect of apheresis and corticosteroids
unlikely [44].
9.2. Multiple Sclerosis (with Relapsing-Remitting and Progressive MS Sub-Sections)
Magana et al. postulated the duration of the disease and preserved deep tendon reflexes as
important clinical predictors [41]. A different approach was followed by the study group of Stork et al.,
who conducted a single-center cohort study with 69 MS patients, evaluating treatment response
in relation to histopathologically defined immunopathological patterns of MS [34]. As early active
demyelinating MS lesions can be divided in 3 different immunopathological patterns of demyelination,
Stork et al. demonstrated that patients with pattern 1 and 2 are most likely to benefit from apheresis
treatment, especially in patients with pattern 2 who show signs of a humoral immune response in
particular. Patients with pattern 3 most likely do not benefit from apheresis treatment. During our
studies, we also became aware of the fact that patients having a good response to apheresis treatment
were significantly younger than non-responders [44]. This observation may be due to a decrease in
remyelination efficiency, as proposed by Sim et al. [90]. A gender-related treatment benefit towards the
female gender was identified in sub-groups of MS patients [44,91].
9.3. Neuromyelitis Optica
In a large study performed by Kleiter et al., it was shown that PE or IA exerts a better recovery
from acute relapses in patients suffering from neuromyelitis optica if they had isolated myelitis [92].
More recent studies focused on the plasma anti-aquaporin-4 immunoglobulin G antibody as a positive
predictor for treatment success with PE or IA in patients suffering from neuromyelitis optica spectrum
disorder [12]. In both studies, particularly, patients with a positive anti-aquaporin-4 immunoglobulin
G antibody responded well to the treatment with PE and IA. In addition to that, no advantage was
revealed for either PE or IA. The disease specificity of anti-aquaporin-4 immunoglobulin G antibody is
almost at 100% and clinical studies with immunohistochemical evidence suggest that this antibody
plays a central role in the pathogenesis of neuromyelitis optica spectrum disorder [93].
These predictors can thus be summarized according to various variables. Table 3 provides
a compilation.
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Table 3. Predictors of apheresis response. EDSS = Expanded Disability Status Scale; MRI =magnetic
resonance imaging. * Pediatric patients only.
“Multiple Sclerosis” (with Relapsing-Remitting and Progressive MS Sub-Sections)
Classification Predictor Citation Meaning
Clinical signs and
symptoms
EDSS ≤ 5 [43] Indicates good apheresis response
Preserved deep tendon reflexes [41] Indicates good apheresis response
Demographics Younger age [44] Indicates good apheresis response




Gadolinium positive MRI lesions [43] Indicates good apheresis response
Histological type 1 and 2 pattern [34] Indicates good apheresis response
Histological type 3 pattern [34] Indicates poor apheresis response
Pre-treatment
No disease modifying drugs [43] Indicates good apheresis response
Short duration of disease [41] Indicates good apheresis response
“Neuromyelitis Optica”




Isolated myelitis [85] Indicates good apheresis response
Laboratory values Anti-aquaporin-4 IgG positive [12] Indicates good apheresis response
“Mixed”
Classification Predictor Citation Meaning
Apheresis Early initiation [44,60,80,88] Indicates good apheresis response
Clinical signs and
symptoms
Lower baseline scores on the EDSS,
visual outcome, and gait scales [94] * Indicates good apheresis response
Pre-treatment Cumulative corticosteroid doses [44] Irrelevant for apheresis response
10. Therapeutic Efficacy and Time Course
As for the time course of the therapeutic effect, the current literature agrees on regular neurological
follow-ups after 6 months, manifesting a continuous and maximal clinical effect of the apheresis
treatment [41,44,60,80]. Therapeutic effects over such a long period of time suggest immunomodulatory
actions of apheresis rather than antibody removal on its own [95]. Those immunomodulatory actions
happen most likely at the level of Th-cells and CNS-associated proteins, like the myelin basic protein.
The prolonged therapeutic effect can be thought of as a clinical correlate of the immunomodulatory
components of therapeutic apheresis. Furthermore, the duration of the apheresis induced therapeutic
effect can be involved in the treatment process of initiating or changing disease-modifying drugs.
11. Conclusions
The focus of this current issue is the use and comparison of immunoadsorption and plasma
exchange in the treatment of multiple sclerosis with the main concern of acute relapses.
Based on the studies of the current literature and performance of a meta-analysis, including
690 studies, 40 observational and 1 randomized with a total of 1383 patients, plasma exchange and
immunoadsorption are treatment options of equal effectivity for acute glucocorticosteroid-unresponsive
multiple sclerosis relapses.
For the meta-analysis randomized-controlled trials, prospective cohort studies, retrospective
studies, and case series with sufficient information on therapy response of plasma exchange or
immunoadsorption were included. Studies with heterogeneous mixing multiple sclerosis, clinically
isolated syndrome, and/or neuromyelitis optica patients regarding therapy response were not included
if the treatment response was not specified separately in the individual indications.
Plasma exchange has a therapy response of 76.6% in relapsing-remitting multiple sclerosis (RRMS)
and clinically isolated syndrome (CIS), 53.9% in progressive multiple sclerosis (PMS), 71.5% in isolated
optic neuritis, and 72.5% in neuromyelitis optica (NMO). Immunoadsorption (IA) has a therapy
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response of 80.6% in relapsing-remitting multiple sclerosis and clinically isolated syndrome and 100%
in neuromyelitis optica.
Early treatment initiation with a median of 2–3 weeks and a patient age below 50 are considered
to be beneficial regarding a treatment success. In addition to that, a treatment count of 5 to 7 with one
plasma volume is also beneficial for treatment success, whereas patients suffering from progressive
multiple sclerosis have a lower beneficial rate of apheresis therapy. Both immunoadsorption and
plasma exchange have a high safety profile and a high tolerability regarding side effects.
Nevertheless, data situation is too heterogeneous regarding procedures and technical
implementation to be finally assessed.
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Abstract: Intravenous methyl prednisolone (IVMPS) represents the standard of care for multiple
sclerosis (MS) relapses, but fail to improve symptoms in one quarter of patients. In this regard,
apart from extending steroid treatment to a higher dose, therapeutic plasma exchange (TPE) has been
recognized as a treatment option. The aim of this retrospective, monocentric study was to investigate
the efficacy of TPE versus escalated dosages of IVMPS in refractory MS relapses. An in-depth
medical chart review was performed to identify patients from local databases. Relapse recovery
was stratified as “good/full”, “average” and “worst/no” according to function score development.
In total, 145 patients were analyzed. Good/average/worst recovery at discharge was observed in
60.9%/32.6%/6.5% of TPE versus 15.2%/14.1%/70.7% of IVMPS patients, respectively. A total of
53.5% of IVMPS patients received TPE as rescue treatment and 54.8% then responded satisfactorily.
The multivariable odds ratio (OR) for worst/no recovery was 39.01 (95%–CI: 10.41–146.18; p ≤ 0.001),
favoring administration of TPE as first escalation treatment. The effects were sustained at three-month
follow-ups, as OR for further deterioration was 6.48 (95%–CI: 2.48–16.89; p ≤ 0.001), favoring TPE.
In conclusion, TPE was superior over IVMPS in the amelioration of relapse symptoms at discharge
and follow-up. This study provides class IV evidence supporting the administration of TPE as the
first escalation treatment to steroid-refractory MS relapses.
Keywords: multiple sclerosis; optic neuritis; plasma exchange; relapse; class IV; steroids
1. Introduction
The treatment of acute multiple sclerosis (MS) relapses has remained unaltered for decades.
The use of high-dose short-term intravenous (methyl-) prednisolone (IVMPS; 500–1000 mg per day for
three to five days) is the accepted treatment for relapses [1,2]. Of note, adrenocorticotropic hormone
(ACTH) gel is an alternative for patients who do not tolerate corticosteroids. Moreover, although it
has been suggested that intravenous immunoglobulins (IVIG) may be a therapeutic option if steroids
J. Clin. Med. 2020, 9, 35; doi:10.3390/jcm9010035 www.mdpi.com/journal/jcm101
J. Clin. Med. 2020, 9, 35
are contraindicated, two well conducted randomized controlled trials showed that IVIG as an add-on
treatment with IVMPS did not confer additional benefit [3,4].
Interestingly, around 25% of patients remain with significant disability 14 days after IVMPS
treatment initiation [5]. For these patients, one option is IVMPS treatment escalation (up to 2000 mg daily)
for a further three to five days, as recommended by the national guidelines [2,6]. An alternative option
is therapeutic plasma exchange (TPE), which has been proven effective in one small randomized trial
that showed the superiority of TPE over sham treatment [7]. The effectiveness of TPE has been reported
for all demyelinating disorders of the CNS, including optic neuritis (ON), clinically-isolated syndrome
(CIS) and relapsing-remitting MS (RRMS) [8–10]. Consequently, several guidelines recommend TPE as
an adjunctive treatment for increasing the chances of recovery for steroid-refractory relapses [11,12].
However, most studies evaluating TPE lacked an active comparator (such as escalated IVMPS)
and comprised heterogeneous treatment regimens. Also, patients with demyelinating diseases
other than RRMS were included in the study populations [7–9]. Evidence for IVMPS treatment
escalation is to a large part based on a single study that compared MRI endpoints but not clinical
endpoints [6]. Furthermore, IVMPS treatment escalation exhibited additional, non-genomic effects
in animal models [13]. Robust clinical evidence for the currently recommended treatment sequence
(initiation treatment with IVMPS, first escalation treatment with IVMPS, second escalation treatment
with TPE) is still lacking [6,11,12].
We here analyzed patients with acute relapses of RRMS, CIS or isolated ON who were treated
with escalated IVMPS, TPE, or a combination of both.
2. Experimental Section
2.1. Patients
Between January 2013 and December 2017, all of the in-patients in our department were screened.
We identified patients diagnosed with RRMS, CIS, or isolated ON, who received a full course of
IVMPS (1000 mg daily for five days without an oral taper) as initial treatment (referred to as “initiation
treatment” throughout the manuscript). In a second step, we selected patients who received further
relapse treatments (referred to as “escalation treatment” throughout the manuscript) and reviewed
their medical chart in detail, using a standardized electronic case report form. All patients included in
our analysis were hospitalized in our clinic for both the initiation as well as the escalation treatment.
The inclusion criteria for final analysis were:
(i) established diagnosis of RRMS or CIS according to 2017 revised McDonald criteria [14] or
optic neuritis in absence of any other infectious or inflammatory disease of the CNS (especially
neuromyelitis optica spectrum disorders)
(ii) significant relapse with an increase of the Expanded Disability Status Scale (EDSS) score [15] of at
least 1.0 in MS/CIS patients or a decrease of the best-corrected visual acuity (VA) in patients with
isolated ON in analogy to a decrease of at least 1 according to the visual function system score
(FSS) derived from the EDSS, as inclusion criteria for both initiation and escalation treatment
(iii) escalation therapy with either 2000 mg methylprednisolone per day for five days, five cycles of
therapeutic plasma exchange or a combination thereof following initiation therapy with 1000 mg
per day over 5 days
(iv) completion of escalation treatment within six weeks from relapse onset
Therapeutic plasma exchange was performed with a COM.TEC cell separator (Fresenius Hemo-Care
GmbH, Bad Homburg, Germany). All patients received treatment via central venous catheters every
other day, for a total of five sessions. Per session, one plasma volume was processed, while human
albumin solution (5%) was used for substitution. The blood flow rates were 50–70 mL per min.
All patients underwent regional pre-centrifugal anticoagulation with citrate, followed by post-centrifugal
calcium application. In four cases, the treatment-free interval was extended by another day due to
excessive hypofibrinogenemia.
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Patients with the following criteria were excluded:
(i) pregnancy, as determined by pregnancy test
(ii) diagnosis of other systemic inflammatory disorders within the observation period
(iii) onset of relapse symptoms more than one month prior to initiation treatment with IVMPS
(iv) documentation of a secondary progressive disease course within the observation period
For the patients who received more than one escalation treatment within the observation period,
we only evaluated the first relapse to avoid preselection bias.
2.2. Assessment of Effectiveness
To overcome limitations of the EDSS in depicting acute, relapse-associated disability, we decided
to classify our patients into different response categories. For statistical analysis we applied FSS-based
stratification as proposed by Conway and colleagues, which stratifies treatment responses based on
peak- and recovery-FSS distances into “good/full”, “partial”, or “worst/no” recovery [16]. We show a
modified matrix, as previously used, with outcome stratification in Figure S1 [17]. The outcomes were
evaluated after treatment completion and at follow-up (3 months after discharge).
Relapses were considered as monosymptomatic when Kurtzke’s FSS of the affected system
exceeded the other FSS by at least 1 point. Consequently, if this condition was not given, the relapse
was regarded as polysymptomatic. In this regard, patients that either showed similar relapse FSSs
for pyramidal and cerebellar functions (3 patients) or pyramidal and sensory functions (5 patients),
were assigned to their FSS that was EDSS-defining at follow-up. In addition, 4 patients with spinal
lesions displayed a similar FSS for bowel and bladder function and pyramidal function. These patients
were subjected to the FSS group “pyramidal”, as no patients were identified with bowel and bladder
dysfunction as monosymptomatic relapse.
2.3. Assessment of Safety
We also screened patients’ medical charts for severe adverse events and graded the identified
events according to recommendations made in the “Common Terminology Criteria for Adverse
Events”. The CTCAE classification is as follows: I: asymptomatic testing or mild symptoms without
necessity for specific intervention; II: local or noninvasive intervention indicated; III: severe, but not
immediately life-threatening event, hospitalization or prolongation of hospitalization necessary; IV:
life-threatening event; V: death related to event. The study conduct was ethically approved by the
local institutional review board of the University of Muenster, Germany (2017-298-f-S).
2.4. Statistical Analysis
The continuous variables are presented as median and interquartile range and compared between
groups using a Kruskal–Wallis test. The categorical variables are presented as absolute and relative
frequencies and compared using Fisher’s exact test.
To evaluate the influence of multiple variables on the occurrence and outcome of serious adverse
events, we applied logistic regression. The results are described with odds ratios (OR), the respective
95% confidence intervals (CI), and Wald-test p-values. Either “worst or no treatment response following
first escalation treatment” or “stable course versus further deterioration at follow-up” or “development
of severe adverse events” were used as dependent variables.
All analyses are explorative and should be interpreted accordingly. p-values below 0.05 are
considered significant; no adjustment for multiple testing was applied. Statistical analysis was
conducted with SPSS Version 25 (International Business Machines Corporation (IBM), Armonk, USA).
2.5. Data Availability Statement
Anonymized data will be shared upon request from qualified investigators.
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3. Results
3.1. Patients
Between January 2013 and December 2017, a total of 541 patients received initiation treatment
for MS relapses. Of those, 193 (35.7%) patients were admitted for escalation treatment and all had a
persistent functional deficit as defined above. A total of 127 (65.8%) patients received a second course
of IVMPS as a first escalation treatment, while 66 (34.2%) patients were directly subjected to TPE.
For our final analysis we could include a total of 145 patients: 99 out of 127 patients who received a
second course of IVMPS, and 46 out of 66 patients who were directly subjected to TPE. Of note, 53 out
of 99 (53.5%) patients were subjected to TPE as the second escalation treatment. None of the TPE
patients were re-exposed to increased doses of IVMPS (for consort plot see Figure 1).
 
Figure 1. RRMS in-patients who were treated at the study site between January 2013 and December
2017 are described here. The data focus on those patients who received a full course of intravenous
methyl prednisolone (5 × 1 g IVMPS) as the first escalation treatment after relapse. Patients who
received a lower dosage (e.g., 3 × 1 g IVMPS) were excluded from the primary analysis.
Baseline characteristics of all treatment groups (IVMPS, TPE, and IVMPS + TPE) are shown
in Table 1. Patients who did not receive additional TPE presented with lower peak relapse EDSS
(median: IVMPS: 2.0; TPE: 3.0; IVMPS+TPE: 3.0; p = 0.003). Otherwise, patient characteristics showed
no significant differences. The patients were, on average, young and early in their disease course,
with only one patient being above 60 years old. The median time from retrospectively identified
disease manifestation to current presentation was 1 year, and for 40% of patients it was their first
demyelinating event.
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Table 1. Rescue therapy patient baseline and follow-up characteristics compared between treatment groups.
TPE IVMPS IVMPS+TPE p
Patients, No. 46 46 53 -
Age, yr, median (IQR) 33 (29–45) 36 (27–43) 31.5 (27–41) 0.410 *
Male sex, No. (%) 13 (28.3) 14 (30.4) 14 (26.4) 0.922 #
MS duration, yr, median (IQR)
- since onset 1 (0–3) 1 (0–4) 1 (0–4) 0.574 *
- since diagnosis 0 (0–2) 0 (0–2) 1 (0–3) 0.322 *
Relapses during last two years,
median (IQR)
0.5 (0–1) 0 (0–1) 0 (0–1) 0.765 *
first demyelinating event, No. (%) 19 (41.3) 20 (43.48) 18 (33.96) 0.636 #
Baseline EDSS, median (IQR) 0 (0–1) 0 (0–1) 0 (0–2) 0.397 *
Relapse EDSS, median (IQR) 3 (2–3) 2 (2–3) 3 (2–3) 0.003 *
Affected function system, No. (%)
0.236#
- visual 25 (54.4) 25 (47.2) 19 (41.3)
- pyramidal 4 (8.7) 4 (7.6) 8 (17.4)
- brainstem 8 (17.4) 13 (24.5) 10 (21.8)
- cerebellar 3 (6.5) 7 (13.2) 1 (2.2)
- sensory 6 (13.0) 3 (5.7) 8 (17.4)
- cerebral 0 (0.0) 1 (1.9) 0 (0.0)
Time to initiation treatment, d,
median (IQR)
3 (1–7) 3 (1–5.25) 3 (1–5) 0.650*





(10–15.25) 11 (8.5–14) 0.087*
Patient baseline characteristics compared between the different treatment groups. No.: Number; yr.: years; IQR:
interquartile range. * Significance levels were calculated using a Kruskal–Wallis test. # Significance levels were
calculated using Fisher’s exact test.
One hundred and thirty-two patients fulfilled the 2017 revised McDonald criteria for the diagnosis
of RRMS at relapse onset, whereas eight patients presented with isolated optic neuritis and five patients
fulfilled the criteria for CIS. There were no differences in distribution between escalation treatment
groups (p = 0.756).
Accordingly, the majority of patients did not receive disease modifying treatment (DMT) at relapse
onset (62.1%). The treatment approved for mild to moderate courses of RRMS was administered to
22.8% of patients, whereas 15.2% received substances approved for the treatment of active RRMS
(for a detailed description of administered DMT, see Table S1). The DMT subset use was evenly
distributed between groups (p = 0.793). In 137 out of 145 patients the relapse was considered
monosymptomatic. The most common relapse presentation was optic neuritis (69 patients; 47.6%).
Generally, the frequencies of affected functional systems did not differ significantly between treatment
groups (p = 0.236). Polysymptomatic relapses occurred in eight patients with infratentorial or spinal
lesions and were assigned as outlined in the methods, according to their FSS that was EDSS-defining
at follow-up.
3.2. Immediate Effects of Escalation Treatment
According to the previously described FSS-distance related analysis matrix, 28 (60.9%) patients
showed good/full recovery following TPE, while 15 (15.2%) patients showed good/full recovery
following escalation treatment with IVMPS. Partial recovery was observed in 12 (32.6%) TPE treated
patients and in 15 (15.2%) IVMPS treated patients. Finally, no or worst recovery was documented in three
(6.5%) TPE treated patients and in 69 (69.7%) IVMPS treated patients (p < 0.001, see Figure 2A). Next,
53 (53.5%) patients underwent rescue therapy with TPE following IVMPS, whereas the other patients
received no further treatment prior to discharge irrespective of their response. Precise information on
why no further treatment was given was not always available; patients’ refusal of apheresis treatment
was documented as reason in at least eight cases.
105
J. Clin. Med. 2020, 9, 35
 
Figure 2. Different response groups following escalation treatment regimens are illustrated (green: good
response; yellow: average response; red: worst response). (A) Upper bar represents patients who
received IVMPS as the first escalation treatment (n = 99). Lower bar represents patients who received
TPE as the first escalation treatment (n = 46). (B) Subgroup of patients who received two courses of
escalation treatment (n = 53). Upper bar shows treatment response after first escalation with IVMPS
and lower bar represents results following second escalation with TPE.
After the second escalation treatment with TPE, 25 (47.2%) patients showed a full response and
17 (32.1%) patients remitted partially, while 11 (20.7%) patients were unresponsive to the treatment
(see Figure 2B). We performed regression analyses in order to evaluate the possible confounders and to
check whether the higher proportion of treatment-resistant patients following IVMPS+TPE versus
TPE alone was systematically influenced by different factors/confounders. Logistic regression analysis
included “sex”, “age”, “affected function system (visual vs. other)”, “disease duration”, “baseline
EDSS”, and “time to treatment initiation”. The adjusted odds ratio for “worst/no” treatment response
was 39.01 (95%–CI: 10.42–142.71; p<0.001), favoring TPE treatment as the first escalation treatment
(for full regression model see Table S2).
3.3. Sustained Effects of Escalation Treatment
Most patients were revisited at our outpatient clinic three months after discharge in order to
re-evaluate the outcomes of relapse treatment and to initiate immunomodulatory treatment. A total
of 135 (93.1%) patients were evaluated, with no significant differences between groups in terms of
attendance (IVMPS: 93.0%; TPE: 90.5%; IVMPS+TPE: 91.8%; p = 1.000). The median follow-up duration
was 95.5 days (IQR: 86–112), with again no relevant differences between treatment groups (p = 0.379).
Eight patients reported further relapses with symptoms distinct from previous ones (6 patients/IVMPS
group, one patient/TPE group, and one patient/IVMPS+TPE group); and three of these relapses affected
the same functional system (optic nerve: two; brainstem: one; onset 53, 64, and 82 days after discharge,
respectively). After excluding these patients, we re-evaluated the FSS according to the Conway model.
In the IVMPS group, we found a significantly larger proportion of deteriorating patients (41.9%;
vs. 12.2% for IVMPS+TPE and 7.1% for TPE; p = 0.001). The multivariable odds ratio for further
deterioration of relapse symptoms at follow-up was 6.65, favoring the conduction of TPE (95%–CI:
2.52–17.54; p<0.001; for full regression model see Table S3).
3.4. Safety
Out of 145 patients, 116 (80.0%) experienced at least one single adverse event (Table 2).
IVMPS treatment was frequently associated with hypertension, hyperglycemia, and hypokalemia,
making it necessary to regularly substitute potassium (orally). Temporary insulin treatment was
necessary in 14 patients (IVMPS: 6; IVMPS+TPE: 8; TPE: 0). Conversely, coagulopathy was associated
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with apheresis treatment. However, those events were mostly considered ◦II according to CTCAE.
Infections were observed more often in patients who received two courses of IVMPS and among those,
four were considered CTCAE ◦III due to the prolongation of hospitalization. In particular, one case
of central venous catheter-associated septicemia required 14 days of vancomycin treatment until full
recovery. Hypotension and coagulopathy each resulted in at least one treatment interruption in 28
TPE treated patients, whereas treatment interruption due to hypertension occurred in two IVMPS
treated patients (systolic blood pressure>180mmHg each). Notably, we observed thromboembolic
events in four out of the 99 patients exposed to escalated IVMPS, including one case of cerebral venous
sinus thrombosis.







Hypertension (>135 mmHg SBP) 1 (2.2) 11 (19.6) 17 (32.1)
Hyperglycemia (>7.2 mmol/L) 1 (2.2) 20 (43.5) 32 (60.4)
Hypokalemia (<3.5 mmol/L) 4 (8.7) 29 (63.0) 43 (81.1)
Coagulopathy (aPTT>50 s or
INR>1.7)
16 (34.8) 2 (4.4) 14 (32.1)
Thrombosis
- Cerebral venous sinus - - 1 (1.9)
- Femoral veins - 1 (2.2) 1 (1.9)
- Jugular veins/CVC - - 1 (1.9)
Infection
- Thrombophlebitis 1 (2.2) 3 (6.6) 1 (1.9)
- Urinary Tract 4 (8.7) 8 (17.6) 9 (17.0)
- Respiratory Tract - 2 (4.4) 1 (1.9)
- CVC infection/septicemia - - 1 (1.9)
(Temporary) treatment
interruption
- Coagulopathy 4 (8.7) - 7 (13.2)
- Hypotension 5 (10.9) - 7 (13.2)
- Hypertension - 1 (2.2) 1 (1.9)
- Psychosis - 2 (4.4) -
- CVC dislocation 1 (2.2) - 2 (3.8)
Pneumothorax 1 (2.2) - -
Patients with at least 1 event 29 (63.0) 38 (82.6) 49 (92.5)
Overview of adverse events documented during hospital stay. Numbers in brackets represent percentages. Numbers
in bold indicate CTCAE ◦III events. TPE: therapeutic plasma exchange, IVMPS: intravenous (methyl-) prednisolone,
SBP: systolic blood pressure; aPTT: activated partial thromboplastin time; INR: international normalized ratio; CVC:
central venous catheter.
We evaluated whether the amount of previously administered IVMPS (initiation treatment with
IVMPS and first escalation treatment with TPE vs. initiation and first escalation treatment with IVMPS
and second escalation treatment with TPE) influenced the risk for serious adverse events (defined as
CTCAE ◦III) during TPE treatment. The model resulted in an adjusted odds ratio of 4.63, favoring early
treatment with TPE (95%–CI: 1.35–15.91; p = 0.015). However, severe adverse events were also more
abundant in patients with longer disease duration, higher baseline EDSS, or longer time to treatment
initiation (for full regression model see Table S4).
4. Discussion
Several studies have documented the beneficial effects of TPE treatment in acute relapsing MS,
but virtually all study designs suffered from significant limitations. Studies were either one-armed,
had varying treatment regimens, or consisted of a heterogeneous study population in terms of
age, pre-treatment, disability, and disease subgroups (CIS, RRMS, and ON; but also neuromyelitis
optica-spectrum disorders and other non-specified entities of CNS-demyelination) [8,9,18,19].
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Moreover, a relevant proportion of studies on apheresis treatment solely included ON patients
and only a few studies with diverse RRMS patient populations described the affected function
systems or acute lesion localization in detail. Consequently, next to escalated IVMPS, the international
guidelines recommend TPE as one option for treatment escalation following relapse, while refraining
from recommending a specific treatment sequence [11].
Our retrospective cohort is well-defined and representative of more than 500 MS in-patients treated
for acute relapses in our hospital within the past 5 years. These MS patients were young and mostly
at the beginning of their symptomatic phase and therefore of special interest. Effective therapeutic
interventions in this early phase of MS may positively influence long-term outcomes, as both relapse
frequency and residual disability can be significantly impacted [20,21].
In our cohort, early apheresis treatment resulted in significantly higher response rates compared
to escalation treatment with IVMPS. Interestingly, patients who underwent two courses of IVMPS
prior to TPE showed poorer response at discharge compared to patients who only had one course of
IVMPS prior to TPE. One explanation could be the longer time to apheresis treatment when conducted
as the second instead of as the first escalation treatment. Notably, previous studies recommended the
initiation of apheresis no later than six weeks after relapse onset in order to allow for the maximum
efficacy of TPE, and all patients in this study were below this threshold [22–24]. We also hypothesize
that the restitution of blood–brain barrier function, as induced by excessive doses of corticosteroids,
might hamper the drainage of immunoglobulins and further inflammatory factors towards the blood,
where they are ultimately cleared by TPE [25]. Ultimately, MS lesion pathology could have differed
between patient groups. A so-called “type-2 lesion pattern”, which is defined by the presence of
immunoglobulins within MS lesions, was identified as a strong predictor for the success of TPE [24].
However, this information is usually not available in clinical routines and markers that have been
supposed to be associated therewith, such as the presence of ring-enhancing lesions, could not be
evaluated here, as MRI data were not regularly available.
As revealed by follow-up data three months after discharge, patients who underwent apheresis
treatment exhibit a lower risk for further deterioration, which is in accordance with a previous report [22].
A likely explanation is the higher capacity of apheresis treatment to stop neuroinflammation and
consecutive neuroaxonal degeneration, while IVMPS reverts the conduction block but fails to prevent
nerve cell death [26]. This hypothesis is supported by the higher frequency of new relapses in patients
who did not receive apheresis treatment, although in the short- and mid-term IVMPS treatment has
been associated with a reduction in relapse frequency [27]. However, treatment outcomes after three
months were supposed to be representative of long-term residuals, as further recovery was less likely
beyond this time point in previous studies [28].
In terms of safety, there are some disadvantages of combining escalated IVMPS and TPE. Patients
are exposed to high doses of IVMPS, including all the possible side- effects, without having a
demonstrable benefit compared to TPE treatment alone. In line with this; we observed a significant
increase of complications for the IVMPS escalation group, including several serious adverse events
such as thromboembolism or severe infections.
As is typical for retrospective analyses, potentially unknown confounders that might have guided
treatment decisions, such as the personal preferences of the treating consultant as well as the patient,
health behaviors, comorbidity and MRI characteristics, challenge our study. In this context, we are not
able to retrospectively address the criteria underlying the decision to treat a patient with TPE directly
in the first escalation, rather than with escalated doses of IVMPS. Moreover, we have to deal with
several limitations, such as bias from the selection and availability of data, recall bias, choice of relevant
outcome and the methods of analysis. Furthermore, we have to be aware of limitations concerning the
validity of our findings, as it is likely that adverse events are probably underestimated, since it was not
known that this information was going to be of interest.
However, a large number of patients in our cohort experienced their first demyelinating event
and we analyzed only the first relapse per patient, even though intra-individual differences in
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steroid-responsiveness over time have recently been described [29]. Furthermore, the previously
known poor response to steroids used for relapse treatment was not documented anywhere in our
medical charts.
In summary, our study found particular advantages of TPE over escalated IVMPS in escalation
treatment of MS relapses. We recommend the rapid admission of steroid-refractory patients to apheresis
treatment without escalated IVMPS treatment and identify the need to prospectively evaluate this
approach in a contemporary patient cohort.
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Abstract: Almost every kind of inflammation in the human body is accompanied by rising C-reactive
protein (CRP) concentrations. This can include bacterial and viral infection, chronic inflammation and
so-called sterile inflammation triggered by (internal) acute tissue injury. CRP is part of the ancient
humoral immune response and secreted into the circulation by the liver upon respective stimuli.
Its main immunological functions are the opsonization of biological particles (bacteria and dead
or dying cells) for their clearance by macrophages and the activation of the classical complement
pathway. This not only helps to eliminate pathogens and dead cells, which is very useful in any case,
but unfortunately also to remove only slightly damaged or inactive human cells that may potentially
regenerate with more CRP-free time. CRP action severely aggravates the extent of tissue damage
during the acute phase response after an acute injury and therefore negatively affects clinical outcome.
CRP is therefore a promising therapeutic target to rescue energy-deprived tissue either caused by
ischemic injury (e.g., myocardial infarction and stroke) or by an overcompensating immune reaction
occurring in acute inflammation (e.g., pancreatitis) or systemic inflammatory response syndrome
(SIRS; e.g., after transplantation or surgery). Selective CRP apheresis can remove circulating CRP
safely and efficiently. We explain the pathophysiological reasoning behind therapeutic CRP apheresis
and summarize the broad span of indications in which its application could be beneficial with a focus
on ischemic stroke as well as the results of this therapeutic approach after myocardial infarction.
Keywords: CRP; apheresis; stroke; inflammation
1. General Introduction
Inflammatory processes involve a plethora of signaling pathways and affect the whole body, even if
their origin is most often locally restricted in an acute setting. Mounting an inflammatory response is
the body’s strategy to primarily eliminate any cause of tissue damage and subsequently repair the
injury [1]. This is rooted in the evolutionary background that damage is mainly caused by pathogens
or at least exacerbated by them within an external wound. In this case the elicited inflammation is
beneficial in fighting infiltrating bacteria or viruses as well as restoring tissue homeostasis. However,
healing of injured tissue often happens at the cost of still healthy tissue/cells and involves additional
cell death as collateral damage [2]. In specific situations, these negative effects outweigh the positive
aspects of the inflammatory reaction. Whenever an injury is “sterile”, meaning it occurred internally
without pathogen involvement, inflammation aggravates deterioration by elimination of additional
J. Clin. Med. 2020, 9, 2947; doi:10.3390/jcm9092947 www.mdpi.com/journal/jcm113
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cells, which were either vital or only slightly and reversibly impaired. This happens for example
after ischemic injury like stroke or myocardial infarction, leading to a larger extent of organ damage,
increased scarring and thereby worsening clinical outcome [3,4]. Likewise, negative effects dominate
in situations when the immune system produces an excessive general reaction that is not justified by
the trigger [5]. For example, during acute pancreatitis, a systemic inflammatory response syndrome
(SIRS), or an acute bacterial or viral infection (Sepsis) the inflammation might cause widespread tissue
injury, which might result in multiple organ failure [6].
Although a plentitude of proteins is involved in inflammation, many of them are cytokines or
modulators that do not actively participate in the elimination of pathogens or cells [1]. Several mediator
proteins play a key role.
One of the acute-phase mediators directly involved in these pro-inflammatory processes is
C-reactive protein (CRP) which was discovered by Tillett and Francis in 1930 [7]. CRP is well-established
as one of the most reliable markers of inflammation, rising dramatically during any type of inflammation.
It has been shown that CRP as an inflammatory mediator not only reflects tissue damage, but also
aggravates the severity of damage and contributes causally to course and outcome of various diseases [8].
Therefore, CRP has to be regarded not only as a marker, but also as an active pro-inflammatory protein.
2. Role of CRP
CRP is a sensitive, reliable and early indicator of inflammation and infection. Evolutionarily
highly conserved, this pentameric molecule is part of the ancient humoral immune response and
involved in various immunological pathways as a key mediator [9,10]. It is predominantly synthesized
and secreted into the blood circulation by hepatic cells as a response to trauma, inflammation,
or infection. In these situations, the proinflammatory cytokines interleukin 6 (IL-6) and, to a lesser
extent, interleukin 1β (IL-1β) as well as tumor necrosis factor @(TNF@) induce CRP expression on the
transcriptional level [11–14]. Following an acute phase stimulus, serum CRP values increase up to
levels a few thousand times higher than the normal (healthy) concentration of human CRP (0.05 to
3000 mg/L) [15,16]. The half-life in plasma is about 19 h [17,18].
After secretion, CRP efficiently detects and opsonizes bacteria upon their infiltration and initiates
their phagocytosis by activation of complement [19,20]. This is probably its original purpose as one of
the most ancient proteins within the humoral immune system.
However, CRP also detects and binds to endogenous cells [21,22]. Cells, which are either apoptotic,
energy-depleted, or simply exposed to stressors like the acidic and often ischemic environment of
inflammation display conformational and biochemical changes of their membrane [23]. One of
these changes is the formation of lyso-phosphatidylcholine (LPC) by partial hydrolyzation of
phosphatidylcholine (PC). To this end, one of its two fatty acid groups is removed by the secretory
phospholipase A2 type IIa (sPLA2 IIa) [24,25]. This phospholipase is secreted and activated by
inflammation (IL-6) and marks the beginning of detrimental destruction of still viable tissue after e.g.,
ischemia [26–29]. LPC is thereby accessible in the plasma membrane of dead, damaged, or inflamed
cells. The CRP pentamer binds to LPC with high avidity in a so-called cooperative manner and
subsequently mediates the elimination of these cells, similarly to infiltrating pathogens, by activating
the classical complement pathway [30–35]. Complement C1q binds to CRP directly and mediates the
binding of C2–C4 [36]. Thus, these cells are irreversibly marked for phagocytes which dispose the
marked cells. Phagocytes in turn secrete IL-6 which induces the synthesis of additional CRP by the
liver, subsequently amplifying the immune response. This way, more cells become marked by CRP
(Figure 1).
Importantly, this mechanism facilitates binding of CRP to actually still vital cells, which may
potentially regenerate with more CRP-free time. By interacting with complement, CRP triggers the
destruction and therefore negatively affects the regeneration of tissue. By now, a large body of data
obtained from animal experiments demonstrates that this CRP-mediated mechanism plays an active
role in exacerbating ischemia and reperfusion-induced damage [37–43].
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Figure 1. Molecular pathomechanism of CRP-mediated tissue damage. Upon inflammation or
acute oxygen-deprivation, cells display a dramatic shortage of adenosine triphosphate (ATP). ATP is
essential to prevent apoptosis which manifests in the outer cell membrane: Phosphatidylcholine
(PC) is converted into lyso-phosphatidylcholine (LPC) by phospholipase (sPLA2 IIa). Due to the
lack of ATP, this alteration cannot be reversed. CRP subsequently binds to LPC on anaerobic cells
and recruits complement factors (C1q-C4). These opsonized cells will be disposed by phagocytes,
which in turn induce CRP synthesis. Without CRP or in situations with low CRP concentrations
(e.g., after CRP apheresis), energy deprived-cells are spared and may switch back to aerobic
metabolism, repair molecular changes and revitalize again, leading to an overall reduced tissue
damage [41,43–45]. CRP C-reactive protein; C1q Complement component 1q; IL-6 Interleukin 6; LPC
Lysophosphatidylcholine; PC Phosphatidylcholine; sPLA2 IIa secretory phospholipase A2 type IIa.
On the molecular level it is not fully elucidated yet whether pro-inflammatory signaling is mediated
by the pentameric, native form of CRP, or if CRP dissociates into its non-covalently bound monomers
upon binding to LPC, which then exhibit novel binding capacities and other specific functions [46–48].
Publications which described anti-inflammatory actions of pentameric CRP hypothesized that CRP
switches functions by undergoing structural changes. Although various quaternary structures of CRP
are still not well proven in the physiological context, it might well be possible that CRP monomers exist
in specific inflammatory microenvironments and represent different stages of inflammation [47,49].
It has been clearly shown that CRP is secreted in its native, pentameric form by the liver and-if at all-only
dissociates locally within inflamed tissue. Hence, therapeutic interventions are more efficient targeting
pentameric CRP as high circulating levels are the actual source for its detrimental action [50,51].
Its known physiological function is the disposal of cells (bacteria, necrotic and apoptotic cells).
To date, no pharmacologic inhibitor of inflammation has been proven to be successful in
ischemia-related injuries, since they all featured unfavorable pharmacokinetic profiles or serious side
effects. Therefore, a different strategy is needed to target the detrimental inflammatory response [43,52].
Specifically, targeting avoidable organ damage caused by the action of CRP represents a promising
therapeutic option [43,53]. Decreasing CRP levels could potentially protect salvageable cells and
give them more time to recover. Therefore, removing CRP from the blood circulation interrupts the
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innate cascade and reduces tissue damage [44]. Accordingly, CRP apheresis may potentially present a
promising, highly efficient, and well-tolerated therapeutic option.
3. CRP Apheresis
Extracorporeal apheresis refers to the physical removal of substances from the blood by means
of filtration, precipitation or adsorption. Immunoadsorption defines the specific binding of an
immunologic protein by an adsorber matrix. The elimination of pathogenic substances from the blood
in extracorporeal apheresis constitutes an established therapeutic measure in the clinical routine of
numerous diseases.
The CRP adsorber system (PentraSorb® CRP, Pentracor GmbH, Hennigsdorf, Germany) features
an agarose-based resin, which contains a phosphocholine-derivative as ligand for CRP and is thereby
capable of selectively depleting CRP from blood plasma with an efficiency of up to 94% (under
laboratory conditions) [54]. The adsorber is regenerable and can be used up to a maximum cumulative
treatment time of 24 h (contact with human plasma ≤24 h, according to CE license). In between
treatments the adsorber has to be stored in sodium azide at 2–8 ◦C. CRP apheresis is executed in cycles,
alternating between loading of the adsorber with plasma and regeneration of the column, that follows
a fixed sequence of washing solutions. Loading and washing are controlled by a software module
for automatic plasma flow management (ADAsorb, medicap clinic GmbH, Ulrichstein, Germany;
Figure 2). Blood can be drawn via central or peripheral venous access (cubital veins). Plasma separation
is performed by a blood centrifuge and blood is anti-coagulated 1:15 with citrate buffer (ACD-A;
3% citrate) or heparin. The usual plasma flow through the adsorber is between 25 to 35 mL/min. Blood
flow ranges between 40 and 65 mL/min.
 
Figure 2. Schematic illustration of CRP apheresis. The procedure is described in detail by Ries et al.
2019 [45].
During one treatment, 6000 mL of plasma are usually processed in 12 cycles. A continuous
monitoring of vital parameters, blood pressure and heart rate has to be carried out. Processing of
6000 mL blood plasma takes 4–5 h, depending on the blood flow. Patients can be treated an infinite
amount of times with CRP apheresis, as the blood loss is only minimal. Depending on CRP level and
indication, two to ten treatments on consecutive days are performed. So far, no side-effects have been
reported [45,55–57].
The main advantages of CRP apheresis are the selective removal of the agent by the highly specific
ligand and the good controllability of the process, since unlimited plasma volumes can be processed to
achieve the desired CRP reduction. Drugs are not removed by CRP apheresis.
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4. CRP Apheresis after Ischemic Tissue Damage
The extent of tissue damage during and after an acute traumatic incident defines outcome and
follow-up health. Ischemic lesions, predominantly acute myocardial infarction (AMI) and ischemic
stroke, generate initial organ damage in the acute zone by cell death due to oxygen deprivation and
its magnitude is primarily determined by its duration [58]. Further, neighboring cells which are
deprived of oxygen for a shorter duration or to a lesser extent are damaged but salvageable and
constitute the area at risk (AMI) or penumbra (stroke) [58,59]. The first line of therapy constitutes the
restoration of blood flow to limit the initial ischemic injury. This reperfusion, even though essential to
decrease mortality and morbidity, is attended by an intense and maladaptive immune response, which
augments and accelerates the organ damage and includes the still viable but damaged tissue [60,61].
The elimination of salvageable cells by CRP through this mechanism mediates reperfusion injury
and critically contributes to the already existing deterioration [62,63]. CRP apheresis aims to remove
circulating CRP after AMI and ischemic stroke in order to reduce acute tissue injury and ischemic
reperfusion injury.
4.1. Myocardial Infarction
Patients who recover from AMI often suffer from reduced quality of life and very high risk of
severe complications later on (e.g., second infarct), which implies a huge burden for the health system.
This risk correlates significantly with the extent of myocardial injury and scarring [64,65].
It has long been established that inflammation especially mediated by the innate immune
system extends myocardial injury, however, anti-inflammatory strategies to minimize myocardial
necrosis have failed so far, maybe because these processes are also needed for healing and cardiac
repair [3,4,52,66]. While baseline CRP levels in the healthy state are established as predictor of the
incidence of cardiovascular disease [67–69], serum CRP concentration during and after AMI correlates
with clinical outcome [16,17,70–74]. It is well known that high peak CRP levels during the acute phase
response after AMI correlate with larger infarct size and higher mortality as well as incidence of major
adverse events [17,74,75]. This has been described for more than two decades now and is in line with
the described pathological function of CRP, eliminating cells in the area at risk [8,23,76]. This area
contains cells, which could partially recover after revascularization and reperfusion, but are finally
destroyed by immune-mediated mechanisms, as explained above and shown in detail in numerous
experimental approaches focusing specifically on AMI [39,40,63,70,77,78]. Targeting CRP in AMI
has therefore been proposed previously, but was never achieved due to non-functioning therapeutic
approaches [43,79–81].
Preclinical studies on the efficacy of specific extracorporeal depletion of CRP have been successfully
performed in a porcine animal model of AMI [41,42]. In this study, a mean reduction of CRP levels by
about 50%, a significant reduction of the infarct size and a stabilization of the ejection fraction was
observed. Interestingly, a completely different scar morphology was detected in animals after CRP
apheresis compared to controls [41]. A smaller scar tissue and more vital heart muscle reflected the
efficacy of this treatment strategy (Figure 3, previously published and taken from [41]). AMI was
therefore selected as indication for the first clinical trial of CRP apheresis. CRP apheresis was applied
in patients with ST-elevation myocardial infarction (STEMI) (CAMI-1 trial: “Selective depletion of
C-reactive protein by therapeutic apheresis (CRP apheresis) in acute myocardial infarction”, DRKS
ID: DRKS00008988). Just recently, this multi-center clinical trial has been finished and first data were
shown in Case reports and a publication describing 13 patients as a preliminary report [44,45,55,56].
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Figure 3. Porcine Heart Slices after AMI with and without CRP apheresis. Slices of the left ventricle
14 days after AMI. Slices were generated after an Evans Blue staining of the heart. Circles localize a
characteristic transmural scar of a control animals (left) versus spotted scar morphology after CRP
apheresis (right). Figure previously published and taken from [41].
The CAMI-1 trial tested the hypothesis whether specific depletion of CRP by CRP apheresis can
reduce myocardial infarct size in humans. Endpoints were safety, myocardial infarct size and function
as well as CRP concentration in patients with acute STEMI. A total of 83 patients were recruited at 8
study centers. Plasma CRP levels were reduced by approximately 60% over all performed apheresis
procedures in the CAMI-1 trial. Treatments were safe and well tolerated. There were no serious
adverse effects associated with the treatment [45]. The magnitude of increase of CRP concentration
during the acute phase response after STEMI correlated significantly with the infarct size in control
patients. Patients with similar initial CRP increase, who subsequently underwent CRP apheresis,
showed smaller infarct sizes as well as improved left ventricular function and wall motion (strains)
compared to control patients (unpublished data-submitted). Currently, a CAMI-1 registry is on-going,
collecting more data (DRKS00017481) [44].
4.2. Ischemic Stroke
Stroke is the third most frequent cause of death and the leading cause of serious, long-term
disability worldwide. This disease has a tremendous personal, familiar and socioeconomic impact.
More than 80% of patients suffer from ischemic stroke [82]. To date, restoring rapid reperfusion
of the brain constitutes the only established therapeutic strategy to reduce the size of the infarct
and the consequences of the disease [83]. However, similar mechanisms to AMI take place and
inflammation plays an important role in various stages of ischemic stroke, because several humoral and
cellular mechanisms are set in motion by the occlusion and subsequent therapeutic reperfusion [84,85].
These mechanisms may explain why some patients with ischemic stroke suffer from severe neurological
symptoms despite early and successful recanalization. Several findings substantiate the hypothesis
that CRP plays a similar pathological role as shown in AMI, facilitating the elimination of energetically
challenged and compromised cells in the penumbra.
First, various publications have shown an association between the early inflammatory response
after ischemic stroke and the clinical outcome. The early inflammatory response after stroke has
been identified as a key prognostic factor [86,87]. Patients with favorable clinical outcome feature
significantly lower levels of inflammatory parameters, especially CRP, compared to patients with
poor outcome. Previous studies have described an association between high CRP values after acute
stroke and negative prognosis [88–91]. Muir et al. have shown that CRP levels measured within 72 h
after stroke predict mortality over an observation period of up to 4 years [92]. According to Winbek
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et al., CRP levels 24 and 48 h after onset of symptoms affect prognosis, but not their concentration at
admission [87]. In another stroke study, patients who died during the study period had significantly
higher CRP levels at admission compared to survivors and CRP levels correlated with the clinical
outcome after 3 months follow-up [86]. Further, studies in a rat animal model have shown that infusion
of human CRP enlarges cerebral infarct areas after acute occlusion via a complement-dependent
mechanism [37].
Based on this background, a clinical trial investigating selective CRP apheresis after ischemic stroke
was initiated (CASTRO1 trial: “Selective Depletion of C-reactive Protein by Therapeutic Apheresis
(CRP-apheresis) in Ischemic Stroke”, ID: NCT0441723). The CASTRO trial is designed as a randomized,
controlled, multicentric interventional pilot trial. The aim of the CASTRO trial is to evaluate if CRP
apheresis can be applied safely in patients with ischemic stroke and efficiently lower the CRP level.
Therefore, the primary endpoint is the type and frequency of adverse events and serious adverse
events after apheresis. In addition, potential effects of CRP apheresis on clinical outcome parameters
(cognitive measures, infarct volume, laboratory parameters) will be investigated.
Participants for this trial need to have an ischemic stroke with or without intravenous lysis and
recanalization therapy. The National Institutes of Health Stroke Scale (NIHSS) has to be between
1–24 in order to exclude patients with severe, potentially complicated disease courses. CRP needs to
increase ≥5 mg/L within 72 h after the incident and/or serum CRP concentration needs to be larger
than 10 mg/L. We aim to include 20 patients which are 1:1 randomly assigned to either the control
group (standard guideline therapy) or CRP apheresis in addition to the standard guideline therapy.
The standard therapy of acute ischemic stroke is carried out according to the guidelines of the European
Academy of Neurology [93].
Exclusion criteria are severe dysphagia (risk of aspiration pneumonia), clinical or laboratory
evidence of systemic infection, contraindications against apheresis, Modified Rankin Scale (mRS)
before index event ≥ 3, intracranial hemorrhage, epileptic seizure in the context of the acute event,
pregnancy, and lactation. Treatment and study regime will be implemented into the clinical standard
diagnostic and therapeutic regime after stroke. Since CRP levels begin to rise approximately 8 h after
the ischemic incident and reach their peak after 24 h, the first CRP apheresis will be carried out within
72 h after onset of symptoms. Therefore, CRP apheresis will not delay acute guideline therapies of
stroke, such as intravenous lysis and intraarterial thrombectomy. The complete study flow is illustrated
in Figure 4.
To investigate whether CRP apheresis improves clinical outcome parameters after ischemic stroke,
patients will undergo assessments according to standardized clinical scales, namely National Institute
of Health Stroke Scale (NIHSS) score, Barthel ADL index (BI), modified Rankin scale (mRS) and
measurements of infarct volume (via magnetic resonance imaging; MRI). In addition, immunological
and neurodegenerative biomarkers (interleukin-6, serum amyloid A) will be evaluated to objectify
a potential beneficial effect of CRP apheresis on inflammatory pathways. Measurements of primary
and secondary outcome parameters will be performed at baseline (before first apheresis), daily during
apheresis, and 90 days after stroke.
Immunoadsorption with the PentraSorb® CRP is performed with the ADAsorb apheresis device
as described in detail in 3. CRP apheresis is performed for a maximum amount of three times (three
days) or until CRP concentration is below 10 mg/L.
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Screening of patients after primary therapy 
(Review of inclusion and exclusion criteria) 
Information of the study participants, informed consent (study inclusion) 
 
Assessment of the scores 
(NIHSS, mRS) 
 
Applying Shaldon Catheter 
 
1st CRP apheresis 
(start max. 72 h after onset of symptoms) 
 
possibly 2nd and 3rd CRP apheresis, if CRP > 10 mg/L 
(24 ± 12 h after the start of the previous apheresis) 
 
Determination of CRP and biomarker 
(until 5 days post insult) 
 
Assessment of the scores 
(6 ± 3 days post insult, NIHSS, mRS, Barthel index) 
1st MRI 
 
Assessment of the scores 
(12 ± 2 weeks post insult, NIHSS, mRS, Barthel index) 
2nd MRI 
Figure 4. Study flow of the CASTRO1 trial. MRI magnetic resonance imaging; NIHSS National Institute
of Health Stroke Scale; mRs modified Rankin scale.
5. CRP Apheresis in Other Indications
Both AMI and ischemic stroke feature a common underlying pathophysiology and the therapeutic
application and benefit after AMI has been already shown. However, reduction of dramatically high
CRP concentrations in other indications which are not defined by an ischemic pathophysiology could
also be beneficial. The overcompensating immune reaction which often triggers SIRS after surgery,
causes detrimental deterioration during acute pancreatitis, or mediates a cytokine storm after infection,
could be dampened with CRP apheresis. Therefore, clinical trials investigating the safety and efficacy
of CRP apheresis during pancreatitis and after coronary bypass surgery are ongoing (CAPRI1-study
DRKS00014265; CABY1-study DRKS00013012). Further, first patients suffering from Covid-19 have
been treated with CRP apheresis in order to inhibit the CRP-mediated autoimmune response leading
to respiratory failure and multi-organ failure [57,94].
6. Conclusions and Outlook
CRP has been established as a general biomarker of inflammation and infection in clinical practice.
Recently, its role as a stable and highly useful prognostic factor for cardiovascular and cerebral disease in
healthy individuals has been widely acknowledged and utilized [95,96]. However, the characterization
of CRP as not only a biomarker but also a mediator or even trigger of immunological destruction of
tissue is widely ignored [8,37,39].
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Therapeutic CRP removal by immunoadsorption might present a logical and promising therapy
for pathologies in which the extent of tissue damage is aggravated by inflammation and correlated
with a worse clinical outcome, including ischemic events.
CRP apheresis has been applied successfully in a controlled multi-center trial in patients with
myocardial infarction (CAMI-1 trial). It showed very few and only moderate side effects and managed
to significantly reduce CRP levels, thereby positively affecting infarct size and left ventricular ejection
fraction [44,45,55,56]. Applying CRP apheresis in ischemic stroke is the next plausible step. However,
the immunological situation in the brain is different. Neurons have a low tolerance to oxidative
stress, and the physiologically important blood-brain-barrier may impair the effectiveness of this
method [97–99].
The CASTRO study will show whether CRP apheresis can be safely performed in patients with
ischemic stroke and also provide preliminary results whether reducing the concentration of serum
CRP levels facilitates reduction of tissue damage of the brain, consequently improving clinical outcome
measures compared to the control group.
Other anti-inflammatory therapies have been investigated in AMI and ischemic stroke, such as
colchicine [100], anti-CD18 agents [101] and agents targeting IL-1 or IL-6 [102–104]. CRP removal
intends to stop the destruction of tissue already during the acute event. Furthermore, targeting
specifically and selectively CRP may constitute a superior choice because it does not cause a pleiotropic
effect. The maximum removal of CRP in patients was 79% by now. This leaves enough CRP for
potential repair processes. Importantly, cardiac or neural repair is not impaired by the intervention
as opposed to former pharmacological interventions like the methylprednisolone trial in myocardial
infarction which resulted in a catastrophic outcome [105].
Preliminary evidence suggests that CRP apheresis induces very few side effects and features a low
risk profile [45]. One drawback is that the procedure takes relatively long. Nevertheless, CRP apheresis
fits well into the management of stroke patients because it does not collide with acute measures and
may therefore complement methods aiming at reperfusion.
The acute inflammatory response has two facets. For one thing it plays a key role in initial host
defense against infections. But on the downside, it can cause collateral damage of tissues. Especially in
situations with an inciting sterile stimulus, the cost-benefit ratio is unfavorable.
CRP as an ancient protein of the innate immune system physiologically disposes cells and reacts
to almost every disturbance of tissue homeostasis. Therefore, the span of potential indications for CRP
apheresis is broad, and the ongoing clinical trials will illuminate whether this therapy is beneficial in
these specific indications.
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Abstract: Autoimmune encephalitis (AE) is a rapidly progressive inflammatory neurological disease.
Underlying autoantibodies can bind to neuronal surfaces and synaptic proteins resulting in psychiatric
symptoms, focal neurological signs, autonomic dysfunction and cognitive decline. Early and effective
treatment is mandatory to reduce clinical symptoms and to achieve remission. Therapeutic apheresis,
involving both plasma exchange (PE) and immunoadsorption (IA), can rapidly remove pathogenic
antibodies from the circulation, thus representing an important first-line treatment in AE patients.
We here review the most relevant studies regarding therapeutic apheresis in AE, summarizing the
outcome for patients and the expanding clinical spectrum of treatment-responsive clinical conditions.
For example, patients with slowly progressing cognitive impairment suggesting a neurodegenerative
dementia can have underlying autoantibodies and improve with therapeutic apheresis. Findings are
encouraging and have led to the first ongoing clinical studies assessing the therapeutic effect of IA in
patients with anti-neuronal autoantibodies and the clinical presentation of dementia. Therapeutic
apheresis is an established and well tolerated option for first-line therapy in AE and, potentially,
other antibody-mediated central nervous system diseases.
Keywords: autoimmune encephalitis; limbic encephalitis; NMDAR (N-Methyl-D-Aspartat); antibody;
paraneoplastic; apheresis; plasma exchange; immunoadsorption
1. Introduction
Autoimmune encephalitis (AE) is a rapidly progressive inflammatory neurological disease with
subacute onset. Patients may present with behavioral changes and altered mental status as well as
reduced levels of consciousness and new focal neurological signs or epileptic seizures [1]. Furthermore,
deficits in working or short-term memory frequently occur.
AE comprises both, antibody-mediated and paraneoplastic, i.e., cytotoxic T-cell-mediated,
encephalitides. Clinical presentation is diverse and depends on the specific underlying antibody
(Table 1). As more and more novel antibodies and new clinical phenotypes are being identified,
the incidence is rising and currently estimated at 5–10 per 100,000 inhabitants per year [1]. Age and
gender preferences are often specific for a given antibody. In some cases, the exact target of novel
antibodies is not known yet. In other cases, even if the underlying antigen is known, the pathogenic
relevance still awaits scientific clarification.
1.1. Antibody-Mediated AE
The most common and best-known form of antibody-mediated AE is NMDA (N-Methyl-
D-Aspartat) receptor (NMDAR) encephalitis, defined by cerebrospinal fluid (CSF) IgG antibodies
targeting the NMDA type glutamate receptor. Patients present with subacute onset of psychiatric
J. Clin. Med. 2020, 9, 2683; doi:10.3390/jcm9092683 www.mdpi.com/journal/jcm127
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symptoms, autonomic instability, focal neurological signs and behavioral changes as well as
new-onset epileptic seizures and reduced levels of consciousness. Other AE-defining autoantibodies
bind directly to excitatory transmitter receptors besides NMDAR (such as AMPA (α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors), inhibitory transmitter receptors (GABAB
(gamma-aminobutyric acid B), GABAA (gamma-aminobutyric acid A), glycine receptors), ion channel
subunits and cell adhesion molecules (Caspr2 (contactin-associated protein 2), IgLON5) or soluble
synaptic proteins (LGI1 (leucine-rich, glioma inactivated protein 1).
Autoimmune dementia might be considered a sub-form of AE with predominant cognitive
deficits. Cognitive impairment is a common feature in AE. For instance, patients with encephalitis
caused by LGI1 antibodies showed markedly impaired verbal and visuo-spatial memory as well
as a significantly reduced hippocampal volume. A severe clinical course correlated with more
pronounced structural damage of the hippocampus and correspondingly a worse overall memory
performance [2]. As patients show good response to immunotherapy, especially in the early stage
of disease, prompt and sufficiently “aggressive” treatment including apheresis is highly important.
Interestingly, the cognitive deficits in LGI1 encephalitis can come in isolation and lead to the working
diagnosis of a primary neurodegenerative disease such as Alzheimer’s. Increasing awareness and the
search for autoantibodies such as LGI1 are needed and can result in the early identification of dementia
patients with an immunotherapy-responsive phenotype [3,4].
1.2. Paraneoplastic AE
In contrast to the neuronal surface antibodies, antibodies in classical paraneoplastic neurological
syndromes (PNS) bind to intracellular antigens (such as Hu, Ri, Yo or Ma2 antibodies) and therefore
do not cause the neurotoxicity directly; they rather serve as valuable biomarkers for an underlying
tumor, often small cell lung cancer and gynecological tumors. The neuronal damage in these cases
is, rather, caused by cytotoxic T-cells with oligoclonal T-cell receptor expansion and autoreactivity
against neuronal structures. Among the antibodies targeting intracellular antigens, GAD (glutamic
acid decarboxylase) and amphiphysin antibodies are an exception as they are not necessarily associated
with a tumor and seem to be pathogenically relevant despite their intracellular antigen location [5].
Table 1. Most important antibodies and clinical syndromes.
Antigen Clinical Presentation Age/Gender Tumor Type
Antibodies against neurotransmitter receptors [6]
NMDAR [7]
Schizophreniform psychosis, perioral
dyskinesia, epileptic seizures, coma,
dystonia, hypoventilation






syndrome, refractory status epilepticus
and epilepsia partialis continua
Younger adults;
m > f (1.5:1) Hodgkin lymphoma
GABAbR LE with frequent epileptic seizures Older adultsf =m
50% lung cancer
(SCLC)






LE, Ophelia syndrome (depression,
agitation, hallucination, memory deficits,
personality changes)
Young adults,
m > f (1.5:1) Hodgkin lymphoma
GlycinR
PERM (progressive encephalomyelitis
with rigidity and myoclonus), SPS,
cognitive deficits
Older adults
f =m Thymoma (<10%)
DPPX




f <m (1:2.3) Not known
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Table 1. Cont.
Antigen Clinical Presentation Age/Gender Tumor Type
Antibodies against ion channel subunits or cell adhesion molecules [8,9]
LGI1 Facio-brachial dystonic seizures (FBDS),amnesia, psychosis, LE, hyponatremia
Adults > 40 years,
m > f (2:1) Rare
Caspr2
LE, neuro-myotonia, Morvan syndrome,
can slowly progress over up to 1
year;similar to LGI1, but no hyponatremia
Elderly
m > f (9:1) Thymoma possible
IgLON5
REM- and non-REM sleep disorders,
sleep apnea, stridor, dysarthria,
dysphagia, dysautonomia, movement
disorders, dementia
Older adults, f =m Not known
Antibodies against intracellular (onconeural) antigens [10,11]





Ri (ANNA-2) OMS, CS, encephalomyelitis >90%, Ovary, breastcancer
Yo (PCA-1) CS >90%, Ovary cancer
Ma2 LE, CS, diencephalic/hypothalamicinvolvement
>90%, Testicular,
lung cancer
CV2 (CRMP5) Encephalomyelitis, LE, CS >90%, SCLC,thymoma
Amphiphysin SPS >90%, Breast, SCLC
GAD SPS, LE, ataxia Middle aged,f >m (4:1)
Tumor association
rare
LE: limbic encephalitis, SPS: Stiff-person syndrome, OMS: Opsoclonus-myoclonus syndrome, CS: cerebellar
syndrome, SCLC: small cell lung cancer, PCD: paraneoplastic cerebellar degeneration.
1.3. Therapy for AE
At this point, there is no clear evidence-based treatment standard for AE. Established treatment
strategies for first-line therapy of AE include high-dose corticosteroids (three to five days course of
1000 mg intravenous methylprednisolone), intravenous immunoglobulins (IVIG) (2 g/kg body weight
over three to five days), as well as therapeutic apheresis. Cyclophosphamide and the CD20-antibody
rituximab (1000 mg, with the first two administrations at day 1 and day 15 followed by six months
intervals) might be added in case of persisting or relapsing symptoms and as a long term maintenance
therapy. Most centers favor a low threshold for rituximab initiation given its good safety profile
and potential effect in preventing relapses. Many other treatments have been used with variable
success, including mycophenolate mofetil, methotrexate or azathioprine. It is broadly agreed that
immunotherapy needs to be started as early as possible after symptom onset to be most effective.
Nevertheless, marked recovery can be seen in some patients with antibody-mediated AE in whom
therapy is only started months after disease onset. The choice of adequate therapy depends on the
clinical syndrome and the underlying antibody. However, comparative treatment studies in patients
with AE are sparse and focus on the most common forms of AE, such as NMDAR encephalitis.
In paraneoplastic AE with antibodies targeting intracellular proteins, rituximab, intravenous
immunoglobulins and therapeutic apheresis often have only little effect as the antibodies are not
directly pathogenic. Here, neuronal damage is caused by cytotoxic T-cells. Evidence of a tumor
requires prompt and complete removal in order to withdraw the auto-antigen expressed by the tumor
that triggers the production of autoantibodies. Nevertheless, despite advanced immunotherapy and
tumor removal, in many cases neuronal damage in paraneoplastic AE progresses.
Therapeutic apheresis and the removal of autoantibodies is a major therapeutic option in AE.
The pathophysiological binding of antibodies to their antigens can thereby be reduced.
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2. Search Strategy
To conduct the review, we followed the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines and screened the articles independently for their respective
eligibility [12].
2.1. Inclusion Criteria
We included all articles about patients with autoimmune encephalitis—antibody-mediated as
well as paraneoplastic—treated with plasma exchange or immunoadsorption. Treatment regimen,
such as concomitant immunotherapy, as well as details about the apheresis itself (plasma exchange
(PE) or immunoadsorption (IA), number of courses) had to be specified in the article. Further, outcome
measures, such as the modified Rankin Scale (mRS) or structured neuropsychological assessment
had to be provided. The mRS ranges from zero (no symptoms) to six (death from the disease), and a
change of ±1 mRS point is considered as clinically significant improvement or deterioration. Cut-off
for independent living is at ≤2 mRS points.
2.2. Search Strategy
The following strategy was used to find previous literature and trials (Figure 1): MEDLINE (medical
literature analysis and retrieval system online) was searched for articles published up until 30 June 2020
in English or German. The Medical Subject Headings (MeSH) terms used were “autoimmune
encephalitis” and “apheresis” (37 hits), “plasma exchange” (104 hits) or “immunoadsorption” (12 hits).
Furthermore, the references of the included articles were screened for potential additional articles.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
diagram of the reviewed literature.
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3. Results
3.1. Therapeutic Apheresis in Autoimmune Encephalitides
Therapeutic apheresis is an important treatment option in a range of inflammatory central nervous
system diseases [13]. It has been proven to be beneficial in primary demyelinating disease as well as in
encephalitis caused by antibodies targeting neuronal proteins [14] (Table 2).
Therapeutic apheresis has been shown to be safe and effective leading to measurable laboratory
and clinical improvement in several inflammatory diseases of the central and peripheral nervous
system, including myasthenia gravis, Guillain-Barré syndrome and multiple sclerosis. Apheresis is
recommended by the German Society of Neurology as escalation treatment of severe courses of AE.
Patients should be treated with apheresis at least five times every other day. In cases with predominant
CSF antibodies seven to ten treatment courses are usually needed for relevant reduction of CSF antibody
titers. Before receiving therapeutic apheresis, patients mostly show either severe clinical symptoms on
hospital admission or an insufficient response to therapy with high-dose cortisone or IVIG.
Much has been learned from acquired myasthenia gravis, which represents a “model disease”
for the much later discovered forms of autoantibody-mediated AE. It could first be demonstrated
that removal of the disease-defining acetylcholine receptor antibodies using plasma-exchange led to
marked symptom improvement [15]. Antibodies in antibody-mediated AE are mostly directed against
neuronal surface antigens. Emerging studies have demonstrated that clinical symptoms relate directly
to pathogenic autoantibodies. For example, isolated human monoclonal autoantibodies from patients
with NMDAR encephalitis targeted the NR1 subunit of the NMDAR and were alone sufficient to induce
morphological and electrophysiological changes in the neurons, and to lead to synaptic dysfunction by
downregulation of NMDAR [16]. Thus, the pathogenic effect is caused by the antibodies themselves,
indicating that removal of these antibodies can disrupt the disease-causing mechanisms.
Therapeutic apheresis has been shown to improve clinical symptoms in different
antibody-mediated diseases. According to the American Society for apheresis (ASFA) guidelines PE and
IA are strongly recommended for different antibody-mediated encephalitis forms ranging from low to
moderate evidence. In contrast, the therapeutic role of apheresis is not yet established for paraneoplastic
neurological syndromes and individual decision-making is necessary [23]. In NMDAR encephalitis,
recovery and symptom remission often correlate with a reduction of antibodies, in particular with
a decline in CSF titers. In this way, antibody titers can serve as intra-individual disease biomarkers
and support treatment decisions [24]. Efficacy of therapeutic apheresis relates to the extracorporeal
elimination of circulating serum antibodies, redistribution of antibodies from the extracellular space
and a number of secondary immunomodulatory changes. The inflammatory processes during AE
are likely to involve a leakier blood-brain barrier, which might support further redistribution of
autoantibodies from the central nervous system into the blood [25].
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3.2. Therapeutic Procedure for Apheresis
Therapeutic apheresis offers two different procedures. On the one hand is plasma exchange
(PE), where a defined plasma volume is removed and replaced by human albumin or fresh frozen
plasma. On the other hand is immunoadsorption (IA), a procedure that more specifically removes
immunoglobulins and immune complexes by passing the plasma over an adsorber column, allowing
reinfusion of the patients’ own plasma. Two different IA procedures were used in the reviewed articles:
either a regenerative double column system or a disposable tryptophan column. Tolerability and
therapeutic effects do not show relevant differences between PE and IA in recent studies [14,19,26].
Related to the procedure is a rare risk of pathogen transmission in PE due to substitution with
donor-derived blood components, which is not existent in IA [19]. However, angiotensin-converting
enzyme inhibitors need to be paused for a minimum of 48 h prior to IA, otherwise there exists a risk of
IA-associated bradykinin-release syndrome. Main side effects are not caused by the apheresis directly,
but are rather related to the necessary central venous catheter. They include bleedings, hematoma,
infections, thrombosis or damage caused by the puncture [22].
Usually a minimum of five sessions of apheresis is performed. When patients show a CSF
predominant antibody, more sessions are generally needed in order to eliminate the antibody in the
central nervous system. Most studies included in this review describe a central venous catheter in an
internal jugular vein as vascular access. Only Hempel et al. use a peripheral vein to perform IA and in
order to treat patients as outpatients. However, they report significant patient drop-out due to a failure
of repeatedly accessing the vein [20].
The treated plasma volumes can be calculated using Sprenger’s formula [27]. Depending on the
protocol, a total of 1.5–2.2 plasma volume is processed in PE, whereas in IA 2000–2500 mL plasma per
session are treated [19,22]. Patients treated with PE receive a replacement solution, such as 4% human
albumin or fresh frozen plasma. Treatments take place every other day, although the first two to three
sessions can be conducted on consecutive days in selected cases. Due to the central venous catheter,
anticoagulation is necessary to minimize the risk of thrombosis.
3.3. Initiation of Therapy with Apheresis and Prior Treatment
The specific mechanism of antibody removal has been shown to be a more beneficial treatment
of NMDAR encephalitis than intravenous methylprednisolone alone. In a retrospective study 2/14
patients showed significant clinical improvement following steroids, whereas 9/14 patients who
received additional PE improved in the mRS during the third and fifth cycle of apheresis [17]. This is
likely to be related to the high therapeutic specificity and therefore efficacy of therapeutic apheresis
compared to intravenous immunoglobulins (IVIG) or high-dose corticosteroids. Early diagnosis and
prompt start of a sufficiently “aggressive” therapy are mandatory for symptom reduction and long-term
remission. Interestingly, a study by Heine et al. showed that treatment delay was not associated with a
significantly worsened outcome [19], whereas Onugoren et al. found that, in patients with irreversible
damage of brain structures, such as fixed hippocampal sclerosis, no clinical improvement could be
achieved by IA [22].
Many patients with AE treated with apheresis receive prior treatment with high-dose steroids or
IVIG. The decision for treatment with apheresis is often only made after unsuccessful or incomplete
recovery after these other therapies. It has been shown that both patients who did and patients who
did not receive prior treatment benefitted from apheresis [19]. In all studies analysed, a substantial
part of the patients (up to more than half) received apheresis as initial treatment.
In the study by Onugoren et al. all patients except one out of 19 were treated with high-dose
prednisolone (median dose 4.9 g) in parallel to IA [22]. It is reported that in some patients
immunosuppressive therapy with steroids is continued on a maintenance dose [18]. Especially,
patients with antibodies to LGI1 respond well to continued treatment with steroids [8,9].
Apheresis in patients with AE is most established in the acute phase of the disease. However,
repeated apheresis might also be applied in refractory disease with clinical signs of AE and constant
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detection of high antibody titers. Yet in one study, repeated IA after 4.5 months (median) in six patients
with antibodies against NMDAR, LGI1, Caspr2 and GAD that responded insufficiently to a first series
of IA, did not show any further clinical improvement measured by mRS [22].
In case of an underlying malignancy, tumor removal is essential for improving further
disease course.
3.4. Effects of Treatment with Apheresis in Patients with AE
A better outcome in patients with NMDAR encephalitis was strongly associated with an early
start of immunotherapy (less than 40 days after symptom onset) [28]. Response rate in general
is considerably higher when therapy initiation is started early [29] and includes improvement in
state-of-the-art imaging and neuropsychological assessments [30].
According to a prospective study, symptoms that responded best to apheresis include apathy,
aphasia, stupor, sleep disorders, agitation, myoclonus and dystonia, sensory neuropathy, apraxia and
seizures [19]. In another study, in the majority of patients the modified Rankin Scale (mRS) improved
by ≥1 point. It is of note that no patient worsened during apheresis in these studies.
Treatment efficacy is more pronounced in patients with antibodies against cell surface antibodies
(NMDAR, LGI1, Caspr2, mGluR5) or in patients with intracellular synaptic antibodies (GAD), whereas
no positive treatment effect was observed in patients with paraneoplastic intracellular antigens
(anti-Hu) [19,22]. Marked reduction of serum antibodies occurred during the first five sessions of IA,
but titers dropped further when apheresis was continued. Five days after IA a median decrease in
titers of 97% and 64% was noted for serum and CSF, respectively. Interestingly, the decrease further
continued until the next follow-up (median time after IA 3.9 months) [22]. In a retrospective study,
all cerebral magnetic resonance imaging (MRI) changes in 17 patients with NMDAR encephalitis
decreased [18].
Marked and rapid effects of apheresis can be seen in patients with epileptic seizures concerning
seizure frequency. This was seen for patients with LGI1 and Caspr2 antibodies, where five out of seven
patients became seizure free immediately after initiation of therapy with IA [22]. This treatment effect
results in reduction or even complete removal of antiepileptic drugs.
Several case reports point to the efficacy of PE in drug-resistant status epilepticus caused by AE
in children and adults. Both convulsive and non-convulsive status have been described as being
responsive to apheresis. In patients with abnormal electroencephalogram (EEG) prior to apheresis,
EEG normalization was observed after 5 cycles of PE. EEG improvement correlated with decrease in
antibody titers [31,32].
Treatment of severe AE complicated by status epilepticus or autonomic instability might need to
take place on an intensive care unit. On the ICU, benefit from immunotherapy, including apheresis,
strongly depends on medical complications associated with a prolonged ICU stay [33].
In patients with predominantly psychiatric symptoms related to treatable autoimmunity,
corticosteroids are often hesitantly used given the potential side effect of steroid-induced psychosis.
Overall, notable neuropsychiatric side effects can occur in up to 6% of patients who receive steroids [34];
however, in antibody-mediated AE the clinical improvement with immunotherapy quickly outrivals
any steroid-related effects on psychiatric symptoms according to our experience.
In paraneoplastic AE with antibodies targeting intracellular proteins, therapeutic effects of
rituximab, IVIG and therapeutic apheresis are usually limited as the antibodies are not directly
pathogenic, but neuronal damage is caused by cytotoxic T-cells [19,26]. Furthermore, diagnosis in
paraneoplastic disease is often delayed and substantial irreversible neuronal cell damage has already
occurred at the time of therapy initiation. Discontinuation of therapy should be considered in patients
in whom brain damage has progressed to an advanced stage in MRI after three to six months despite
intensified immunotherapy.
After therapeutic apheresis with both PE and IA, a transient spurious intrathecal immunoglobulin
synthesis of all three subclasses (IgG, IgA, IgM) can be observed. The transient intrathecal Ig fractions
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and increased IgG index are due to dropped serum IgG levels following apheresis. This “intrathecal
pseudo-synthesis” regularly occurs in the first two days after apheresis in a majority of patients [35].
Thus, one needs to consider these abnormalities for interpretation of CSF results from lumbar puncture
shortly after apheresis in order to prevent false diagnostic assumptions.
3.5. Future Treatment Options for Apheresis
Clinical indications for therapeutic apheresis in AE might expand to less recognized
antibody-mediated conditions in the near future. We could recently demonstrate that asymptomatic
mothers of a child requiring psychiatric in-patient diagnostics carried low-level pathogenic human
NR1 antibodies more frequently than control mothers having a healthy child [36]. To better understand
this possible connection, we developed a murine model of pregnancy-related materno-fetal antibody
transfer. Here, human monoclonal NR1 antibodies diaplacentally transferred to the offspring, enriched
in the fetal circulation and brain, caused neurotoxic effects during neonatal development, inducing
brain network changes, and led to neuropathological disorders in the offspring persisting into
adulthood [36]. Given the relatively high frequency of NR1 autoantibodies in the healthy human
population, the findings indicate a novel disease principle with high clinical relevance for lifelong
neuropsychiatric morbidity in the affected children [37]. Most importantly, these pathologies are
potentially treatable with apheresis in asymptomatic mothers, but further studies are needed to
better understand the frequency of autoantibodies, the susceptible window during pregnancy and the
contribution of genetic and further risk factors. Further, this seems not to be limited to the NMDAR,
as other maternal anti-neuronal autoantibodies may similarly cause neurodevelopmental disorders in
the offspring, such as with antibodies against Caspr2 [38].
The use of therapeutic apheresis has been shown to be safe in pregnant women, both for mother
and fetus. A recent Italian study evaluated the use of apheresis during pregnancy. Among 48 pregnant
women receiving apheresis one had suspected autoimmune encephalitis. Adverse events occurred in
2.1% of all patients analysed, which is reported to be lower than the Italian average. Peripheral veins
are preferred as a vascular access during pregnancy to avoid the risks associated with a central venous
catheter [39].
3.6. Apheresis in Children with AE
Children with autoimmune disorders such as antibody-mediated AE can also be treated with
therapeutic apheresis. PE was retrospectively evaluated in 22 children. All children had been treated
with IVIG and/or steroids before PE. Each patient received a median number of six PE sessions.
No PE-related mortality was observed and adverse events occurred in 2.2%, which is the expected
average. Adverse events consisted of hypotension and urticaria. In total, three pediatric patients
with antibody-mediated encephalitis were treated with PE, two patients improved and one patient
showed partial recovery with persistent neurological deficits after three-year follow-up. One patient
with paraneoplastic encephalitis did not benefit from PE and was lost to follow-up [40]. Another
prospective observational study evaluated 535 children with acquired demyelinating syndrome or
encephalitis treated with steroids, IVIG or PE. Here, pediatric patients with autoimmune encephalitis
other than acute disseminated encephalomyelitis (ADEM) had the highest frequency of poor outcome.
However, the individual treatment decisions were not specified [41].
3.7. Autoimmune Dementia and Treatment with Apheresis
Compared to ‘classic’ AE with subacute onset of neuropsychiatric as well as behavioral
symptoms, antibody-associated dementias are a more slowly progressing group of diseases where
decline in working and short-term memory as well as visuo-spatial deficits are the most prominent
features. Detection of high-level autoantibodies in patients with dementia is rare, but autoimmune
dementias represent a form of cognitive decline that is potentially treatable. A Mayo clinic study
reported improvement of cognition in 64% of patients with suspected autoimmune dementia
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after immunomodulatory treatment [29]. An underlying autoimmune mechanism and response
to immunotherapy is more likely when patients do not fulfill routine criteria for established
neurodegenerative dementia forms, but rather present with subacute onset, psychiatric symptoms,
fluctuating disease course, shorter delay to treatment, seropositivity for a specific autoantibody and
inflammatory CSF [29].
In a retrospective study analyzing 286 CSF and serum samples of patients with different dementia
forms, 16% of the serum samples had NMDAR IgA, IgM or IgG antibodies compared to 4.3% in a
healthy control group [42]. Besides the spectrum of known and established pathogenic antibodies,
there might be an even broader range of autoantibodies for which pathogenicity has not yet been
confirmed. It is unclear from these studies whether anti-neuronal autoantibodies develop secondarily
to neurodegeneration or whether they primarily contribute to and drive the disease. It is highly
possible that neurodegeneration leads to the presentation of autoantigens from dying neurons with
consecutive establishment of a specific autoimmune response. In this way, formed autoantibodies
may contribute to synaptic dysfunction, further accelerate cognitive decline or contribute to clinical
symptoms such as behavioral abnormalities commonly present in dementia patients.
Another recent target in dementia patients are autoantibodies against G protein-coupled receptors.
In a small trial analyzing the effect of IA in patients with mild to moderate dementia and agonistic
autoantibodies (agAAB) against α-adrenergic receptors, treatment with four cycles of IA not only
caused disappearance of autoantibodies, but resulted in stabilization of the cognitive and mental
condition during the follow-up period of 12–18 months [20]. Another study that is currently recruiting
(ClinicalTrials.gov Identifier: NCT03132272) investigates the effects of IA in patients with Alzheimer’s
disease positive for agAAB. The group aims to demonstrate discontinuation of the vascular remodeling
and slowing of cognitive decline following IA treatment.
Apheresis not only has an acute effect on disease activity but can be used for longer lasting
immunomodulation. In case of uncertainty of the immunological findings, first-line therapy including
steroids or apheresis may serve as a diagnostic test to support the autoimmune etiology [43]. In our
experience, however, short-term treatment (such as intravenous high-dose steroids for three to five
days) cannot demonstrate clinical improvement in autoimmune dementia in most cases, thus requiring
longer administration for four to six weeks (e.g., daily 0.5 mg/kg prednisone).
Based on the new developments in this field, the ongoing identification of dementia-associated
autoantibodies and the concern about overlooking treatable etiologies, we now offer diagnostic
antibody testing in serum and CSF to every patient with suspected dementia in our memory clinic at
the department of neurology at Charité. In this way we increasingly identify patients with a working
diagnosis of Alzheimer’s, frontotemporal dementia or atypical dementia who have new or established
autoantibodies against neuronal and glial proteins, as exemplarily shown in the case vignette of an
81-year-old gentleman (Box 1).
Detection of antibodies against neurochondrin (Figure 2) in this patient led to immunotherapy
with IA. The observed clinical improvement prompted B-cell depleting therapy with rituximab that
led to long-term stabilization.
The patient participates in an ongoing clinical trial (DRKS00016017) analyzing the role of
anti-neuronal and anti-glial surface antibodies in cognitive disorders and potential improvement
following IA. The study aims to identify dementia patients who harbor autoantibodies against structures
of the central nervous system using cell-based assays for detection of established autoantibodies
as well as screening assays using indirect immunofluorescence on unfixed murine brain sections.
Autoantibody-positive patients with cognitive decline can enroll in the study and receive therapeutic
apheresis (Figure 3). Treatment includes five to six IA sessions over a 12-day course. Cognitive
performance is evaluated prospectively and compared to historic controls. Patients further undergo
structural und functional MRI before and after IA. CSF analysis evaluates the reduction of autoantibody
levels over the course of IA and the potential utility of further biomarkers of neurodegeneration,
such as micro-RNAs.
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Box 1. Clinical case of autoimmune dementia.
An 81-year-old dementia patient presented to our outpatient memory clinic at the department of Neurology
at Charité—Universitätsmedizin Berlin with deficits in working and short term memory as well as difficulties in
concentration. Symptoms began nine months prior to presentation with increasing loss of orientation for place
and time, confusion and reported visual hallucinations. Brain MRI at symptom onset was unremarkable apart
from microangiopathic lesions in the left temporoparietal lobe (Figure 2A). Basic CSF analysis showed markedly
increased protein. Symptoms improved after several weeks without specific therapy, but anterograde memory
deficit persisted. During the following months, two episodes with re-appearance of confusion occurred, but
lasted only for days.
In our center, the patient showed a persisting dysexecutive syndrome with amnestic and visuo-constructive
deficits and apraxia. No other neurological deficits were observed. Montreal cognitive assessment showed
mild cognitive impairment with a score of 21 out of 30. A second CSF analysis revealed normal cell count, but
still increased protein of 1288 mg/L (normal <450 mg/L). No infectious cause was found. Extensive search for
anti-neuronal autoantibodies in serum and CSF including indirect immunofluorescence staining on rodent brain
sections detected neurochondrin IgG antibodies in the CSF (Figure 2B).
The diagnosis of AE with oligosymptomatic memory deficits was established. A three-day course of
intravenous methylprednisolone with 1 g/day led to improved gait, but no impact on cognition was observed.
Because of the persisting memory deficits, two months later five sessions of IA were administered every other
day and resulted in reduction of CSF neurochondrin antibody titers (Figure 2C). The patient reported vertigo
during IA, but vital signs were unremarkable at all times. After IA, the patient described improved concentration;
his wife reported better organization of daily life and his ability to care for himself again. In the Bristol Activities
of Daily Living Scale the patient improved from 20 points to 9 points.
The patient’s autoantibodies targeted neurochondrin, a leucine-rich protein expressed not only in the brain,
but also in bones and cartilage. As neurochondrin is located intracellularly, the pathogenicity of neurochondrin
antibodies is unclear and they might only be a biomarker of autoimmunity including T-cell-mediated
neurotoxicity [44]. Neurochondrin expression is highest in cerebellar Purkinje cells, brainstem, lateral parts
of the central amygdala nuclei and the hippocampal pyramidal cells. Antibodies against neurochondrin bind
robustly to the hippocampus, cerebellum and amygdala, while binding to the striatum, thalamus and cerebral
cortex is less pronounced [45]. Patients described so far presented with rapidly progressing cerebellar ataxia,
brainstem signs and neuropsychiatric symptoms.
Figure 2. Autoantibodies against neurochondrin. (A) MRI T2/FLAIR (fluid-attenuated inversion
recovery) of the 81-year-old dementia patient was largely unremarkable apart from few microangiopathic
lesions in the left temporoparietal lobe. (B) Indirect immunofluorescence of murine cerebellum sections
demonstrated CSF IgG antibodies against neurochondrin (GCL, granule cell layer; PC, Purkinje cells;
ML, molecular layer). (C) Following immunotherapy with five sessions of IA, antibody titers in CSF
were markedly reduced.
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Figure 3. Immunoadsorption in autoantibody-positive patients with cognitive impairment—trial
protocol. Patients with confirmed autoantibodies against central nervous system antigens and
progressing cognitive impairment receive immunotherapy with five sessions of IA together with
detailed neuropsychological, MRI and CSF biomarker assessment. Follow-up monitoring includes two
visits after three and 12 months.
3.8. Closing Remarks and Outlook
Predictors for beneficial outcome after treatment with apheresis in patients with AE include
start of the treatment early in the disease before substantial irreversible brain damage has occurred.
Nevertheless, after longer periods from symptom onset to therapy initiation, apheresis can also result
in symptom improvement. Immunotherapy with steroids or IVIG prior to apheresis does not seem to
have an effect on the overall outcome. Especially in patients with severe disease courses apheresis is a
major treatment option and should be initiated early, possibly together with other immune therapies.
For selected patient groups such as children and pregnant women as well as patients requiring
ICU treatment, the safety and efficacy of apheresis could also be shown.
According to all studies reviewed, the ASFA guidelines and the recommendations given by
the German Society of Neurology, no benefit of apheresis in patients with onco-neuronal antibodies
could be shown. Here, results are inconsistent, with most patients showing no therapeutic effect after
apheresis, or even further deterioration, but in single patients clinical improvement could sometimes
be seen. A clear treatment response to apheresis, both, PE and IA, is established in patients with
antibodies against surface antigens or synaptic antigens. In the articles screened for this review,
there was no difference in outcome of patients treated with PE or IA. Therapeutic apheresis is a valuable
option within the complex multimodal immune therapy of AE. The benefit of treating patients with
antibody-mediated AE with apheresis by far outweighs the possible side effects that were not severe
and were mainly associated with the central venous catheter. Furthermore treatment with apheresis
may be complicated by the necessity of an ICU setting and poor patient cooperation.
Although predominant humoral autoimmunity seems to be rare in dementia patients and requires
further study, the search for autoantibodies in these patients allows the detection of potentially
treatable dementia forms and holds the potential to prevent further cognitive decline in selected
patients. Thus, therapeutic apheresis is not only an important first-line therapy in patients with AE
but may be increasingly considered in further patients who are positive for autoantibodies against
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neuronal structures. This already includes patients with cognitive decline but may in the future expand
to novel clinical indications ranging from antibody-associated psychosis to autoantibody-positive
pregnant women.
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Abstract: Multiple sclerosis (MS) is the most abundant inflammatory demyelinating disorder of the
central nervous system. Despite recent advances in its long-term immunomodulatory treatment,
MS patients still suffer from relapses, significantly contributing to disability accrual. In recent years,
apheresis procedures such as therapeutic plasma exchange (TPE) and immunoadsorption (IA) have
been recognized as two options for treating MS relapses, that do not respond to standard treatment
with corticosteroids. TPE is already incorporated in most international guidelines, although evidence
for its use resulted mostly from either case series or small unblinded and/or non-randomized trials.
Data on IA are still sparse, but several studies indicate comparable efficacy between both apheresis
procedures. This article gives an overview of the published evidence on TPE and IA in the treatment
of acute relapses in MS. Further, we outline current evidence regarding individual outcome predictors,
describe technical details of apheresis procedures, and discuss apheresis treatment in children and
during pregnancy.
Keywords: immunoadsorption; acute relapsing multiple sclerosis; plasma exchange; therapeutic
apheresis
1. Introduction
In multiple sclerosis (MS), the complex interplay between environmental factors and susceptibility
genes leads to the development of inflammatory brain lesions defined by oligodendrocyte death
and axonal damage, recovery of function and structural repair, post-inflammatory gliosis, and
neurodegeneration. Besides, disruption of the blood–brain barrier (BBB) and enhanced transendothelial
migration of immune cells early in the course of MS likely contribute to the disturbance of neuronal
integrity [1]. Numerous reports describe MS as a primarily T cell-mediated disorder [2,3]. However,
findings such as immunoglobulin and complement deposits in demyelinating brain lesions, the
presence of intrathecal immunoglobulin synthesis, and results from clinical trials on B cell depletion
therapies suggest a pivotal role for B cells as well [4–6]. Several well-accepted roles for B cells in MS
include the secretion of the central nervous system (CNS)-directed autoantibodies, B cell-dependent
maturation of autoreactive CD4+ T cells, and dysregulation of cytokine responses [7–9].
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Despite great advances in disease-modifying treatment, treatment for acute MS relapses has
remained largely unaltered for the past 20 years, namely treatment with intravenous or oral
corticosteroids [10]. The administration of high-dose intravenous methylprednisolone (IVMPS;
up to 1000 mg daily) over a period of three to five days usually represents the first step in acute MS
relapse treatment and has been endorsed by national and international guidelines, ever since a first
prospective, randomized trial showed superiority of IVMPS compared to placebo [9,11]. The rationale
here is primarily attributed to a non-genomic response, including a direct effect on cellular membranes,
leading to a suppression of cell-mediated processes (suppression of immune-cell-migration, restitution
of BBB integrity), as well as dose-dependent induction of T- cell apoptosis [12,13]. Although there is
evidence for faster recovery of relapses by IVMPS treatment, there have been notable proponents for
no effect of IVMPS treatment on long-term disability [14]. Furthermore, approximately one-quarter of
the patient’s clinical improvement is not sufficient after the first course of IVMPS [15]. In this context,
apart from extending steroid treatment to a higher dose (up to 2000 mg daily for five additional days),
apheresis procedures, such as therapeutic plasma exchange (TPE) and immunoadsorption (IA) are
considered as an alternative after their proven success in other neurological diseases [16–18]. Here,
the lead (immuno)-pathogenetic principle for both apheresis modalities (TPE and IA) is based on
the removal of circulating, pathogenic humoral factors such as autoantibodies, immune complexes
and inflammatory cytokines, and the modification of pro-inflammatory mediators and co-stimulatory
signals linked to T and B cell-mediated autoimmunity [19–21].
However, guidelines have no uniform recommendations on using TPE or IA in acute
steroid-refractory MS relapses. Both procedures are recommended by the German Society of Neurology
for escalation treatment of acute relapsing-remitting MS (RRMS) exacerbations not responding to
the first IVMPS course [22]. The American Academy of Neurology also advises the use of TPE for
adjunctive treatment of relapsing forms of MS (Level B), while IA is not addressed [23]. In 2016, the
American Society for Apheresis published evidence-based guidelines for the clinical use of therapeutic
apheresis, considering 16 neurological disorders. The modality recommended for most of these
disorders was TPE. The clinical indication category assigns TPE for treatment of MS to category II
(“apheresis accepted as second-line therapy”) and IA for treatment of RRMS to category III (“optimum
role of apheresis therapy is not established”) [23].
Since several studies demonstrated that residual deficits persist after MS relapses and contribute
to a stepwise progression of disability, fast and adequate therapy of relapses is indispensable, and
the optimal treatment sequence has to be well defined [24,25]. Thus, we here aimed to conduct
a review of the published literature that provides a general overview of available evidence using
apheresis treatment in inflammatory demyelinating relapses, and in more detail outlines specific
treatment-determining aspects.
2. Search Strategy
To conduct this review, we followed PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) guidelines [26]. The articles were independently screened for eligibility.
2.1. Inclusion Criteria
Studies had to meet the following inclusion criteria:
a. Cohort: Reporting response rates of at least one patient with an established diagnosis of
clinically-isolated syndrome (CIS) or RRMS (according to the McDonald or Poser criteria) or
optic neuritis (ON) in absence of any other infectious or inflammatory disease of the CNS after
treatment due to an acute relapse that is unresponsive to steroids [27–30].
b. Treatment regimens: Apheresis was preceded by relapse therapy with high-dose steroids.
No concomitant immunomodulatory relapse treatment was carried out simultaneously while
using the apheresis procedures. Technical details of apheresis procedures adhered to current
guidelines described in the 2016 consensus paper (number of TPE/IA courses: 4–7 (mean);
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patient’s estimated plasma volume (EPV) per session: 0.6–2.5; for TPE: Fluid replacement with
albumin) [31].
c. Outcome measure: Reporting at least one clinical outcome measure of apheresis; such as the
expanded disability status scale (EDSS), its functional systems scores (FSS), or visual acuity
(VA) [32].
Application of inclusion criteria: a. was mandatory for inclusion. If criteria b. and/or c. were not
met, authors were contacted for additional data. Only in the case of insufficient information were the
studies ultimately excluded.
2.2. Search Strategy
To identify studies, MEDLINE was searched for relevant articles published between 1 January
1980 and 30 April 2019 (in the English or German language). Additionally, we decided to evaluate
abstracts from international conferences, namely Annual Meeting - American Academy of Neurology
(AAN) and European/ Americas committee for treatment and research in multiple sclerosis (ECTRIMS/
ACTRIMS). Medical Subject Headings (MeSH) terms used were ‘multiple sclerosis’, and ‘plasma
exchange’ or ‘immunoadsorption’. Furthermore, reference lists of published articles and abstracts
were screened for additional studies (Figure 1).
Records identified through database
(MEDLINE) searching
(1966 – 04/19)
Records identified through other
sources
n = 8









Full text articles excluded
for reason
n = 45
Total of studies included
n = 63
Figure 1. PRISMA flow diagram of the reviewed literature.
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3. Results
3.1. General Efficacy of Apheresis Procedures
3.1.1. Therapeutic Plasma Exchange in Acute MS Relapse
TPE is an extracorporeal blood purification technique separating plasma from blood and involves
the removal of patient plasma and the replacement with another fluid. TPE treatment of isolated
ON, acute RRMS, and CIS, refractory to conventional pulsed IVMPS, has been evaluated in several
studies [19,33–42]. Unfortunately, studies assessing functional outcomes of apheresis treatment used
different outcome measures, usually referring to either the EDSS or its FSS. Reasoning that the most
sensitive outcome was likely to be the one that addressed relapse-related disability, several studies
primarily assessed changes in the ‘target neurologic deficit’ (TND), defined as the predominant symptom
matching the FSS [19,34,35,38,42]. To simplify the statistical analysis, the majority of the reviewed
studies classified recovery according to the response categories ‘no, mild, moderate, and marked’
(Table 1) [19,34–36,38,41,43–45]. Satisfying treatment success was mainly defined as ‘marked to moderate’
response. However, some studies also contained different classifications and/or other outcome parameters
such as visual evoked potentials or gait/power scales from Weinshenker [33,39,42,46,47].
Table 1. Classification of treatment response in the reviewed literature.
Level of Improvement Definition
‘no response’ the same or even worse compared to baseline
‘mild response’ clinically detectable improvement but not relevant to function score
‘moderate response’ changes in function score
‘marked response’ major improvement or restitution of function
Here we outline both the response rates defined by the individual studies, as well as a uniform
transformation of the data according to the ‘FSS-based relapse recovery model’ implemented by
Conway and colleagues (Figure 2) [48]. The outcome model was based on the changes between the
peak deficit and maximum recovery in FSS related to relapse (ΔFSS = FSS relapse peak – FSS maximum
recovery). Relapse specific changes in FSS were defined as a ‘good’, ‘average’, or ‘worse’ response to
apheresis. Although patients’ individual EDSS or FSS were not outlined consistently throughout the
different trials, we extracted the indicated FSS of ON, RRMS, and CIS patients where possible, taking
all limitations of comparability into account. Table 2 gives an overview of published TPE data.
Kurtzke functional systems scores
at maximum recovery after a relapse


































Figure 2. Functional systems score (FSS) based relapse recovery model. Good, average, and worse
recovery is assigned based on the peak FSS, and the amount of final stabilized recovery FSS reached.
Modified from Conway et al. [48].
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Studies
Up to now, only two prospective studies have been carried out [33,34]. In 1999, Weinshenker
and colleagues conducted a randomized, sham-controlled and double-blind crossover trial, including
22 patients with acute, steroid-refractory relapses. While 13 patients were diagnosed with RRMS
according to the Poser criteria, the other nine patients suffered from more or less specifically defined
demyelinating disorders [30,33]. Half of the patients received TPE, while the others underwent a sham
procedure in which the blood was separated within the apheresis system but recombined again prior
to re-infusion. Patients that did not achieve a marked or moderate improvement crossed over to the
other treatment arm. At discharge, 8 out of 19 patients (42%) had improved relevantly during the
two-week course of active treatment, compared to 1 out of 17 patients (6%) in the sham group.
The second perspective but not the placebo-controlled study, published in 2009 by Trebst and
colleagues, evaluated 20 patients with acute MS relapses and found a marked to moderate improvement
in 18 out of the 20 patients (90%) following apheresis therapy [34].
Findings in the two prospective studies were underscored by several retrospective trials [19,35,36,38–41].
Two groups demonstrated comparable TPE response rates, revealing a marked to moderate response
in 8 out of 11 patients (73%) and in 28 out of 35 patients (80%) at discharge [19,35]. Corroborating
results from a small case series recorded a marked to moderate response in 3 out of 4 (71%) one month
after TPE [36]. Contrastingly, Ehler and colleagues considered the response rate to be much lower:
Following apheresis therapy, they detected a marked to moderate response in only 2 out of 11 patients
(18%), while a mild response was observed in 8 out of 11 patients (73%) [38]. However, the remaining
demographic characteristics and technical details of apheresis, including cycles and processed plasma
volumes (PPV) did not differ substantially compared to other reviewed studies (Table 3). A slightly
lower response rate was also demonstrated in a multicentre study conducted by Llufriu and colleagues
with an improvement (not otherwise specified) in 11 out of 24 patients (46%) only [39]. As this study
evaluated outcomes after six months, and thus later than the other trials, the sustainability of effects
observed after TPE was questionable. Of note, Magana and colleagues also assessed the clinical course
of 60 RRMS and CIS patients six months following TPE and revealed a rate of moderate or even marked
response of 68% [41]. Several other studies with long-term data on apheresis-treated patients revealed
sustained or even increased functionality during follow-up (1 to 14 months) with no new relapses
occurring in between [19,34,35].
Table 3. Overview of technical details on therapeutic plasma exchange (TPE) and immunoadsorption














Weinshenker BG. yes 7–14 1.1 EVP 5% albumin CVA [33]
Trebst C. yes 3–7 3.0–4.2 L 5% albumin CVA [34]
Schilling S. yes 4–6 3.0 L 4% albumin CVA [35]
Schroeder A. yes 4–6 50 mL/KgBW 5% albumin CVA [19]
Habek M. yes 5–10 1.5 L 5% albumin N/A [36]
Ehler J. yes 3–8 2.2–3.5 L 5% albumin PV, CVA [38]
Llufriu S. yes 5–15 125–166 EPV 5% albumin N/A [39]
Magana SM. yes 2–20 1.1–1.4 EPV 5% albumin, FFP N/A [41]
Lammerding L. yes 5 15 EPV 5% albumin CVA [42]
Immunoadsorption (tryptophan-based)
Koziolek M. yes 5 2.5 L None CVA [46]
Mauch E. yes 5–6 2.0 L None PV, CVA [47]
Schimrigk S. yes 3–6 2.0–2.5 L None CVA [44]
Schimrigk S. yes 3–6 2.0–2.5 L None CVA [45]
Trebst C. yes 5–7 2.5 L None CVA [43]
Heigl F. yes 6 2.0 L None PV, CVA [49]
Abbreviations: CVA (central venous access), EPV (estimated plasma volume), FFP (fresh-frozen plasma), IVMPS
(intravenous methylprednisolone), kgBW (kilogram per body weight), liter (L), PV (peripheral vein).
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For a uniform transformation of data, according to the Conway model (Figure 2), six studies were
accessible, outlining the patient’s FSS before apheresis and at discharge [19,34–36,38,42]. In total, 181
patients were included in this analysis. Forty-four patients (24%) experienced a good response, 89
patients (49%) an average response, and 48 patients (27%) a worse response.
3.1.2. Immunoadsorption in Acute MS Relapse
IA has entered the field of MS treatment as a new important method for selective extracorporeal
adsorption. In contrast to standard TPE, the eluted plasma can be reinfused during IA, suggesting
a better tolerability and safety profile [50]. Two technical options have been developed: Single-use
tryptophan-based adsorbers and reusable IgG Protein A containing staphylococci-based adsorbers
(PrA-adsorbers). Single-pass devices are used for only one session, while their capacity is limited
to approximately 2.0 to 2.5 L (L) of plasma volume. A treatment with tryptophan adsorber and
conventional plasma separator results in an elimination of 30% of immunoglobulin IgG and IgM, 15%
of IgA, 10% of the patient’s total protein and approximately 60%–70% of the fibrinogen during a single
treatment, with a PPV of 2 L [51,52].
In contrast, a semi-selective (defined by the adsorption of mainly immunoglobulins (>95%), but
not directed against a specific antibody) reusable PrA based devices can provide continuous IA to treat
more than one EPV per session. Strong affinity for Fc fragments of immunoglobulins from any source
is a remarkable characteristic of protein A. After one session with a PPV of 2,5 L a decrease in total
serum IgG level of 87%, 55% of the IgA and 56% of the IgM level occur, without a clinically significant
loss of fibrinogen (less than 15%) [53].
In the last two decades, six studies have been published on IA therapy for RRMS or CIS, including
one prospective study [43–47,49]. All studies used tryptophan based adsorbers (Table 3). In order
to compare these to the TPE studies, we separately reviewed the response rates for ON, RRMS, and
CIS patients where possible and further assessed the patient’s FSS according to the Conway outcome
assessment tool [48]. Table 4 gives an overview of the published IA data.
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Studies
One prospective study has been conducted on IA in acute RRMS [46]. Koziolek and colleagues
reported a significant improvement (defined as improved VA with 0.6 cc or more) in 8 out of 11
patients (73%) suffering from acute steroid-refractory ON (mean VA at baseline 0.12 ± 0.12 compared
to 0.47 ± 0.32 at discharge). In four out of six patients (67%), visual evoked potentials could not be
identified before treatment but were re-detectable after IA [46].
Various retrospective studies are in line with these data [43–45,47,49]. Mauch and colleagues
reviewed the clinical course of 14 patients suffering from acute relapses of either RRMS (n = 12) or
secondary-progressive multiple sclerosis (SPMS, n = 2). TND in 12 out of 14 patients (86%) significantly
improved (assessed via EDSS, FSS not further specified) [47]. Corroborating results from Schimrigk
and colleagues revealed 12 out of 15 patients (80%) with a marked to moderate response to IA [44].
In a subsequent retrospective multicenter study, Schimrigk and colleagues analyzed the largest cohort
of MS patients treated with IA thus far, comprising six sites with 147 patients and 786 single IA
treatments [45]. All patients suffered from an acute relapse of either RRMS (111 patients) or SPMS
(36 patients). In 105 patients (71%), the affected TND improved functionally, including 88 patients
(60%) with marked and 17 patients (11%) with moderate treatment response. Further studies indicated
a marked to moderate response in 5 out of 10 patients (50%), and a marked to mild response (not
precisely differentiated) in 53 out of 60 patients (88%) at discharge [43,49].
As the patient’s individual EDSS and FSS was not outlined consistently throughout the IA trials,
a uniform transformation of data was not possible (only the data of 48 patients out of 3 individual
studies were accessible) [43,44,47].
Comment
Guidelines on apheresis therapies currently refer to TPE only, since data on IA are considered
less substantial [54]. Nevertheless, existing studies with individual outcome assessments indicated
IA as effective with similar response rates compared to TPE (42%–90% for TPE vs. 50%–86% for
IA) [19,33–36,38,43–47,49]. The limitations regarding the comparability of studies must be considered
though. Criteria for patient selection and diagnosis significantly changed over time, and, therefore,
characteristics of RRMS trial populations are diverging, probably resulting in lead-time bias [28,29]. In
this context, a significant number of novel pharmacological agents have not just entered the field but
even defined the treatment of active MS to date.
Additionally, the time points for apheresis therapy and evaluation of outcome parameters selected
differed considerably throughout the trials. While EDSS assessment is universally familiar to MS
clinicians and accepted by regulators, it has shortcomings in its variability between examiners, heavy
emphasis on walking, and especially nonlinearity [55]. Consequently, several relapses associated with
upper limb involvement are not reflected in terms of pre-existing gait impairment. Moreover, trials
do not reflect whether a particular patient does not reconstitute at discharge or goes on to develop
a persistent disability. In this context, in addition to evaluating the overall response, future studies
should also cover the time between discharge and recovery, since complete but delayed recovery may
still mean loss of independence and a need for rehabilitation or intermediate care. The main recovery
has been suggested to take place within the first three months following relapse [24]. Hence, if an
outcome is measured at discharge only, it may not be a suitable marker for overall improvement. On the
other hand, a longer observation period carries the risk of detecting disabilities resulting from new
relapses; confirmed disability progression at six months should be included as an outcome parameter
in future study designs.
3.1.3. Comparison of Apheresis Treatments (TPE vs. IA)
Despite the multitude of studies evaluating TPE or IA treatment of acute MS relapses separately,
only a few studies compared both extracorporeal blood purification methods in terms of clinical
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efficacy, safety profile, and serological changes [21,54,56,57]. Assessing IA effectiveness is complicated
even more by the co-existence of different IA systems (tryptophan based absorbers and PrA-based
absorbers).
Studies
Two retrospective studies directly compared the efficacy of both apheresis treatments and described
IA and TPE as equally effective for treating steroid-refractory relapses of MS [21,54]. Muhlhausen and
colleagues included 140 patients with steroid-refractory exacerbation of MS and neuromyelitis optica
(NMO), while Palm et al. compared the clinical efficacy of TPE and IA in acute relapses of RRMS as
well as progressive forms, respectively [21,54].
In terms of treatment safety, IA is associated with fewer side effects and fewer contraindications [56,57].
Accordingly, the reviewed studies revealed a lower rate of adverse events (AE) during and following IA
compared to TPE. Side effects and discomfort were apparent in 0.8%–15% of IA treatments [43–45,47,49].
In contrast, Koziolek and colleagues reported a higher side effect rate, with 22% mild and moderate
AEs occurring during IA (12/55 IA treatments) [46]. Most AEs were classified according to the Common
Terminology Criteria for Adverse Events (CTCAE) category I–II and were related to symptoms
such as transient hypotension accompanied by dizziness and nausea, chest pain, palpitations, and
headache. Side effects classified as CTCAE categories III–IV were mainly caused by vascular access
and catheter-associated complications [45–47,49]. In this context, catheter dislocations (1/266 patients
from all reviewed IA studies, specifying AEs in detail (Table 4)) and infections (3/266 IA patients), and
catheter-associated thrombosis (6/266 patients) with one case of pulmonary embolism represent the
most relevant risks after IA [45–47,49]. Moreover, one case of heparin-induced thrombocytopenia and
one case of bradykinin-associated shock following a single administration of an ACE inhibitor have
been described [49]. No study observed AEs classified as CTCAE category V following IA.
Notably, side effects reported for TPE were classified higher and were apparent in 24%–80% of
all TPE treatments [19,33–36,38,39,42]. In particular, the risk of apheresis-related AEs with CTCAE
categories I–III was higher for TPE than IA. Apart from the symptoms listed above, TPE AEs
were also related to coagulopathy (including fibrinogen decrease), hypogammaglobulinamia, an
allergic rash, paraesthesia, and anemia [33,35,38,39,42]. The rate of catheter-associated AEs were
slightly higher compared to those of IA patients, with catheter dislocations (7/246 patients out
of all reviewed TPE studies, specifying AEs in detail (Table 2), catheter-associated thrombosis
(9/246 patients) and catheter-associated infections (11/246 patients), including one case of severe
sepsis [19,33–36,38,39,42]. Additionally, one patient developed a catheter-associated phrenic nerve
palsy, one patient a pneumothorax, and another patient experienced gastrointestinal bleeding, associated
with hypofibrinogenemia [33,35,42]. Moreover, one patient died due to pulmonary embolism following
TPE [33].
Comment
Based on the current literature, both treatments appear comparably effective. However, several
studies described particular advantages in terms of safety for IA versus TPE [56,57]. IA avoids the
removal of key plasma components with a milder impact on the cardiovascular system and a lower
risk of allergic reactions and coagulopathy potentially underlying the more favorable safety outcomes.
According to American (ClinicalTrials.gov) and European (EudraCT) registries, further clinical
comparative studies are in preparation. A prospective randomized trial, comparing both procedures
in 60 RRMS and CIS patients with acute relapses, has been completed recently (NCT02671682); study
results thus far unpublished.
In terms of technical options, all current IA studies employ single-use tryptophan-based absorber
columns. Although PrA-based absorbers have been shown to be more effective in pure antibody
depletion, the two techniques have not been compared in MS treatment thus far [58]. However, the
responsiveness of steroid-refractory MS relapses to apheresis therapy is unlikely to depend on antibody
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clearance alone, since the clinical course of the disease is not correlated with autoantibody titers, and
identification of crucial antibody targets remains elusive [59,60].
3.2. Individual Predictors of Apheresis Outcome
Comprehensive predictive models of individual treatment response to apheresis are lacking.
This includes clinical, radiographic, and serological features to characterize individual differences in
apheresis outcome. Several factors may exhibit a predictive value for apheresis response, including age,
sex, monofocal or multifocal relapse manifestation, the affected functional system, previous success or
failure to apheresis procedures in a preceding relapse, as well as technical aspects of TPE and IA [41,61].
However, the current literature is controversial, and whether predictors should be included in clinical
decisions remains to be defined.
Using individual patient data from the respective studies, we performed an analysis of the
literature using the Conway Matrix (Figure 2) to identify predictive factors for the TPE response. We
included all studies that met the above inclusion criteria and outlined the complete sets of individual
patient data, including all predictors we aimed to analyze. Overall, we included five studies with a
total of 146 patients [34–36,42,62]. Statistical analysis was performed with R 3.6.1. The mean of the
predictors was determined and categorized by the TPE response. Next, the data were scaled, centered,
and depicted in a heatmap (Figure 3A). In order to determine the adjusted odds ratio of the predictors,
a multivariate binomial logistic regression was performed (Figure 3B). Adjusted odds ratios with
confidence intervals were displayed in a forest plot. Due to insufficient data in the IA arm, analysis in
this cohort was not possible.
Figure 3. Predictive values of TPE response assessed by the functional systems score (FSS)-based relapse
recovery model. (A) Predictive risk heatmap, applicable in individual patients, using three different
outcome classifications (good, average, and worse) according to the Conway matrix (Figure 2) [48]. The
heatmap depicts the scaled means of the variables. The red color indicates older patients (Age), with a
higher prevalence of not suffering the first demyelinating event (Duration), a long interval between
symptom onset and initiation of TPE (Interval), higher occurrence of male patients (Male), and a higher
prevalence of relapse manifestations other than optic neuritis (no ON). (B) A forest plot of the predictive
values of the TPE response in a multivariate logistic regression analysis. The x-axis represents the
respective adjusted odd ratios for a worse versus good response. Odds ratios are outlined with a 95%
confidence interval (CI; OR >1 no predictive value of treatment response, <1 statistic significant value
associated with beneficial apheresis response). Data were generated in the RRMS and CIS patient
cohort of five individual studies, including a total of 146 patients. All patients received TPE due to
steroid unresponsive relapse [34–36,42,62].
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3.2.1. Patient Dependent Variables (age, sex, neurological status, disease duration, and previous
success or failure to apheresis)
Several studies have shown that the relapse recovery after IVMPS treatment linearly declines with
age [48,63]. Correspondingly, our analysis of the literature revealed a positive association between
poor TPE outcome and older age (Figure 3) [34–36,42,62]. This finding was statistically significant, as
the adjusted OR for age was 0.93 (0.87–0.98, p <0.05).
Moreover, one observational study associated the male sex with a more favorable treatment
response [61]. Of note, our analysis confirmed this observation, also indicating a trend towards a beneficial
TPE response in male patients (Figure 3). However, this finding was not statistically significant.
Magana and colleagues further postulated a shorter disease course to be associated with a
favorable TPE outcome [41]. We evaluated the impact of the disease course by implementing two
groups: The first demyelinating event vs. not the first demyelinating event. Our analysis showed the
superiority of the first demyelinating event compared to not, for treatment response to TPE and thus
confirmed the above-mentioned observation (Figure 3) [34–36,42,62]. However, this finding was not
statistically significant either.
Additionally, a retrospective study by Llufriu and colleagues revealed a positive correlation
between the absence of disease modifying treatment (DMT) and more frequent response to TPE [39].
Since the respective demographic data of these patients are not mentioned in this study, it is not
possible to specify whether this finding is based on a younger patient cohort or a shorter disease course.
However, the predictive value of DMT has not been corroborated by other studies [41,62].
In addition, it can be assumed that a favorable response to apheresis in a preceding relapse
provides a beneficial predictive value. In this context, rare individual case reports from the literature
support this assumption [19,36]. However, the number of cases is small (n = 3) and not accessible for a
systematic analysis.
Comment
To date, no patient-related response predictors have been confirmed for apheresis. However,
regarding the discussed aspects above, our analysis revealed that older age, longer disease duration,
and female sex were associated with poorer TPE outcomes (Figure 3) [34–36,42,62]. Although we
performed uniform evaluation techniques and only included original studies that contained both the
same patient cohort and a comparable TPE protocol according to current guidelines, we have to be
aware of limitations concerning the validity of our findings, such as bias in the search strategy or
methodological bias.
In the long-term, further clinical trials are needed to break new ground towards personalized
MS relapse therapy. Apart from the factors mentioned, there are others of interest that have not been
addressed in the studies thus far. These include the baseline annualized relapse rate, radiological, and
immunological findings.
3.2.2. Impact of the Affected Functional System
It has been discussed whether both subsequent long-term disability and post-relapse recovery are
linked to the site of relapse manifestation [41,63–65]. Magana and colleagues described the highest
response rates after TPE for brainstem and cerebellar impairments [41]. However, a relapse manifesting
as ON has also been described to be associated with more favorable treatment response [48,65]. This
is worth mentioning, as the proportion of patients suffering from acute ON varies considerably
throughout the reviewed trials (TPE: 0%–100% [19,34–36,42,62]; IA: 25%–100% [43–47,49].
To provide better comparability, we analyzed the study data and extracted the indicated VA,
transforming the values into a standardized outcome assessment tool as described above (Figure 2) [48].
Of note, demographic features such as age and sex, the dose of received steroids, the duration between
symptom onset and apheresis treatment, and the number of treatment cycles did not differ between
the trials.
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We were able to extract a total of 151 patients from the 10 studies, treated with either TPE (n =
92) or IA (n = 59) due to acute steroid-refractory ON [19,34,35,38,42–45,47,49]. Based on the described
outcome definition, 30 out of 151 patients (20%) showed “good” recovery, 66 out of 151 patients (44%)
showed “average” recovery, and 55 out of 151 patients (36%) showed “worse” recovery at discharge.
IA resulted in a slightly higher proportion of patients with “good” recovery (14/59 patients, 24%)
compared to TPE (16/92 patients, 17%). However, regarding the rate of non-responders, the available
data indicated the inferiority of IA (31/59 patients, 52%) compared to TPE (24/92 patients, 26%).
In contrast, nine studies outlined the data of patients with relapse other than ON, including in
a total of 119 patients [19,34–36,38,42–44,47]. As the respective studies did not further specify the
affected functional system consistently, we included all these patients in one comparison between ON
and relapses other than ON. Compared to the findings above, 29 out of 119 patients (24%) showed a
good recovery (27/90 patients (30%) in the TPE, 2/29 patients (7%) in the IA group), 55 out of 119 (46%)
an average recovery (40/90 patients (44%) in the TPE, 15/29 patients (52%) in the IA group), and 35 out
of 119 (30%) a worse recovery (23/90 patients (26%) in the TPE, 12/29 patients (41%) in the IA group),
at discharge.
Data on the comparison of ON vs. relapses other than ON regarding the TPE modality are
separately outlined in Figure 3 (ON vs. No ON).
Comment
Except for acute ON, individual FSS was not indicated in the majority of the reviewed studies.
This prevented further analysis of whether a specific disorder or symptom would respond more
favorably to apheresis than another. Transforming VA to the new outcome model allowed us to analyze
the response rate of ON to apheresis throughout the respective trials and compare them to relapses
other than ON. Response rates to apheresis were homogeneously distributed, except for the study
from Trebst and colleagues [19,34,35,38,42–45,47,49]. In this study, all five patients with ON showed a
“worse” response to IA, and also during follow-up, only one patient improved [43]. Since both the
technical data of apheresis and the demographic features of the patients did not differ from other trials,
the cause for non-improvement remains elusive.
As already mentioned, we generated a heat map from the TPE data to demonstrate predictive
factors of the TPE response (Figure 3). Although the finding was not statistically significant, there is a
trend towards a favorable TPE outcome for relapses other than ON (no_ON, Figure 3). Unfortunately,
we were not able to perform a corresponding analysis in the IA group due to missing data points.
Nevertheless, findings encourage further investigations. Randomized controlled trials, investigating
the response rates to both apheresis techniques regarding the relapse manifestation, with the treatment
of the same individual plasma volume by TPE and IA, respectively, are needed.
3.2.3. Time to Treatment Induction/Escalation
Time from symptom onset to apheresis initiation has been of interest in many studies [34,35,39,
42,43,61]. Llufriu and colleagues demonstrated that time from relapse onset to TPE initiation was
significantly shorter in patients who improved after treatment compared with those who did not
respond [39]. When the days from symptom onset to apheresis initiation were stratified as ≤5 days,
16–60 days, and ≥60 days, a corresponding decrease of response rate was found (67% vs. 43% vs. 8%,
respectively). Other groups also confirmed this time dependency [46,61]. Nonetheless, several studies
demonstrated that even with a late TPE start patients markedly improved or recovered fully [34,38,49].
In this context, Trebst and colleagues showed treatment success with IA following a mean interval of
47.2 days—with patients being successfully treated even after more than 100 days following relapse
onset [43].
Our analysis of the literature using the Conway outcome assessment tool revealed a slight, but
statistically significant better TPE outcome, when initiated shortly after symptom onset (adjusted OR
for shorter interval = 0.96 (0.92–0.99, p <0.05)) (Figure 3).
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Comment
A short time interval between relapse onset and apheresis initiation is considered as a strong
predictor of a good outcome, assuming nerve conduction in the early stages is blocked but not
irreversibly damaged [19,35,39]. Consequently, it is recommended to initiate apheresis within six
weeks after relapse onset [35,61]. However, apheresis should also be considered at later stages in
patients with persistent symptoms. Unfortunately, no data exist thus far to aid the identification of
potential responders. Nevertheless, we assume time to apheresis is one important modifying factor
related to treatment outcome.
3.2.4. Pre-Treatment with Steroids
Currently, there is no satisfying estimation of the contribution of steroid-treatment before apheresis
to treatment success. The reviewed literature includes patients having received 2.0–15 g IVMPS prior to
apheresis [19,33,34,36,38,43,45–47,49]. Steroids were administered after a median of 8–12 days (range:
1 to 68 days) after symptom onset and the time interval between the start of IVMPS and apheresis
varied between 3 to 92 days. A limitation in all the studies is the absence of a placebo-treated control
group. Thus, a spontaneous late improvement or a delayed effect of corticosteroids cannot be formally
excluded. However, several aspects suggest the effects are directly associated with the apheresis
procedure: No obvious correlation was apparent between the IVMPS dosage and treatment outcome,
even when accounting for demographic and clinical features such as FSS, age, or sex [34,35,43]. Further,
after a period of non-recovery prior to apheresis, symptoms began to improve soon after TPE or IA
initiation [19,38,47,49]. In this context, several studies showed that most of the patients started to
improve after the third cycle [19,38,47,49].
Further, we recently completed the first retrospective comparative study of double dose steroids
and TPE in acute relapses of RRMS and CIS, including 145 patients [42]. All patients received 5g IVMPS
before escalating treatment with either extended dose of IVMPS (2g/day over additionally five days),
TPE (five cycles every other day, one EPV per session) or the combination of both (IVMPS, subsequently
TPE). The treatment response was assessed according to the FSS-related outcome assessment tool
described above (Figure 2). Good/average/worse recovery of relapse symptoms at discharge was
observed in 60.9%/32.6%/6.5% of TPE patients vs. 15.2%/14.1%/70.7% of IVMPS patients. Of note, in
patients who received TPE after escalated IVMPS treatment, the outcome was significantly inferior
compared to those who received TPE as a first-line escalation treatment (multivariate odd’s ratio for
worse recovery = 39.01 (10.41–146.18; p <0.001)).
Comment
Thus far, there is no standard treatment approach for ongoing relapse regarding steroids and
apheresis modalities. Consequently, guidelines recommend both therapies as possible options for
relapse escalation treatment but give no recommendations towards a specific treatment sequence [66].
Our retrospective comparison of escalated IVMPS vs. TPE revealed significantly higher response
rates at discharge in the TPE group and in patients who underwent only one course of IVMPS prior
to TPE [42]. As a possible explanation, it can be hypothesized that restoring BBB permeability with
IVMPS treatment may, in fact, hinder the elimination of inflammatory mediators within the CNS via
apheresis. Another explanation could be the longer time to apheresis treatment when conducted as the
second instead of first escalation treatment.
Based on both assumptions, it may be preferable to choose a more aggressive therapy (TPE or IA)
in cases of severe relapse, rather than the escalated IVPMS treatment. However, we recommend that
the rapid admission of steroid-refractory patients to apheresis treatment without escalated IVMPS
treatment should be prospectively evaluated.
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3.2.5. Number of Apheresis Courses and the Impact of the PPV
Guidelines currently recommend five to seven courses of apheresis treatment with a PPV according
to 1.0 to 1.5 EPV [16]. An extension of further cycles can be considered on an individual basis in
cases of non-response [22]. These recommendations are mostly derived from calculations of antibody
concentrations. Antibody removal during a single TPE or IA treatment is limited, since (pathogenic)
antibodies are often produced in abundance, with high tissue concentrations, and slowly equilibrated
between their extravascular and intravascular distribution [67,68]. At least five separate treatments are
required to eliminate 90% of the initial total antibody burden [69]. Further, especially for TPE, it is
preferable to perform procedures every other day since exchange volumes per session are limited by the
cumulative alteration of global hemostasis parameters and potentially increased bleeding risk [70,71].
Correspondingly, fibrinogen requires 48 h to recover to half of the pre-treatment level [70]. With regard
to the studies discussed in this review, a comparable protocol was applied with regard to the technical
aspects of therapeutic apheresis such as the volume of whole blood processed (number of cycles,
number of plasma volumes exchanges per cycle), and replacement solution and vascular access, in line
with recent national and international guidelines (Table 3) [31].
Comment
Current recommendations are based on calculations of antibody equilibration rates. However,
there is plenty of evidence that apheresis treatment also eliminates additional soluble factors involved
in acute inflammation [21]. Thus far, no studies exist examining the elimination kinetics of these
additional factors. For clinical routine, the optimal number of cycles needs to be balanced in terms of
achieving the best resolution of symptoms on the one hand, and keeping hospitalization times as short
as possible on the other hand. In the reviewed studies, the first therapeutic effects typically occurred
after a median of three apheresis cycles [19,38,47,49]. Consequently, based on kinetic considerations
and clinical observations, a minimum of three to five cycles should be performed.
3.3. Apheresis Treatment in Special Situations
Although apheresis is an established therapy for adults, there is limited experience and literature
on the application of apheresis in childhood or during pregnancy. The International Pediatric Multiple
Sclerosis Study Group currently recommends TPE for children with severe relapses who do not improve
after high-dose IVMPS or have contraindications; IA has not been implemented in the guideline [72].
However, established treatment standards for children are still lacking, and most apheresis protocols
are derived from studies in adult patients [73].
Additionally, every fourth woman with MS experiences a relapse during pregnancy, and nearly
every third suffers from a relapse in the first three months after birth [74]. Although the amounts of
IVMPS in breastmilk are low, breastfeeding should be avoided for several hours after a high maternal
dose and might occasionally cause temporary loss of milk supply [75]. Moreover, especially within the
first trimester of pregnancy, high doses of IVMPS bear serious risks (preterm birth, a lower bodyweight
of the child, and/or facial/palatal cleft) [76,77]. Thus, alternative treatment options are warranted.
According to international guidelines, both apheresis procedures are recommended as an escalation or
second-line therapy in pregnant patients with steroid unresponsive relapses [66,78].
Studies
In 2013, Koziolek and colleagues reported on the largest cohort of children undergoing apheresis
treatment for severe attacks of demyelinating disorders (including RRMS; NMO-spectrum disorders
and acute disseminated encephalomyelitis) refractory to IVMPS, demonstrating high and sustained
recovery rates (88%) after five cycles of either TPE or IA [79]. These findings correspond to a
retrospective study by Bigi and colleagues [80]. Five pediatric patients (median baseline EDSS 2.0;
range: 0–3.5) were treated with TPE due to a severe attack of RRMS (median EDSS of relapse 6.5;
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range 4 to 7). The mean reduction in EDSS at discharge was 3 points, sustained at follow-up after
three months.
Concerning treatment safety, De Silvestro and colleagues outlined a 5.6% rate of AEs in pediatric
apheresis [81]. Corroborating rates were observed by Koziolek and colleagues, indicating four relevant
side effects (hypotension, acute dyspnoea, catheter dislocation, and decreased serum fibrinogen) in 50
treatment courses in 4 patients (8%) [79]. However, in a retrospective study by Michon and colleagues,
a much higher AE rate was detected for pediatric patients treated with either TPE or IA (55% of all
procedures, n = 137) compared to adult patients (16.2% of all procedures, n = 86) [82].
Further, one retrospective study and several case reports suggest TPE and IA treatment for acute
RRMS relapse during pregnancy and breastfeeding, considering them as rather a safe option [75,83,84].
In 2018, Hoffmann and colleagues conducted the largest retrospective study on this special cohort thus
far, analyzing the use of tryptophan IA during pregnancy and breastfeeding in 24 patients. Twenty
patients were treated with IA during pregnancy, and four patients received IA postnatal during the
breastfeeding period. In 83% of patients, a rapid and marked improvement of the TND was achieved,
defined either as an EDSS decrease of ≥1.0 point or improvement in VA ≥20% at discharge. Moreover,
no clinically relevant side effects were reported in connection with the 138 IA treatments [75].
Comment
Published experience of apheresis procedures in children is limited, and most of the indications
for treatment and the technical and procedural aspects of the procedure are also extrapolated from
adult data and experience [82].
Koziolek and colleagues showed that apheresis in children suffering from acute relapses of
demyelinating disorders seems to be as effective compared to treating adult patients [79]. However,
special risk factors need consideration, including citrate toxicity, extravascular volume shifts, and
difficulty related to vascular access [82]. Therefore, apheresis therapy in children requires a
multidisciplinary approach involving expertise in children, intensive care medicine, and nephrology.
Prospective studies are clearly warranted to optimize treatment protocols and to avoid permanent
disabilities in this sensitive age group.
During pregnancy, apheresis represents a therapeutic option both in first and second-line relapse
treatment. In this context, IA can be considered superior to TPE for several reasons. Plasma levels
of numerous hormones undergo pronounced shifts during pregnancy [85]. The protective effect of
pregnancy on MS disease activity seems to be at least in part, mediated by the immunomodulatory
effects of these hormones. This supports the use of IA to preserve protective plasma proteins, instead
of discarding them as with TPE. A further advantage of avoiding plasma substitution is the reduced
risk of allergic reactions and infections, as well as the reduced impact of coagulation factors [86]. In
contrast to TPE, most coagulation factors remain unaffected by IA, except fibrinogen, especially in
terms of tryptophan based IA [87]. However, no fibrinogen substitution was required in pregnancy IA
studies [75]. Thus, reduced bleeding risk in the perinatal period and reduced thrombotic risk due to
the reduction of antithrombin can be achieved with IA treatment compared to TPE [88]. Moreover,
since IA has a milder impact on the cardiovascular system, including hypotension, it can be assumed
that it is superior in terms of placenta perfusion.
3.4. Closing Remarks and Outlook
Relapses are a hallmark of MS and often associated with significant functional impairment and
decreased quality of life. Consequently, MS relapses need to be recognized and treated quickly using
valid therapeutic methods. Although evidence for apheresis treatment in MS relapse is mostly derived
from either case series or unblinded or retrospective cohorts—especially IA has thus far not been
considered in international guidelines—both procedures have become an alternative to escalated and
repeated pulsed steroid therapy. In respect to our recent comparison of escalated IVMPS and TPE,
apheresis procedures should even be considered as a first-line escalation treatment [42].
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In regard to the preferred apheresis modality and according to the literature, IA should be regarded
as a method of equivalent therapeutic efficacy compared to TPE, probably offering greater safety in its
use. This is particularly relevant in special populations such as children and during pregnancy.
As the long-term goal is to enable personalized MS relapse therapy, the predictive value for
apheresis response is of high interest. In this regard, our analysis and several studies highlighted
time to treatment as an important and modifiable factor related to outcome (Figure 3) [39,46,61].
Consequently, apheresis should be applied as early as possible in the course of a relapse. However,
since some cases describe full recovery for patients even late after symptom onset, a strict regimentation
to the suggested six-week period is not recommendable. Further, our analysis considers younger
age, male sex, shorter MS disease duration, and a relapse not manifesting as ON to be associated
with beneficial apheresis response (Figure 3). However, these parameters (eventually apart from
sex) are associated with beneficial relapse outcomes in general [89,90]. Of note, using binomial
regression models, both predictive values—male sex and shorter interval between apheresis initiation
and symptom onset—were statistically significant (adjusted Odd-Ratio (OR) for age: 0.93 (0.87–0.98, p
<0.05); OR for shorter interval = 0.96 (0.92–0.99, p <0.05). However, as in all systematic reviews, we
have to deal with several limitations, such as bias from selection and publication of studies, availability
of data, choice of relevant outcome, methods of analysis, and interpretation of heterogeneity. Therefore,
we should keep in mind that systematic analyses should neither be a replacement for well-designed
randomized studies.
In this regard, intervention studies with a prospective, randomized, controlled design are required
to compare:
(I) TPE vs. IA (with the same plasma volume exchange (TPE) or adsorbed (IA)), and
(II) Escalated IVMPS vs. apheresis.
With regard to the study protocol, at least five cycles should be performed every other day.
Considering the diversity of MS presentation, multiple patient-related clinical outcomes should be
combined with surrogate endpoints [91]. Both outcome analyses at discharge and in the long-term
(follow-up period of at least three months) are recommendable. Since it remains largely unclear by
which cellular and molecular pathways apheresis affect disease activity, an analysis of blood samples
and IA columns would also be of high interest.
There are several hypotheses regarding the mechanism of action of the different apheresis
techniques, but their discussion is beyond the scope of this review. In this regard, previous studies
provided evidence that the response to apheresis treatment is associated with the immunopathological
pattern, indicating that the pattern of the two patients who showed signs of a humoral immune
response benefited the most [40]. Anyways, knowledge about the predominant lesion pathology
is usually unavailable in clinical routine as MS patients do not undergo a brain biopsy. Given the
strong effects in the overall population of both TPE and IA, the procedures should be offered to all
patients with severe and/or refractory relapses. We assume that, currently, the selection of the definitive
technique will be determined by side effect profile and availability. However, trials are ongoing and
will be published in the nearer future.
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